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ABSTRACT OF THE DISSERTATION
THE EFFECTS OF ARTEMISIA DERIVED NATURAL PRODUCTS ON
ADIPOGENESIS
by
Steven Abood
Florida International University, 2017
Miami, Florida
Professor M. Alejandro Barbieri, Major Professor

For the first time in human history, more people worldwide suffer from obesity
than are undernourished. Numerous health complications are associated with obesity
including cardiovascular disease, Type 2 Diabetes, cancers of reproductive tissues,
stroke, depression, anxiety disorders, and Alzheimer’s disease. A deeper understanding of
the anti-adipogenic effects and mechanism of action of sesquiterpene lactones may have
pharmacological import in the continuing search for therapeutic modalities to ameliorate
the effects of this global obesity epidemic.
Dehydroleucodine (DhL), 11,13-dihydro-dehydroleucodine (DH-DhL), and
dehydroparashin-B (DhP), sesquiterpene lactones extracted from or derived from
compounds extracted from Artemisia douglasiana, were investigated for their antiadipogenic effects on 3T1-L1 preadipocytes.
Dehydroleucodine inhibited the expression of C/EBP and PPARand also
strongly blocked the expression of C/EBPβ, an early stage biomarker of early
adipogenesis, in a concentration-dependent manner. Dehydroleucodine arrested the cell
cycle at the G0/G1 phase, increased p27 and decreased both cyclins A and D and their

vii

partners (e.g., CDK2 and CDK4). Furthermore, DhL downregulated expression of
histone demethylase JMJD2 as well as repressed the expression of histone
methyltransferase MLL4, which in turn diminished the expression of C/EBPand
PPARrespectively.
11,13-dihydro-dehydroleucodine blocked the accumulation of lipid droplets and
inhibited the expression of PPARγ and C/EBPβ. Collectively, the results indicate that the
inhibition of early stage preadipocyte differentiation by DH-DhL may be associated with
cell cycle arrest at the G0/G1 phase.
Dehydroparashin-B significantly decreased the accumulation of lipid content and
downregulated the expression of CEBP PPARγ and CEBPα as well as FAS.
Interestingly, the addition of DhP inhibited the number as well as the size of the lipid
droplets during the differentiation of 3T3-L1 preadipocytes. Taken together, this data
suggests that DThP has an important inhibitory effect on cellular pathways regulating
adipocyte differentiation.
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I. INTRODUCTION
1.1. The Epidemiology of Obesity
On the eve of the apocalypse, the German Renaissance painter Albrecht Dürer
completed his magnum opus, a woodcut of the four horsemen from the Book of
Revelations (Bartrum et al. 2003). It was a work which simultaneously unsettled and
resonated with the populace, as the riders, avatars of famine, pestilence, war, and death,
gave symbolic representation to the existential fears of both Dürer's generation and those
manifested in archetypal events through the history of human evolution. Primary among
these fears was that of famine, represented in Dürer's work by the rider of the black horse,
who is curiously depicted as robust and healthy, perhaps because he has taken all the
prosperity of the land for himself (as the scale he is holding which is tipped in his favor
may indicate) (Bartrum et al. 2003). As the world failed to end and the 16th century
began, the fears of a starvation seemingly inseparable from the shift to an agricultural
society continued as 95 famines ravaged medieval Britain and 75 afflicted medieval
France. In the 20th century, a century in which the rider of the black horse claimed 70
million lives, the fear of starvation continued (Bartholomew 2004; Devereux 2000).
Famine's rampage was only to subside in recent decades with industrialization and
globalization mitigating but not dissipating famine's Malthusian check on exponential
population growth (Malthus 1798; Suweisa et al. 2015). Technology may have tamed
Famine's reign, but the threat of his re-emergence to savage the fields once again remains
in a world of fluctuating grain and synthetic nitrogen markets, climate change, water
insecurity, human conflicts, and the fragilities of an increasingly interconnected world
food system (Suweisa et al. 2015; Lal 2004).
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There is no concomitant existential fear of obesity in the historical record. Even
the Christian sin of gluttony, codified in the Seven Deadly Sins by the Desert Fathers of
the 3rd century A.D., was subject to opprobrium not because of the physical danger of
obesity to oneself, but because of the moral danger to one's soul from selfishly depriving
the community of food and subjecting it to starvation by taking more than one's fair share
(Aquinas 1981). The phenomena of food sharing is observed in nonhuman primates (de
Waal 1989). The opprobium of those who refused to engage in food sharing, may have
been a driver of hominid evolution through its reinforcement of a system of mutual
obligation (de Waal 1989). The tribalism that both stems from and reinforces this norm,
as well as punishes its breach, is linked in folklore to the existential fear of famine, often
manifested by an outsider to the group. This outsider is either an avatar of famine itself or
its epiphenomena of infanticide, cannibalism, disease and death, such as the wendigo of
Algonquin traditions, the fear gorta of Irish mythology, the ghoul of Arabic mythology,
the gashadokuro of Japanese mythology, or the zombie of modern pop culture (Yeats
2015; Haddawy 1995; Foster 2015).
And yet, while no obesity monster haunts our collective consciousness, for the
first time in human history, more people worldwide suffer from obesity than are
undernourished. In a recent study published in The Lancet that pooled data from adults in
186 countries, it was reported that there were 641 million obese people worldwide in
2014, compared to 462 million underweight people (Di Cesare et al. 2016). What is
remarkable is the rapidity, too fast for a memetic shift, that the transition has occurred
from a primarily undernourished to over nourished planetary population.
The Lancet study found that the number of obese people worldwide had risen
from 105 million in 1975 to 641 million in 2014. In contrast, during this same period, the
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number of underweight people rose from 330 million to 462 million. In just four decades,
an incredible planetary caloric shift occurred in which the prevalence of underweight
Homo sapiens transitioned from more than triple that of obese members of the species, to
a world in which obese individuals outnumber underweight individuals by 179 million
(Di Cesare et al. 2016).
1.1.1. Measuring Obesity
To understand these figures, we must understand how obesity is most commonly
measured, and the validity of this measure, as well as its limitations. The most widely
used criteria is body mass index (BMI), which is defined as the weight of a person in
kilograms divided by the square of their height in meters (Ortega et al. 2016).
BMI is strongly associated with the proportion of body mass that consists of
adipose tissue among all races and ethnic groups so far examined (Gallagher et al. 2000).
However, since it remains an indirect measure of adipose tissue amount, and instead
simply measures a height to weight ratio, certain mesomorphic individuals may
erroneously be aggregated as false positives (Ortega et al. 2016). In these cases, BMI will
not accurately reflect a concept of obesity where excessive adipose tissue accumulation is
the defining metabolic characteristic (Ortega et al. 2016).
There is also some variation in the average amount of adipose tissue at a given
BMI between different racial and ethnic groups. For Caucasian populations,
classifications include underweight (BMI less than 18.5 kg/m2), normal weight (BMI
from 18.5 to 25 kg/m2) and overweight (BMI over 25 kg/m2). Within the overweight
category, there is obese (BMI over 30 kg/m2), severely obese (BMI over 35 kg/m2 but
less than 40 kg/m2), morbidly or extremely obese (BMI over 40 kg/m2 but less than 50
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kg/m2), and super obese (BMI over 50 kg/m2) (Ortega et al. 2016). However, people of
Asian descent have higher fat mass, especially visceral fat, for any given BMI (Araneta et
al. 2005). Thus, for individuals of Asian descent, BMI is categorized differently: for
instance, the overweight category consists of a BMI of 25 to 27.5 kg/m2 (compared to
over 25 kg/m2 but less than 30 kg/m2 in Caucasians), and obesity is defined as a BMI of
greater than or equal to 27.5 kg/m2 (Araneta et al. 2005). BMI remains a useful but
imperfect measure of obesity (Ortega et al. 2016)..
Another measure, abdominal adiposity, a waist circumferential indicator of
visceral fat, is associated with the cardiovascular risk, and is a better predictor of insulin
sensitivity in men ages 50 to 95 than oxygen consumption (VO2 max), BMI, or
percentage body fat percentage (assayed via dual-energy X-ray absorptiometry or
hydrodensitometry) (Racette et al. 2006). Like BMI, abdominal adiposity also exhibits
slight categorical variations among different races and ethnicities: for abdominal
adiposity, increased cardiovascular risk is defined as greater than or equal to 94 cm in
European men, and greater than or equal to 80 cm in European women, but greater than
or equal to 90 cm in men and greater than or equal to 80 cm in women, of South Asian,
Chinese, and Japanese descent (Racette et al. 2006).
1.1.2. Global Changes in Obesity Rates
Although the aforementioned survey (Di Cesare et al. 2016) and other surveys of
global obesity (Ng et. al 2014) may vary in exact estimates, obesity rates have ballooned
globally in the last several decades. For instance, in the study conducted by Ng et al.,
overweight (a BMI of 25kg/m² or higher) and obese individuals rose globally from 857
million in 1980 to 2.1 billion in 2013 (Ng et al. 2014). By most measures, over a third of
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the world’s population today are either overweight or obese (Di Cesare et al. 2016; Ng et
al. 2014).
Morbid obesity continues to climb in economically affluent countries in both
adults and children. While lower BMI categories of obesity have slightly slowed their
rates of increase, obesity prevalence in developing countries continues to skyrocket. If
these trends continue, by 2030 an estimated 58% of the world’s adult population will be
overweight (38%) or obese (20%) (Di Cesare et al. 2016).
1.1.2.1. Gender and Obesity
Globally, obesity is more prevalent in women than men, but has increased at a
greater rate in men. In men, global prevalence of obesity increased from 34 million cases
(3.2%) in 1975 to 266 million (10.8%) by 2014. In women, global prevalence of obesity
increased from 71 million (6.4%) to 375 million women (14.9%) (Di Cesare et al. 2016).
By 2014, more than twice the number of women than men (126 million versus 58
million) were severely obese (BMI over 35 kg/m2) (Di Cesare et al. 2016). Additionally,
women are disproportionately affected by morbid obesity (BMI over 40 kg/m2) compared
to men regardless of age, race, or ethnicity (Di Cesare et al. 2016).
1.1.2.2. Regional Trends in Obesity Rates
Over half of the world’s 671 million obese people live in one of 10 countries:
China, the United States, India, Russia, Brazil, Mexico, Egypt, Germany, Pakistan, and
Indonesia (Wise 2014).
In 2014, China overtook the United States as the world's leader in absolute
numbers of obese people. Nearly a fifth of the world's obese people, 43.2 million men
and 46.4 million women, live on Chinese soil. What is striking is the rapidity of the
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increase: in less than two decades, between 1993 and 2009, obesity nearly quadrupled in
Chinese men (from 3 to 11%), and doubled in Chinese women (from 5 to 10%). For
absolute rates of severe obesity, China moved from 60th place in the world for men and
41st place for women in 1975, to 2nd for both men and women in 2014 (Di Cesare et al.
2016).
The United States remains close behind China in absolute numbers of obese
individuals, with 41.7 million obese men and 46.1 million obese women. Almost 65% of
US adults are overweight or obese (World Health Organization 2015; Ogden et al. 2014;
Boyle et al. 2010; Wang and Beydoun 2007). Like China, obesity rates in America rose
sharply in a miniscule amount of time: from only 1990 to 2000 for instance, the
percentage of obese people in the United States increased from 21 percent to 33 percent,
and 66 percent of Americans are now overweight or obese (Ogden et al. 2014). Some
estimates postulate that if these trends continue, over 85% of adults in the United States
will be overweight or obese by 2030 (Boyle et al. 2010).
Within the United States, rates of obesity in three subpopulations - adults of
African ancestry (47.8%), Hispanic ancestry (42.5%), and non-Hispanic Caucasians
(32.6%), range from three to five times greater than obesity rates among those of Asian
ancestry (10.8%)(Di Cesare et al. 2016). In adults of African ancestry, 56.6% of women
are obese compared with 37.1% of men (Ogden et al. 2013).
To the south, in Mexico, obesity rates have increased by15% since 2000, with a
full 71.3% of adults now overweight or obese (38.8% overweight and 32.4% obese).
Extreme obesity increased by 76.5% between 2000 and 2012 (Wijnhoven et al. 2013).
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Across the Atlantic, in Europe, prevalence of obesity varies by region with
Eastern Europe, southern Italy, and southern Spain exhibiting higher rates than Western
and Northern Europe (Gallus et al. 2015). France exhibits the lowest European obesity
rates (4.0 and 6.2% in French men and women, respectively), while the Czech Republic
exhibits the highest European rates (30.0 and 32.0% in Czech men and women,
respectively) (Gallus et al. 2015).
In Polynesia and Micronesia, 45% of men and 50% of women are obese (Di
Cesare et al. 2016). At the other end of the spectrum, South Asia has the highest
prevalence of underweight individuals, with 23.4% rates of underweight in men, and
24.0% in women, and obesity prevalence is less than 2% in Burundi, Timor-Leste, and
regions of central, east, and west Africa (Di Cesare et al. 2016).
1.1.2.3. Childhood Obesity
In China, between 1993 and 2009, aggregated overweight and obesity rates rose
from 6 to 13% in children 6 to 17 years of age (Liang et al. 2012). In the United States,
between 2003 and 2007, obesity rates in children increased from 6 to 16% (Singh et al.
2010), and between 2000 and 2014 extreme obesity in children doubled (Di Cesare et al.
2016). The prevalence of overweight amongst children in the United States tripled
between 1971 to 2004, increasing from 5% to 15% (Singh et al. 2010). In babies under
the age of one in the United States, adipose tissue mass doubled between 1970 and 1990
(Ailhaud and Guesnet 2004).
1.1.3. Morbidity and Mortality of Obesity
1.1.3.1. General Health Effects
Obesity shortens life expectancy by 6.5 years for those with a BMI between 40
and 44.9 kg/m2, which is more than normal weight participants who currently smoke
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cigarettes (compared to those whom have never smoked) (Kitahara et al. 2014). For those
with a BMI between 55 and 55.9 kg/m2, it shortens life expectancy by 13.7 years
(Kitahara et al. 2014).
The evidence is overwhelmingly against the concept of benign obesity for the vast
majority of health conditions. To borrow a concept from virology, obesity can be viewed
as an initial infection that predisposes individuals to a myriad of disease states, or
secondary infections. Obesity increases the prevalence of multiple disease states
including cardiovascular disease (Freedman et al. 1999), atherosclerosis (Wofford et
al.1999), diabetes (Sartipy and Loskutoff 2003), hypertension (Pi-Sunyer 2002), insulin
resistance (Sinha et al. 2002), dyslipidemia (Klop et al. 2013), fatty liver disease (Ray et
al. 2013), gall bladder disease (Galal 2003), obstructive sleep apnea (Leon-Cabrera et al.
2015), osteoarthritis (Griffin 2008), asthma (Gennuso 1998), and cancer (Lagra et al.
2004) (see Figure 1 below).
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Figure 1. Health complications associated with obesity
1.1.3.2. Cardiovascular Disease
Ischemic heart disease and stroke are the leading causes of death both globally
and in the United States (Lozano et al. 2010). Overweight and obesity increases risk for
ischemic heart disease, stroke, hypertension, dyslipidemia, and dysglycemia (Reilly and
Kelly 2011).
1.1.3.3. Diabetes
Diabetes was estimated to afflict 14% of the adult population in the United States
in 2010 (Boyle et al. 2010). Various estimates predict that diabetes prevalence will rise
to between 21 and 33% by 2050 (Boyle et al. 2010). Compared with normal weight
individuals, being overweight increases the risk of developing type 2 diabetes by a factor
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of three. Eighty percent of individuals with diabetes are overweight or obese. Persons
with diabetes have 2.1 times the risk of death of those without diabetes (Abdullah et al.
2010).
Additionally, the association between obesity and diabetes may actually be
underreported: one study reported that only 39% of the death certificates of individuals
with diabetes who died of cardiovascular disease mentioned diabetes (McEwen et al.
2006). Thus, if indicative of wide spread practice, this misclassification could have led to
an underreporting of obesity-associated deaths for diabetes.
1.1.3.4. Cancer
Six percent of all new cancers (33,966 in males and 50,535 in females) may be
attributable to obesity (Polednak 2008). As discussed in the previous section, obesity is a
major risk factor for diabetes. In turn, diabetes is a risk factor for most cancers (Flegal et
al. 2007). Additionally, obesity is associated with both increased risk and increased
mortality of leukemia and esophageal, colon, pancreatic, postmenopausal breast,
endometrial, renal, gallbladder, liver, ovaries, and prostate cancer (Flegal et al. 2007).
1.1.3.5. Diminished Recovery Outcomes
A recent meta-analysis of obesity in trauma care reported that obesity was
associated with a 45% increased risk of mortality (Liu et al. 2013). Additionally, an
obesogenic BMI doubles the risk of major complications during trauma care (Liu et al.
2013). These poorer recovery outcomes stem from higher risk of influenza, pneumonia,
bacteremia, and sepsis in obese patients (Huttunen and Syrjanen 2013).
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1.1.3.6. Enhanced Pregnancy Risks
A 2011 meta-analysis reported that overweight and obese women had
significantly higher miscarriage rates compared with women with a normal BMI
(Rittenberg et al. 2011). In addition, obese women have overall lower pregnancy and live
birth rates, compared to women with a BMI in the normal range (Rittenberg et al. 2011).
1.1.3.7. Mental Health
A meta-analysis of the correlation between obesity and depression concluded that
obese persons have a 55% increased risk of developing depression over time (Luppino et
al. 2010). Obesity is also associated with an increased 25% risk of developing an anxiety
disorder (Simon et al. 2006).
Individuals who are overweight in midlife have a 26% increased risk of
developing some form of dementia, a 33% increased risk of vascular dementia, and a
35% increased risk of Alzheimer's disease (Anstey et al. 2011).
Obese older adults exhibit higher rates of atrophy in their frontal lobes, anterior
cingulate gyrus, hippocampus, and thalamus (Driscoll et al. 2012). A prospective cohort
study that followed a group of normal weight and highly active individuals, and a group
of overweight and inactive individuals, over the course of seven years, found that the
overweight individuals presented a nearly 40% increased risk of poor mental functioning
(Lindholm et al. 2013).
1.1.3.8. Health Effects of Childhood Obesity
Unfortunately, obesity in childhood either results in the development of many of
these pathological conditions or leads to increased risk for them later in life. Obesity in
childhood or adolescence is associated with twofold or higher risk of adult hypertension,
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diabetes, asthma, coronary heart disease, and stroke (Sinha et al. 2002; Freedman et al.
1999). In addition, obesity in children and adolescents is associated with smaller
orbitofrontal cortex gray matter volume, with concomitant impairment of certain domains
of executive function, such as inhibitory control (Barkin et al. 2013).
1.1.4. Economic and Other Costs of Obesity
It is estimated that obesity and obesity-related conditions cost $190 billion dollars
per year of additional healthcare spending, or 21% of total U.S. healthcare expenditures.
Obese men are estimated to incur an additional $1,152 per year in healthcare costs, and
obese women incur an additional $3,613 per year (Cawley and Meyerhoefer 2012).
Obesity also takes an economic toll on employers through the cost of
absenteeism. Obesity-related absenteeism is estimated to cost employers between $3.38
billion ($79 per obese individual) and $6.38 billion ($132 per obese individual) each year
in the United States (Trogdon et al. 2008).
In terms of maintaining the national defense, in 2008 it was reported that 5.7
million men and 16.5 million women who would otherwise have been eligible for
military service under the U.S. Army's current active duty enlistment standards, were
disqualified for exceeding weight and body fat requirements (Cawley et al. 2012). This is
a dramatic shift from a century earlier, in 1901, when under nutrition and malnutrition
caused one third of recruits to be either too short (under the 5 foot minimum) or too weak
for military service (Cawley et al. 2012).
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1.2. The Evolution of Obesity: How we got Fat
1.2.1. The Mismatch Paradigm Part 1: Primordial Food Scarcity and Caloric
Expenditure
It is evident from this litany of epidemiological data that a rapid global increase in
the accumulation of adipose tissue in Homo sapiens has occurred. Sub-Saharan Africa
now remains the only region in the world where obesity is not common (Haslam and
James 2005). It is also evident that this transformation from an undernourished to
overnourished planet has occurred far too quickly to implicate a primarily genome-wide
mechanism of change. Why the global increase in such a short time span? The short time
span that led to the creation of an obese planet points towards a mismatch between our
modern environment and the primordial environment in which our obesogenic genes
developed as a leading explanatory model for the obesity epidemic (Philipson and Posner
2008). Environments of either food scarcity or surplus could have led to different
strategic behaviors of feeding and movement to fulfill the fundamental drive of hunger
and provide sufficient energy to maintain homeostatic and allostatic conditions (Eaton
and Eaton 2003). A primordial environment of food scarcity could have selected for a
genome biased towards adipose tissue storage (Neel 1962). If so, our obesogenic genome
is therefore mismatched with the modern environment of food surplus, and the decrease
in movement and caloric expenditure required to obtain this food. This basic mechanism
could explain the rapid shift from a negative to positive energy balance and the resulting
global incidence of excess adipose tissue storage.
One historical example of a mismatch paradigm that may illustrate the general
plausibility of an environmental shift as a mechanistic construct for pathologies concerns
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a shift from a vitamin C rich environment to a vitamin C deficient environment. It is
hypothesized that primates, fruit bats, and guinea pigs once had the ability to synthesize
vitamin C in the liver, as many organisms today can. However, as hinted at by the
vitamin C rich diets of modern apes and monkeys, the primordial environment was likely
rich in vitamin C and the ability to synthesize vitamin C in the liver was unessential and
eventually lost (see Figure 2 below). This new physiological construct, like the thrifty
genotypic and phenotypic proclivity towards adipose tissue storage, only became
maladaptive when the environment shifted: in this case, to an environment of vitamin C
scarcity on sailing ships in the 1600s and 1700s resulting in the pathology of scurvy,
which is characterized by vitamin C deficiency (Milton 1999).

Figure 2. Early hominin adaptations which support long distance movement and
increased fat storage
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Why the need in Homo sapiens for a genotype that would support a proadipogenic phenotype in the first place? Why the hypothesized shift from a pregenus
Homo diet that was likely vegetarian to one where Homo sapiens, like modern day
chimpanzees, bonobos, and baboons, were motivated to seek out high energy density
animal calories? (Milton 1999; Bunn 1981).
The selection for and maintenance of a larger body size that could support more
adipose tissue may have allowed the genus Homo to metabolically rely on both these
adipose reserves and low caloric food such as plant underground storage organs (Laden
and Wrangham 2005). Such low caloric food would return too low a rate of energy for a
smaller animal that could not rely on fat stores while entering into the caloric deficit
necessary to seek out such foods (Laden and Wrangham 2005).
The need to rely on adipose tissue stores to survive in a food-scarce environment
is a central explanatory tenet for the development of an obesogenic phenotype (Aiello
and Wheeler 1995). However, a corollary hypothesis is that an increase in high energy
density food acquisition, and a concomitant adipose tissue-storing thrifty phenotype, were
the costs of the development of larger brains (Aiello and Wheeler 1995). The Homo
sapien brain, a high-fat organ of approximately 33% lipid content, accounts for roughly
2% of a person's body weight, yet demands at least 20% of the body's energy
consumption (Magistretti and Allaman 2015). So, to maintain the energy requirements of
a larger brain necessary for a cognitive processing capacity that supports survival,
especially in times of food scarcity, a genotype that favored the storage of adipose tissue
reserves would be selected for (Aiello and Wheeler 1995).
In addition to maintaining the normal high metabolic energy requirements of
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larger brains, a pro-adipogenic genotype and the motivational circuits to seek out higher
energy density foods may have been necessary for infant brain development (Wang et al.
2002). Since the pelvic girths of species in the genus Homo limit the birth size of the
infant brain to approximately 250 to 300 cubic centimeters, most of human brain growth
occurs after birth supported by energy obtained from lactation (Martin 1981). Since the
fatty acid composition of milk is affected by dietary fatty acid intake (Milligan et al.
2008), it is possible that through a kin selection mechanism through which their offspring
would benefit, females were selected for with enhanced motivational circuits to seek out
and store adipogenic food sources. Human babies are among the fattest of all mammal
babies (Kuzawa 1998).
Why the selective pressure for larger brains? One theory postulates that in a
virtuous cycle, larger brains were selected for because although they required increased
energy consumption, the increased cognitive capacity increased success in acquiring high
energy density foods (Aiello and Wheeler 1995). This increase in available energy
consumption and the advent of cooking which decreased the energy consumption
required by the gut, continued to make more energy available for the development and
maintenance of larger brains (see Figure 2 above) (Wrangham and Conklin-Brittain
2003).
This expensive tissue hypothesis of brain development postulated a shift from
continuous feeding on low energy density foods (scavenger gatherers) to intermittent
high energy density foods which facilitated the development of larger brains (with
increased energy expenditure and metabolic demands). This led to increased success in
obtaining high density energy foods through cognitively complex activities such as
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hunting and the advent of cooking (Aiello and Wheeler 1995). High density foods and
increased cooking allowed for more easily digestible nutrients, which may have led to a
smaller gut with less metabolic requirements, saving nutrients for the development of an
even larger brain in a virtuous cycle (Aiello and Wheeler 1995). Behind and resulting
from this increased brain development most likely was the establishment of a
motivational reward circuit to fuel the sustained search for high density foods (see Figure
2 above) (Wang et al. 2002). The crux of the mismatch paradigm is the transition from a
niche of food scarcity where this reward circuit was highly sensitive to the pursuit and
acquisition of high energy density foods to the modern environment of food surplus
(Power 2012).
The glycemic index is a measure of the increase in blood glucose concentration
following ingestion of a food. The glycemic index of the majority of foods in this early
environment was likely low, as simple sugars may have been available only seasonally
from fruit or episodically as when honey from a bee hive was located (Aiello and
Wheeler 1995).
How was high energy density food obtained? Through the movement required to
track game, movement which required the development and maintenance of cognitive
modules which increased focus, memory, and the complex thinking necessary to
communicate and hunt in groups (Shafia et al. 2017). Just as factors stimulated by
movement such as an increase in brain derived neurotrophic factor (BDNF) helped
stimulate the growth and maintenance of hippocampal neurons necessary to support the
memory needed to become better hunters, the dopaminergic motivational pleasure circuit
emanating from the ventral tegmental area to the nucleus accumbens likely was co-opted
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to motivate movement over vast distances to find this food (Wang et al. 2002). There
may be utility in conceiving of obesity related pathologies not as the introductions of
harmful vectors (such as one would think of infectious agents such as viruses, bacteria or
prions) but as the removal of an evolutionary strategy that positively supported both
physical and mental health as a side effect of the physiological needs selected for to
optimally acquire scarce foods.
The calorie expending movement to obtain high energy density foods in this early
environment may have consisted of persistence hunting, where the bipedal Homo sapien
hunter, although slower than the prey sought over short distances, would exhaust it by
tracking it through alternating periods of running and walking (Liebenberg 2008). A
relatively hairless body which enhanced the ability to thermoregulate through sweating,
the ability to carry water, and the ability to carry and throw projectile weapons, all likely
aided this endurance based strategy (Liebenberg 2008) (see Figure 2 above). Persistence
hunting is still utilized by the San people in the central Kalahari Desert in Southern
Africa and by the Raramuri people of Northwestern Mexico (McDougall 2011).
1.2.2. The Mismatch Paradigm Part 2: Modern Food Surplus and Movement Deficit
1.2.2.1. Food Ubiquity, Ease of Acquisition and Altered Composition
The ability of modern Homo sapiens to instantly conjure up high energy density
food by reaching in his/her pocket and tapping his/her fingers a few times on a small
rectangular object to order a round, caloric rich delicacy directly to him, would befuddle
his primitive ancestor. The dopaminergic fueled motivational hunger drive is no longer
linked to movement. The unconditioned response of movement (that the unconditioned
stimuli of hunger formerly triggered) is now replaced with new conditioned behavioral
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responses that use technological mechanisms to obtain food without caloric expenditure
(see Figure 3 below).

Figure 3. Our obese planet
The obesogenic results of food delivery without the caloric costs of acquiring prey
and evading predators is observed in the weight gain of non-human animals taken from
their natural habitats into zoological parks, homes, and labs, where food is ubiquitous and
divorced from effort (Klimentidis et al. 2011; Power et al. 2001).
How did a planet historically ravaged by famine manage to transition to a food
ubiquitous one? The discovery of an artificial nitrogen fixation process, the Haber-Bosch
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process, by German chemists during World War I, was indispensible in the production of
crops that increased the capacity of the world's food supply and resulted in a population
explosion where in a little over a century, Homo sapiens multiplied from 1.6 billion in
1900 to over 7.4 billion today (Smil 1999). Through a process which converts
atmospheric nitrogen (N2) to ammonia (NH3) by a reaction with hydrogen (H2) using a
metal catalyst under high temperatures and pressures (N2 + 3H2 → 2NH3), nitrogen is
dissociated, and then bonded to hydrogen or oxygen to form inorganic compounds,
primarily ammonium (NH4) and nitrate (NO3) (Vojvodic et al. 2014). The amount of
nitrogen extracted from the atmosphere by the Haber-Bosch process applied to crops
during the decade from 1980 to 1990 is greater than that from all industrial fertilizer
applied previously in human history. It now produces more than 450 million tons of
nitrogen fertilizer per year, and nearly 80% of the nitrogen found in human tissues
originated from the Haber-Bosch process. In combination with pesticides, the HaberBosch process has quadrupled the productivity of agricultural land (Smil 1999; Erisman
et al. 2008).
Food ubiquity has also emerged globally partly because of economic trends such
as a shift in the early 1980s by investors from blue chip companies to food manufacturers
and distributors. This shift pressured these entities to generate short term profits by
increasing output and consumption through larger portion sizes, aggressive marketing,
and value added strategies such as increased food processing and the addition of sugar,
salt, and fat. The cost of fat and sugar are traditionally low cost commodities
(Drewnowski 2000; Drewnowski, 2007) and this low cost, as well as their ability to
activate the dopaminergic motivational circuits to crave high energy density foods,

20

facilitates their utilization to increase perceived value. Due to the mathematical pressures
of fusion and first mover advantages, increasingly oligarchic and monopolistic food
conglomerates have emerged which have repeatedly selected these value-added strategies
to increase market share. For instance, over 20 cents of every food dollar spent in the
U.S. is spent at Walmart, and more than half US grocery market is controlled by only six
retailers (Moss 2013). These economic forces favor the widespread addition of
adipogenic food compositions such as sugar and fat (Moss 2013).
As a result of these forces, the United States food supply (total food produced,
less exports, plus imports) now provides 500 kcal/day per capita more than in the 1970s.
This increased food availability is matched by increased consumption.
Consumption of refined sugar has skyrocketed. Whereas our genes developed in a
Paleolithic environment where one person likely consumed at most 2 kilograms (4
pounds) of honey a year, human sugar consumption rose to 5 kilograms (11 pounds) a
year in 1830, and 70 kilograms (150 pounds) by the year 2000 (Cordain et al. 2005).
Food consumption of the high energy density foods represented 18% of the
calories consumed per capita in the United States in 1977 but 27.7% of total caloric
intake in 1996 (Nielsen and Popkin 2003). Between 1977 and 2002, consumption of
pizza in the United States increased by 425%, and bread is now the number one source of
carbohydrates in children (Subar et al. 1998).
A shift in cereal composition occurred in 1949 when Post became the first brand
to add a sugary coating to their product called Sugar Crisp. Kellogg and General Mills
followed suit, and sugary cereals became the norm, replacing breakfasts traditionally
cooked by mothers who increasingly joined the workforce (Moss 2013). Cereal sales
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rapidly increased from $660 million in 1970 to $4.4 billion by the mid-1980s, and
companies aggressively marketed to promote the norm of highly processed conveniencebased meals as opposed to traditional home-cooked meals (Moss 2013).
During World War II, Coca-Cola President Robert Woodruff implemented a
policy that all American soldiers, regardless of where they were stationed could purchase
Coke for the discounted rate of five cents a bottle, thus establishing a post-war time habit
of sugary drink consumption in a generation of returning servicemen (Moss 2013). From
1970 to 1997, United States consumption of sugary soda had doubled to 54 gallons a year
(Isganaitis and Lustig 2005). From 1977 to 2002, consumption of soda in children
increased by 70% (Isganaitis and Lustig 2005). Soft drinks are the second leading source
of carbohydrates in children (Subar et al, 1998).
Government subsidies and policies also affect food ubiquity. For instance, since
the 1930s the United States government has subsidized dairy farmers (Blayney 2002).
The extracted milkfat is utilized for cheese and pseudo-cheese food products. In less than
four decades Americans tripled their consumption of cheese, eating on average 11 pounds
of cheese a year in 1970, but 33 pounds a year by 2007 (Moss 2013).
The shift in consumption quantity matches a shift in consumption composition. It
is estimated that 56 percent of our calories come from three sources that were absent
when our genes were developing: refined, sugars, bleached flour, and vegetable oils (see
Figure 3 above) (Cordain et al. 2005).
The relative composition of omega-3 and omega-6 fatty acids in Homo sapien
food sources has recently and dramatically altered. Prior to the 1950s, cows were raised
in pastures and ate spring grass, a rich source of omega-3 fatty acids, which then became
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concentrated in dairy products consumed by humans. However, in the 1950s, demand for
dairy products and beef increased, reducing grazing areas, and pastures were replaced by
battery farming which utilized corn, soy, and wheat to feed cattle, all rich in omega-6s
(Weill et. al 2002; Ailhaud and Guesnet 2004). While omega-3s and omega-6s are
optimally balanced in the human body in a 1 to 1 ratio, milk from corn- and soy-fed cows
resulted in an imbalance in this ratio anywhere from 1:15 to 1:40 in favor of omega-6s
(Weill et al. 2002). Similarly, eggs from chickens raised on grass retained a 1:1 ratio, as
opposed to corn fed chickens whose eggs exhibited a 1:20 ratio in favor of omega-6s
(Simopoulos and Salem 1989). Additionally, over the last 100 years, Americans have
undergone an approximately thousand-fold increase in the amount of soybean in their
diet, a source of omega-6s (Blasbalg et al. 2011). Omega-3 fatty acids inhibit
adipogenesis and inhibit inflammation (Ailhaud and Guesnet 2004), and omega-6 fatty
acids promote adipogenesis (see Figure 3 above), as well as coagulation and
inflammation (Weill et. al 2002; Ailhaud and Guesnet 2004). Since the fatty acid
composition of mother's milk is determined by diet, an increase in the mother's diet of
adipogenic omega-6s likely led to the doubling of obesity in children under one between
1970 and 1990 (Jensen et al. 1978; Ailhaud and Guesnet 2004; Ailhaud et al. 2006).
Trans fatty acids, omega-6 oils altered to become solid at room temperature to
increase shelf life, are more inflammatory than regular omega-6s. Additionally, in a
cohort of 19,934 women, it was found that those with high serum levels of phospholipids
trans-palmitoleic and elaidic acids had a risk of breast cancer that was increased 50
percent to twofold in comparison with women with low serum levels (Chajes et al. 2008).
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Apart from fatty acid composition, dairy products have also been altered since the
1993 FDA approval of recombinant bovine somatotrophin (rbST), which increases yields
in cows by 10 to 20 percent. rbST increases bovine IGF-1, and high levels of IGF-1 has
been linked to increased risk of prostate cancer in men and breast cancer in
premenopausal women (Renehan et al. 2004). It is unclear whether any significant
amount of bovine IGF-1 is absorbed in the human bloodstream (Renehan et al. 2004).
Another novel dietary component, high fructose corn syrup, emerged in the
1970s, when rising prices of cane and beets, the two main sources from which sugar was
derived, triggered the search for an alternative. Economically cheap to produce due to
government subsidies on corn, the liquid nature of high-fructose corn syrup enabled it to
be easily added to both food and drinks (Moss 2013). Consumption of sugar-sweetened
soda doubled between 1970 and 2005, and Americans now consume 40 gallons of sugary
soda a year and 71 pounds of caloric sweeteners on average each year (22 teaspoons of
sugar, per person, per day) (Moss 2013). In less than two decades, from 1978 to 1995,
consumption of high-fructose corn syrup in the United States increased from 80 to 132
kcal/day per person (see Figure 3 above) (Johnson et al. 2009). Fructose ingestion
produces smaller increases in circulating satiety hormones compared with glucose
ingestion (Page et al. 2013). Unlike glucose ingestion, fructose ingestion does not result
in deactivation of the striatum, which occurs when initially hungry individuals reach
satiety (Page et al. 2013; Small et al. 2001). Additionally, the hippocampus, the activation
of which consolidates memories and also promotes satiety, showed reduced activity upon
ingestion of fructose (Page et al. 2013; Volkow et al. 2011; Horne et al. 2010).
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1.2.2.2. Change in Eating Norms
Between 1972 and 1995 the United States population increased by barely a third,
but the number of restaurants nearly doubled and the number of fast food restaurants
nearly tripled. During this time period, the percent of calories contributed to our diets by
eating outside of the home increased from 18% to 34%. (Bowman et al. 2004; Bowman
and Vinyard 2004).
This shift towards eating outside of the home was accompanied by an increase in
portion sizes: an increase in daily energy intake of 179 kcal a day by United States
children and adolescents, was associated with an increase from 23.4% to 33.9% of
calories eaten outside the home (see Figure 3 above) (Piernas and Popkin 2011).
A meta-analysis of 72 studies demonstrated that people consistently eat more food
when offered larger portion sizes (Hollands et al. 2015). Additionally, those offered
larger portion sizes do not compensate by eating less during a subsequent meal (Wansink
and Park 1996; Rolls et al. 2004).
1.2.2.3. Movement Deficit
It has been estimated that our energy expenditure per unit of body mass is at less
than 38 percent of that of our Paleolithic ancestors (Cordain et al. 1998). As would
appear obvious, sedentary behaviors are independently and longitudinally associated with
overweight and obesity (see Figure 3 above) (Su et al. 2017).
Another momentous population shift has accompanied the transition from a
famished to an obese planet: in 2009, for the first time in human history, the number of
people living in urban areas (3.42 billion) surpassed the number living in rural areas (3.41
billion). This shift in activity is exacerbated by the exodus from rural to urban
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communities, where individuals are far more likely to engage in occupations divorced
from physical exertion (Popkin, 2001; Prentice, 2005).
This migration was accompanied by the development of transportation technology
and infrastructure which increasingly made human exertion less necessary.
From1980 to 1990, widely publicized kidnapping incidents in the United States
decreased the numbers of children who walked to school from over 80% to less than
33%.
The increasing sophistication of video game technology and the birth of social
media and mobile electronic devices served as technological distracters of our attention.
While we once satisfied dopaminergic motivational circuits through movement to find
food and physical games which likely first originated to hone group hunting skills, we
now receive dopaminergic stimulation through awards obtained by electronic avatars who
move through vast worlds and realms, while we sit in stasis, moving only our fingers.
In 2016 a rare instance of entertainment technology increasing movement
occurred that may be a harbinger of a norm of augmented and virtual reality exercise
based games in the future. The augmented reality game, called Pokemon Go, increased
the activity level of participants by 1473 steps a day on average, a more than 25%
increase compared with prior activity level. In only 30 days, the game added a total of
144 billion steps to US physical activity levels (Althoff et al. 2016). Fittingly, the game's
objective was to track and hunt virtual creatures, a calorie consuming activity more than a
little reminiscent of the persistence hunting of days long past.
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1.2.2.4. Overactivation of the Hypothalamic-Pituitary-Adrenal Axis
Because of cognitive modules that allow us to imagine far into the future and
ruminate into the past, Homo sapiens now experience chronic activation of the
hypothalamic-pituitary-adrenal (HPA axis) threat response system to nonphysical threats
that do not engender physical defensive responses. Like our ancestors, cortisol is released
which stimulates lipid and carbohydrate metabolism and leads to increased blood glucose
levels, insulin, neuropeptide Y, and CRH release, which stimulate increased appetite. In
the environment in which our genes evolved, this made a kind of elegant evolutionary
sense: a threat engendered a physical response which triggered the hunger mechanism in
a feedback loop to replace the calories expended from the physical response. However,
when we react to what we perceive as stressful situations in modernity which do not
physically challenge us by activating our threat response system, we trigger a hunger
reflex without the accompanying caloric expenditure. The result is a tendency towards a
positive energy balance and increased adipose tissue accumulation (see Figure 3 above).
In Cushing's Syndrome, the same chronic activation of the HPA axis is observed, and
obesity is the most common resulting symptom.
1.2.3. The Mismatch Paradigm Part 3: Other Changed Conditions of our Modern
Environment
1.2.3.1. Sleep
In 1960, sleep duration of adults in the United States averaged 8.5 hours.
However, by 2008, adults were averaging 6.8 hours of sleep a night with one in three
adults routinely sleeping fewer than 6 hours a night (Kripke et al. 1979; Swanson et al.
2011). Sleep restriction results in physiological dysfunctions, including those associated
with obesity, such as decreased glucose tolerance, decreased insulin sensitivity, increased
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evening concentrations of cortisol, increased levels of ghrelin, decreased levels of leptin
and increased hunger and appetite. Sleeping less than 6 hours per night doubles the risk
of developing type 2 diabetes in men (Yaggi et al. 2006).
Normally, leptin, a satiety hormone secreted by adipocytes, is mainly dependent
on caloric intake, exhibits a morning minimum and increasing levels throughout the day
culminating in a nocturnal maximum. Ghrelin, a hunger inducing hormone release
primarily from stomach cells, is also higher during the night, but decreases during the
second part of the night suggesting an inhibitory effect of sleep on hunger. During this
second part of the night, leptin levels reach their maximum, also acting to inhibit hunger.
The normal circadian profile of cortisol consists of an early morning maximum,
declining levels throughout the day, a minimal level during the first part of the night, and
an abrupt rise during the later part of the night.
In a study of where participants were deprived of only two nights of full sleep (4
hours total sleep each night), the sleep deprived group exhibited a 18% decrease of leptin
levels and a 28% of ghrelin levels compared to a non-sleep deprived group (10 hours
sleep per night) (Spiegel et al. 2004; Taheri et al. 2004). Growth hormone was also
elevated during waking which could have an adverse impact on glucose metabolism.
Sleep loss also altered pancreatic beta cell secretion so that the cells did not respond to
insulin resistance with increased insulin secretion (Schmid et al. 2007). Subjects
experienced a 24% increase in hunger with a 32% increase in appetite for carbohydrates
(see Figure 3 above) (the nutrient most affected) (Spiegel et al. 2004). Reduced sleep
quality, without change in sleep duration, can also have adverse effects on glucose
metabolism (Tasali et al. 2008).
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1.2.3.2. Social Networks
Obesity exhibits a pattern of contagion through social networks: the chance of
becoming obese increases by 57% if a person has a friend who becomes obese, by 37% if
he or she has an obese spouse, and 40% if a person has an obese sibling (see Figure 3
above) (Christakis and Fowler 2007). Independent of geographical distance, up to three
degrees of separation, individuals with obese friends are more likely to become obese
than would be predicted by chance alone. Mechanistically this phenomena may be due to
behavioral imitation (consciously or through the mirror neuronal system), or through the
shifting of norms (Christakis and Fowler 2007).
Is this propensity for obesity to spread through social networks augmented by
technology that serves as a memory prosthetic to increase social group size? It's
hypothesized that primate brain size correlates with long term memory capacity and that
this serves as an upper limit on the size of a social group that a particular species can
comfortably maintain (Dunbar 1992). Dunbar's number postulates this number to be
approximately 150 for Homo sapiens (Dunbar 1992), while the Bernard Killworth
estimate is 231 (Bernard et al. 1987). If the significant cognitive module is long term
memory capacity, then memory prosthetics such as social media services should augment
the number and thus exacerbate the three degrees of separation effect by increasing the
overall size of the network. Preliminary research has not demonstrated such a group size
extension (Goncalves et al. 2011), but it seems plausible that memory prosthetic
technology that current in widespread use such as online social networks, as well as
emerging technology such as brain-computer interfaces will increase interconnectivity
and make individuals more susceptible to norms, including obesogenic ones.
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The combustible mixture of modern feeding trends combined with a more
sedentary world, and the technological and social forces that cement these two primary
drivers together, are spreading to the developing world. Currently, 62% of the world's
obese population live in developing countries (Ng et al. 2014).
1.2.4. How Environmental Mismatch Affects Health
1.2.4.1. Hypothesized Thrifty Gene Categories
What functions could genes in this hypothesized thrifty genotype affect?
Bouchard suggested five categories of thrifty genes: those associated with appetite,
metabolism or thermogenesis, predisposition for physical activity, adipocyte lipid storage
capacity, and lipid oxidation rate (Bouchard 2007). Additionally, genes that are
associated with adult BMI have been linked with infant growth, pubertal timing and
insulin metabolism (Elks et al. 2010, Hattersley et al. 1998). These genetic transitions are
not detrimental to health in isolation, but as the mismatch theory postulates, when
combined with our modern day environmental niche, increase risk for a multitude of
pathogenic conditions.
1.2.4.2. Physical Conditions: Diabetes, Cancer, Surgical Risk
Tumor metabolism is dependent on glucose consumption: rapid consumption of
glucose is characteristic of multiple kinds of neoplasms (Coller 2014). In fact, excess
glucose consumption is so indicative of tumors, that primary and metastatic lesions can
be identified with a specificity and sensitivity near 90% by using the imaging agent 2[18F]fluoro-2-deoxy-d-glucose, coupled with positron emission tomography (PET)
(Czernin and Phelps 2002).
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The global increase in consumption of high glycemic index foods increases the
population wide propensity for rapid release of insulin and insulin-like growth factor
(IGF), which stimulate cell growth, promote inflammatory factors, and increase the
capacity of tumors to invade neighboring tissue (Grothey et al. 1999; Long et al. 1998).
When BALB/C mice were injected with an aggressive mammary tumor and placed on
three different dietary regimens, mortalities 70 days after injection were 16 of 24 for the
hyperglycemic diet, 8 of 24 for the normoglycemic diet, and 1 of 20 for the
hypoglycemic diet (Santisteban et al. 1985). In prospective studies with humans, high
glycemic diets were associated with cancers of the pancreas, colon, and ovaries (Michaud
et al. 2005; Augustin et al. 2003). These results seem to mirror epidemiologic cancer
statistics where those who eat low sugar Asian diets tend to have five to ten times fewer
hormonally driven cancers than those eating western diets with high glycemic index
foods (Parkin et al. 2005). In women under fifty, those with the highest levels of IGF
were approximately seven times more likely to develop breast cancer than those with the
lowest (Hankinson et al. 1998), and the risk for men with the highest levels of IGF were
approximately nine times of developing prostate cancer (Chan et al. 2002).
In a massive study of over 161,801 healthy postmenopausal women, women with
the higher insulin levels (who were not diabetic or taking hormone replacement therapy),
had almost twice the risk of developing breast cancer within the six year study period
compared to those with lower levels (Gunter MJ et al. 2008). These results mirror the
finding that those with diabetes, which is characterized by high glucose and (if pancreatic
beta cells remain functional) high insulin levels, have increased risk for cancer
(Weiderpass et al. 1997). Additionally, obese individuals have significantly elevated
serum concentrations of pro-inflammatory cytokines IL-5, IL-10, IL-12, IL-13, IFNγ and
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TNF-α (Schmidt et al. 2015). Inflammation depressed immune response may be the
mechanism behind lower vaccine efficacy: for instance, there is an approximately
eightfold increase in the odds of non-responsiveness to hepatitis-B vaccination in obese
versus normal-weight women (Young et al. 2013)
1.2.4.3. Mental Health Conditions
A meta-analysis of studies which included 55,387 individuals, found significant
bidirectional associations between depression obesity (Luppino et al. 2010). Obese
persons had a 55% increased risk of developing depression over time, whereas depressed
persons had a 58% increased risk of becoming obese (see Figure 1 above) (Luppino et al.
2010).
In addition to social and psychological bidirectional factors, physiological
dsyregulation resulting from the obesogenic phenotype, such as increased inflammation,
may have a causal relationship with depression onset. Obese individuals have elevated
levels of pro-inflammatory cytokines (Schmidt et al. 2015) and patients with
inflammatory medical conditions have elevated rates of depression (Shelton and Miller
2010). Patients with inflammatory conditions who are depressed also have upregulated
inflammatory markers compared with patients with these conditions who are not
depressed (Shelton and Miller 2010). Additionally, when the inflammatory cytokine
IFNα is administered to treat diseases such as hepatitis C and malignant melanoma, it
induces depressive symptoms in previously asymptomatic individuals (Loftis et al. 2004).
When TFNα is inhibited, symptoms of depression are reduced in those with inflammatory
disease (Shelton and Miller 2010). Mechanisms involved in a pro-inflammatory response
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such as serotonin depletion, dopamine depletion, and NMDA receptor activation, also
mirror hypothesized mechanistic models for depression(Shelton and Miller 2010).
Other obesogenic mechanisms may also contribute to bidirectional depression
causality. Depression is associated with over activation of the HPA axis. This increases
levels of cortisol, which in the presence of insulin, inhibits lipid-mobilizing enzymes.
This chronic HPA activation could exacerbate lipid storage, especially intra-abdominal
visceral fat, and contribute to the obesogenic phenotype (Björntorp 2001).
As exercise increases pro-tropic brain factors such as FGF-2, VEGF and BDNF,
as well as atrial natriuretic peptide (ANP) which inhibits the HPA axis (as does the
exercise induced increase in the resting tension of muscle spindles), a mechanistic
relationship between consistent movement and the diminution of depression and other
mental health symptoms seems evident (Shafia et al. 2017; Krzeminski 2016; Zhao et al.
2016).
1.3. The Neuroscience of Obesity: How we got Addicted
Hunger is regulated by a motivational reward system which includes
dopaminergic projections emanating from the ventral tegmental area to the nucleus
accumbens (Erlanson-Albertson 2005; Kelley and Berridge 2002; Koob and Le Moal
2005). The hypothalamus, striatum, orbitofrontal cortex, amygdala, and insula are also
implicated in this system (Morton et al. 2006). Endorcrine satiety signals such as high
levels of leptin and low levels of ghrelin can be over ridden due to the palatability of
available food (Pelchat 2002).
Pain and an elevated HPA response to stress can increase perceptions of hunger
and caloric intake, perhaps acting as evolutionary heralds for the possibility of imminent
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periods of food shortage and the resulting need to obtain rapid nutrients to use for
defensive threat responses or to increase adipose stores. Participants in one experiment
ate more sweet-tasting food following a painful experience than they did after a nonpainful experience (Darbor et al. 2016). And in a study of 9 year old children, children
who were more stressed by laboratory challenges, also increased consumption of sweettasting foods (Roemmich et al. 2002).
If some are more likely to turn to eating in times of pain and stress, can over
eating be considered an addictive behavior? The evidence is mixed and the conception of
eating as an addiction is complicated by the fact that unlike other common addictive
behaviors like gambling and drug use, continual satisfaction of the hunger urge is
necessary for survival.
Still, substantial hallmarks of an addictive paradigm are evident: as in other
addictions, anticipation for the reward of food is modulated through the dopaminergic
nucleus accumbens-ventral tegmental axis, and dopamine release results in downstream
subjective feelings of pleasure that are rewarding and reinforcing (Abizaid et al. 2006;
Hyman et al. 2006; Wise and Bozarth 1985). Blocking dopamine receptors increases
appetite and causes weight gain, which suggests that overeating may be a means of
compensation of the blunting of pleasurable responses (Del Parigi et al. 2003).
The molecular evidence reveals that obese individuals have fewer dopamine
subtype 2 (D2) receptors (Wang et al. 2001). A chicken and egg quandary emerges here
as at least two causal possibilities emerge. One possibility is that normal weight
individuals initially possess fewer D2 receptors and eat more to achieve baseline levels of
pleasure from food resulting in obese phenotypes (Wang et al. 2001; Stice et al. 2008).
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Another alternative is that normal weight individuals originally had normal levels of D2
receptors but upon chronic overeating, overstimulate their D2 receptors which lead to
their downregulation (Wang et al. 2004). It is noteworthy that within obese individuals,
the number of D2 receptors is inversely correlated with increasing BMI (Wang et al.
2001). Additionally, D2 receptor density is significantly decreased in chronic drug and
alcohol users (Volkow and Fowler 2000). Future research could begin to resolve these
issues by measuring D2 receptor density in a normal weight cohort, following the cohort
over time, and comparing D2 levels in those that became obese versus those who
remained normal weight.
Evidence also points to the possibility that many obese individuals utilize food
consumption as a substitute for substance addiction. There is an extremely high lifetime
history of any substance use disorder (32.6%, which is over twice that in the general
population) in currently obese patients who are candidates for bariatric surgery
(Kalarchian et al. 2007; Kessler et al. 2005). However, only 1.7% of these currently
obese patients report a current substance abuse disorder (Kalarchian et al. 2007). . It is
plausible that some normal weight individuals who were substance abusers, switched to
food addiction and dropped their substance addiction as they remained obese and
continued their habits of over consumption (Kalarchian et al. 2007).
Obese people also have higher metabolic activity in the bilateral parietal
somatosensory cortex in the regions where sensation to the mouth, lips and tongue are
located (Wang et al. 2002). This raises similar questions to the D2 issue since it remains
to be determined whether this increased somatosensory sensitivity is a cause, effect, or
mere correlate of obesity.
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1.4. The Environment of Obesity: Obesogens, Viruses, Bacteria, and Epigenetics
1.4.1. Obesogens
Obesogens, chemicals in the environment that inappropriately stimulate
adipogenesis and/or triglyceride storage into existing adipocytes (see Figure 3 above),
have been found to have transgenerational effects. Multigenerational phenotypic effects
are effects observed in F1 and F2 offspring, and may be due to in utero exposure to a
chemical. However, with transgenerational (F1 to F3 and beyond) effects, the F3
organism was never exposed to the chemical. Thus an in utero mechanism is impossible.
As the Sherlock Holmes adage states "Once you eliminate the impossible, whatever
remains, no matter how improbable, must be the truth" (Doyle 1890). Having eliminated
the in utero mechanism, what remains is an epigenetic mechanism of transmission (Grens
2015; Stel 2015).
Transgenerational effects of obesogens in rats have been observed with
diethylhexyl phthalate and DDT. These and many other obesogens work by acting as
high affinity ligands for
for two nuclear receptors critical for adipocyte development: the 9-cis retinoic
acid receptor (RXR) and peroxisome proliferator activated receptor gamma (PPARγ)
(Holtcamp 2012).
Expression of PPARγ commits cells to the adipogenic lineage whereas Wnt
signaling inhibits PPARγ expression and diverts mesenchymal stem cells toward the
osteogenic lineage. Tributyltin, another obesogen with transgenerational effects persisting
at least to the F3 generation, acts upon this PPARγ pathway, and suppresses Wnt
signaling to divert stem cells to an adipogenic fate (Holtcamp 2012).
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What is the precise mechanism for these obesogenic epigenetic changes? The
scientist that coined the word "obesogen", Dr. Bruce Blumberg, wrote recently that
"nothing is currently known about how obesogen exposure causes heritable changes in
the genome that alter mesenchymal stem cell fate" (Grens 2015).
However, we can speculate from the evidence available to us. In addition to DNA
methylation (5-meC), 5′ hydroxymethylation at cytosines (5-hmeC) plays a crucial role in
stem cell differentiation. During the adipocytic differentiation of 3T3-L1 preadipocytes,
PPARγ recruits Tet enzymes to its binding sites in adipogenic gene promoters causing
local demethylation, decreased 5-meC and increased 5-hmC (Stel et al 2015). It is
therefore likely that these two methylation processes are implicated in these observed
obesogenic transgenerational effects. As endocrine disrupting chemicals have also altered
epigenomes through histone tail modifications (Li et al. 2010), this may also prove a
fruitful area of obesogenic epigenomic transgenerational research.
Additionally, recently it has been found that many epigenetic changes are harmful
only in the present of concomitant nucleotide base mutations in functionally relevant
genes (Janesick 2014). Therefore, any future attempts at elucidating a mechanism would
be well advised to include the interplay between both the genome and epigenome.
1.4.2. Viruses
In one study, adenovirus-36 (Ad-36) antibodies were found in 30% of obese
versus 11% of nonobese humans (see Figure 3 above) (Atkinson et al. 2005). BMI
amongst both obese and nonobese participants was significantly and directly related to
levels of Ad-36 antibodies (Atkinson et al. 2005). If individuals become obese first and
then acquire Ad-36, one would expect lower antibody levels than those in the nonobese
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population, since obese individuals are often immune suppressed (obese people
vaccinated with hepatitis B virus have a reduced prevalence of antibodies) (Atkinson et
al. 2005). In an in vitro study utilizing 3T1-L1 preadipoyctes, cells infected with Ad-36
differentiated much faster and accumulated triglycerides more rapidly than those infected
with a control virus, Ad-2 (Vangipuram et al. 2004). In a study utilizing male Wistar rats,
inoculation with Ad-36 significantly increased body weight and foot pad weight
compared to controls, and increased expression of pro-adipogenic markers PPAR gamma,
and C/EBPα and β (Pasarica et al. 2006). The Ad-36 viral E4 orf-1 gene stimulates proadipogenic differentiation in both 3T3-L1 and human adipose stem cells (Rogers et al.
2008).
1.4.3. Bacteria
Administration of Lactobacillus reuteri ATCC PTA 4659 was associated with
weight decrease in mice, whereas the administration of L. reuteri L6798 was associated
with weight gain (see Figure 3 above) (Fak and Backhed 2012).
Staphylococcus aureus in feces was found to increase obesity risk during
development and pregnant overweight women have higher concentrations of this
bacteria. This may increase the risk of obesity in these women's offspring due to a
vertical transfer of bacterial populations during birth or rearing (Kalliomaki et al. 2008).
Mice deficient in G-protein-coupled receptors were more likely to have higher
concentrations of B. thetaiotaomicron and M. smithii and are leaner than those with lower
concentrations of these bacteria. (Samuel et al. 2008; De Silva and Bloom 2012).
The presence of Akkermansia muciniphila is also associated with leanness in mice
(Dao et al. 2016; Chakraborti CK 2015).
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1.4.4. Epigenetics
The powerful historical example of the Dutch Hunger Winter of 1944-1945, the
German blockade of the West Netherlands until May 1945, illustrates the important role
of maternal nutrition in offspring adult-onset obesity (Ravelli et al. 1998). Similar effects
were observed in Mao Tse Tung's "secret famine" of 1958-1962 (Li et al. 2010). In the
Netherlands example, approximately 20,000 individuals starved to death and some
mothers were rationed down to 30% of their normal daily caloric intake (Ravelli et al.
1998; Li et al. 2010).
Babies whose mothers were malnourished during the first three months of
pregnancy had a dramatic increase in adult obesity and a decrease in mental functioning
with increased prevalence of schizophrenia, a disorder with an amalgam of symptoms
often characterized by paranoia and auditory hallucinations with a .5-1% global
prevalence with over 50 times the likelihood of attempted suicide. Schizophrenia has a
50% concordance in monozygotic twins (almost three times higher than the 17%
concordance in fraternal twins, illustrating the significance of the epigenome) (Brown
and Susser 2008).
In a way, maternal nutritive epigenomic effects mirror the effects of the mismatch
hypothesis of obesity albeit on a much shorter time scale and via a different mechanism
(genetic versus epigenetic changes). The mismatch paradigm states that our metabolic
and motivational circuits evolved in a niche of food scarcity with intermittent access to
high density foods that could be obtained only through high calorie expending activities
(Neel 1962). The transition from a niche of food scarcity where this reward circuit was
highly sensitive to the pursuit and acquisition of high energy density foods to the modern
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environment of food surplus is the crux of the mismatch paradigm (Neel 1962). Likewise,
an early fetal environment of scarcity mismatched with a post-natal environment of
surplus.
The best studied animal model of maternal epigenetic transmission of obesity due
to nutritional deprivation is feeding pregnant rats a protein restricted (PR) diet. Feeding a
protein restricted diet to pregnant rats (F1 generation) increased glucocorticoid receptor
(GR) expression and reduced expression of 11b-hydroxysteroid dehydrogenase type II,
the enzyme that inactivates corticosteroids, in the liver, lung, kidney and brain of the
offspring (F2 generation) (Bertram et al. 2001). Increased GR activity in the liver upregulates phosphoenolpyruvate carboxykinase expression and activity and so increases
capacity for gluconeogenesis which may contribute to the induction of insulin resistance,
with resulting risk for obesity (Burns et al. 1997).
There is also evidence that feeding a PR diet to pregnant rats up-regulates
glucokinase expression in the liver of the F2 generation, increasing capacity for glucose
uptake (Bertram et al. 2001).
PPARα expression has also been reported to be increased in the liver of the
offspring of rats fed a PR diet during pregnancy and was accompanied by up-regulation
of its target gene acyl-CoA oxidase (Burdge et al. 2007). This is particularly interesting
because PPARα ligands can also bind to PPARγ which, and if such binding occurred
during a critical developmental window, could trigger mesenchymal stem cells to favor
an adipogenic as opposed to an osteogenic lineage (Burdge et al. 2007).
The major epigenetic processes that effect this expression or inhibition of genes
are DNA methylation, histone modification and microRNA (Carey 2013). What is the
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evidence for these mechanisms in maternal transgenerational transmission? It has been
reported that feeding pregnant rats a PR diet-induced hypomethylation of the GR and
PPARα promoters in the livers of juvenile and adult offspring, which was accompanied
by increased mRNA expression of these genes (Slater-Jefferies et al. 2011). This was
associated with an increase in histone modifications at the GR promoter that facilitate
transcription including acetylation of histones H3 and H4 and methylation of histone H3
at Lys4, while those that suppress gene expression were reduced or unchanged (SlaterJefferies et al. 2011). The altered methylation pattern of the PPARα promoter in the liver
was due to hypomethylation of four specific CpG dinucleotides, two of which predicted
the level of the mRNA transcript, in F2 generation and which persisted through adulthood
(Slater-Jefferies et al. 2011; Okamura et al. 2010).
In human subjects, hypomethylation of the imprinted insulin-like growth factor-2
gene in genomic DNA isolated from whole blood from individuals who were exposed to
famine in utero during the Dutch Hunger Winter compared to unexposed same-sex
siblings (Heijmans et al. 2008). Additionally, insulin-like growth factor promoter was
hypomethylated in individuals whose mothers were periconceptually exposed to famine,
while IL-10, leptin, ATP binding cassette A1 and the guanine nucleotide-binding protein
were hypermethylated (Tobi et al. 2009).
Histone methylation, catalyzed by histone methyltransferases and reversed by
histone demethylases, has a crucial role in promoting or inhibiting adipogenesis and
obesity (Takeda et al. 2009).
The nuclear receptor peroxisome proliferator-activated receptor γ (PPAR-gamma)
triggers mesenchymal stem cells to favor an adipogenic as opposed to an osteogenic
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lineage. It is crucial for adipocyte differentiation and is expressed approximately 48 hours
post induction of preadipocytes with differentiation factors such as IBMX,
dexamethasone and insulin. Histone methyltransferases are implicated in PPARγ gene
expression and subsequent adipogenesis. In addition, demethylation of histone H3 at lys9
is associated with resistance to obesity (Okamura et al. 2010).
H3K9 methylation by histone methyltransferase (HKMTs) has been shown to
trigger heterochromatin formation and transcriptionally silence euchromatic regions. Two
HKMTs, Setdb1 and Setd8 are regulated by PPARγ and that their expression leads to
adipocyte differentiation through chromatin modification (Okamura et al. 2010). Setdb1
tri-methylates histone H3K9 while Setd8 mono-methylates histone H4K20. Knockdown
studies show that Setdb1 acts as an anti-adipogenic factor and Setd8 acts as proadipogenic factor. It appears that PPARγ downregulates Setdb1 and upregulates Setd8
(Okamura et al. 2010). In contrast to PPARγ's effect on Setdb1, noncanoical Wnt5a
activates Setdb1 which can drive mesenchymal stem cells down an osteogenic, as
opposed to adipogenic lineage (Takada et al. 2009; Takada et al. 2012).
Transcription factors and chromatin modifying enzymes such as MLL3/4, PTIP,
Wnt/β-catenin signal are associated with altered H3K4 methylation states in the
promoters of PPARγ, CEBPα (Lee et al. 2003). Like PPARγ, CCAAT/enhancer-binding
Proteins (C/EBPs) also play an important role in adipocyte differentiation. CEBPα in
particular, is a key early regulator of differentiation. Activating signal cointegrator-2
(ASC-2), a component of a Set1-like complex named ASCOM (for ASC-2 complex)
which possesses H3K4MT activity, exerts pro-adipogenic function by acting as a
coactivator of both C/EBPα and PPARγ (Viswakarma et al. 2010).
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Two other H3K4MTs, MLL3 and MLL4, are recruited by the PPAR-gamma
activated gene aP2 (along with ASC-2 and ASCOM) (Lee et al. 2003). Additionally, the
histone methylation regulator PTIP (Pax transactivation domain-interacting protein), a
component of the histone lysine methyltransferase (HKMT), that also contains the
aforementioned histone H3K4 methyltransferases MLL3 and MLL4, is also required for
the expression of both PPARγ and C/EBPα (Yongson and Morris 2013).
Canonical Wnt/β-catenin signaling prevents activation of PPARγ and CEBPα by
activating the expression of the nuclear receptor Coup-TFII which in turn recruits the
SMRT co-repressor complex to the first introns located downstream from the first exons
of both PPARγ1 and γ2 mRNAs, maintaining the local chromatin in a hypoacetylated
state accompanied by the repression of H3K4me3 and thereby represses expression of
PPARγ (Jeong et al. 2014). COUP-TFII also inhibits the C/EBPα promoter (Jeong et al.
2014).
The histone demethylase (H3K9 demethylase) JHDM2a has protective effects
against obesity and directly targets PPAR-alpha and Uncoupling protein 1 (Ucp1) (in
skeletal muscle and brown adipose tissue), crucial genes in metabolism, and may
downregulate β-adrenergic signaling (Tateishi K et al. 2009).
1.5. The Fundamentals of Adipogenesis
1.5.1. Types of Adipocytes
The result of these ecological, societal, and psychological changes in food
consumption and movement frequency is the accumulation of adipocytes, the lipid cells
which comprise the majority of adipose tissue. The two primary classifications of adipose
tissue are white adipose tissue, and brown adipose tissue, which have different origins,

43

structures, and functions. Other classifications of adipose tissue include beige adipocytes
and pink adipocytes. The origins of beige adipocytes, (where white adipocytes take on
some of the characteristics of brown adipoyctes such as multiocularism) are
controversial, with the two competing theories of origin consisting of the existence of
precursors in white adipose tissue (Wu et al. 2013) and transdifferentiation (a process
whereby one mature somatic cells transforms into another mature somatic cell without
undergoing an intermediate pluripotent state) (Wu et al. 2013). Pink adipocytes have been
recently been characterized in mouse subcutaneous fat depots during pregnancy and
lactation and consist of mammary gland alveolar epithelial cells (Giordano et al. 2014).
White adipose tissue consists of the majority of lipids present in adult humans and
is utilized as an energy depot (Farmer et al. 2008), whereas brown adipose tissue
primarily functions to produce heat through nonshivering thermogenesis. The differing
processes by which white and brown adipocytes store and metabolize lipids, reflect these
differing functions. White adipocytes accumulate triglycerides then release them via
lypolysis during periods of caloric deficit (Farmer et al. 2008). Brown adipocytes oxidize
their lipid stores in a heat-producing pathway utilizing the mitochondrial uncoupling
protein (UCP), UCP1 (Golozoubova et al. 2001). Mitochondrial uncoupling proteins are
members of the family of mitochondrial anion carrier proteins (MACP) and facilitate the
transfer of anions from the inner to the outer mitochondrial membrane and the return of
proteins from the outer to the inner mitochondrial membrane. UCP1, highly expressed in
brown adipocytes, mediates the ability of brown adipose tissue to produce adaptive heat:
UCP-1 deficient mice were unable to survive long-term exposure to cold temperatures in
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contrast to controls (Golozoubova et al. 2001). In contrast to brown adipocytes, white
adipocytes do not express UCP (Rajan et al. 2014).
It has been hypothesized that the primary role of brown adipose tissue is to
maintain body temperature equilibrium upon birth (Frontini and Cinti 2010). The
developmental biology of each primary kind of adipose tissue would support this: while
white adipose tissue begins to develop in late gestation, brown adipose tissue proliferates
primarily in utero. White adipocytes are larger than brown adipocytes and can range from
10 µm to 100 µm in size (Cinti 2005). White adipocytes increase with increased age of
the organism, while brown adipocytes decrease with increased age (Rajan et al. 2014).
Brown and white adipocytes contain a number of other opposing structural
characteristics: white adipocytes contain unilocular lipid droplets while brown adipocytes
contain multilocular lipid droplets (Rajan et al. 2014). White adipocytes possess lower
iron, mitochondria, and β3 adrenergic receptor concentrations than brown adipoyctes, and
are less sensitive to sympathetic nervous system innervations (Rajan et al. 2014).
Comparatively, white adipocytes have poorly developed capillaries and vasculature, and
area found in subcutaneous, visceral, and epididymal fat pads, while brown adipocytes
are found in the neck, supraclavicular, cervical, and paravertebral regions (Rajan et al.
2014).
Both brown and white adipocytes require key transcription factors to differentiate
successfully into mature adipocytes. For instance, adipocytes require the transcriptional
factor peroxisome proliferator-activated receptor γ (PPARγ) and factors from other
transcription factor families, including CCAAT/enhancer-binding proteins (C/EBPs),
signal transducers and activators of transcription (STATs) (a family comprised of seven
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proteins, when in response to stimulation primarily on cytokine receptors, and are
phosphorylated on tyrosine residues which initiates their migration into the nucleus), and
Kruppel-like factor (KLF) proteins (especially KLF15), which can induce adipogenesis in
non-precursor cells (Mori et al. 2005). Most of these regulators have been discovered in
vitro, utilizing the 3T3-L1 or 3T3-F442A murine preadipocyte cell lines.
Additional transcriptional families important for adipogenesis include SREBP-1,
and AP-1, a large group of transcription factors that include v-Jun, c-Jun, JunB, JunD, vFos, c-Fos, FosB, Fra1, Fra2, ATF2, ATF3/LRF1, and B-ATF (Kim and Spiegelman
1996).
Some transcription factors are particular to white adipose tissue while others aid
in differentiation of brown adipose tissue. For instance, the fibroblast growth factor
family members (which consist of herapin binding proteins) FGF 16 and 19 are
predominantly expressed in brown adipose tissue and are hypothesized to play a central
role in embryonic development of brown adipose tissue (Miyake 1998). Mice over
expressing FGF19 had increased brown adipose tissue mass and gain less white adipose
tissue after caloric excess when compared to controls. In contrast, FGF10 and FGF21 are
primarily expressed in white adipose tissue (Sakaue et al. 2002; Hata et al. 2003).
1.5.2. Stages of Adiopogenesis
While adipogenesis occurs primarily during childhood and adolescence, new
adipocytes are formed during the entire lifespan to replace dying adipocytes or to
increase the storage capacity of adipose tissue that results from an energy surplus (Gavin
et al. 2006). Obesity results from a significant expansion of white adipose tissue because
of adipogenesis resulting in hyperplasia (increased cell number). Additionally, the storage
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capacity of adipose tissue is also increased through adipocyte hypertrophy (increased cell
size) (Sun et al. 2011). In wild type mice, high fat diet feeding initially results in
hypertrophy during the first month, after which hyperplasia becomes the predominant
means of white adipose tissue expansion. Approximately 10% of adipoyctes are turned
over annually in white adipose tissue (Spalding et al. 2008).
While the majority of white adipocytes are thought to be derived from
mesenchymal progenitor cells, bone marrow derived progenitor cells can accumulate in
adipose tissue and differentiate into adipocytes in adults (Rodeheffler and Horowitz
2016). Initially, embryonic stem cells or mesenchymal stem cells from adipose tissue,
commit to become adipocyte precursor cells, and then differentiate into pre-adipocytes.
Cultured preadipocytes undergo proliferation, then express early markers of
differentiation (Cawthorn et al. 2012). Cell-to-cell contact may play a role in activating
mechanisms that induce early differentiation markers (Tong and Hotamisligil 2001).
The differentiation program in 3T3-L1 preadipoyctes is induced over the course
of approximately one week by the inducers dexamethasone (responsible for the
expression of C/EBPδ), isobutylmethylxanthin (IBMX) (responsible for the expression of
C/EBPβ), and insulin (stimulates the cells to take up glucose, which is stored in the form
of triacylglycerol) (Tang et al. 2003) (see Figure 4 below). Although C/EBPβ is
expressed within two to four hours after hormonal induction, it initially lacks the ability
to bind DNA until 10 to 16 hours after induction (corresponding to progression from
G1 to S phase, synchronous reentry into the cell cycle, and the beginning of mitotic clonal
expansion) (see Figure 4 below) (Lo et al. 2013). This progression into S phase requires
down-regulation of p27/kip1 in 3T3-L1 preadipocytes and the activation of cdk2 by
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cyclins E and A (Patel and Lane 2000). Various transcription factors regulate this early
growth arrested stage of adipogenesis, including Kruppel like factor 4 (KLF4) (expressed
with the first 30 minutes post-induction, and peaking at two hours post induction).
Knockdown of KLF4 downregulates C/EBPβ and inhibits adipogenesis (Birsoy et al.
2008). KLF5, KLF9 and KLF15 are also expressed early in the differentiation program. It
has been reported that over-expression of the dominant-negative KLF5 inhibits adipocyte
differentiation while over-expression of wild type KLF5 induces adipocyte differentiation
even in the absence of hormonal stimulation (Oishi et al. 2005; Pei et al. 2011; Mori et al.
2005).
Both dexasmethasone and insulin stimulate the expression of the cyclic AMP
response Element-binding protein (CREB) (Tang et al. 2003). It has been reported that
expression of the active form of CREB in 3T3-L1 preadipocytes is sufficient to induce
adipogenesis as seen by accumulation of triacylglycerols and expression of two adipocyte
marker genes, PPARγ and fatty acid binding protein (Reusch et al. 2000). Additionally,
transfection of 3T3-L1 preadipocytes with a dominant-negative form of CREB blocks
adipogenic differentiation (Reusch et al. 2000).
After growth arrest, adipocytes enter the mitotic clonal expansion stage, which
will be delineated in more detail in later sections of this review (Tang et al. 2003). Next,
adipocytes undergo terminal differentiation, where they express genes specific to the
mature adipogenic phenotype, become spherical, and accumulate lipid droplets, the
morphological hallmarks of mature adipogenic cells (see Figure 4 below) (Fei et al.
2011).
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Figure 4. The timing of adipogenesis
1.5.3. MAPK Signaling
1.5.3.1. Overview of MAPK Signaling
Adipogenic transcription factors perform their roles through the various acts of
adipogenesis within the context of the intricate signaling networks that are responsible for
equilibrium, adaptation, and transformation. The philosopher Jacques Derrida wrote that
"there is no meaning without context", and cells may interpret and process the multitude
of signals in the extracellular environment in different ways, depending on context.
Highly complex and tightly regulated signaling cascades have thus evolved to respond to
the information transmitted from the extracellular environment in the appropriate manner
(Tang et al. 2003). Activation of particular pathways generates a variety of responses;
short-term responses result in cytoplasmic changes, such as redistribution of proteins or
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cytoskeletal modifications, while long-term responses alter gene expression. Signaling
networks are composed of numerous proteins, which provide multiple levels of control
for the cell to regulate their response. One of the key players that has been found to play a
role in multiple signaling networks, including adipogenesis, are the family of mitogenactivated protein kinases (MAPKs). These proteins are involved in a diverse variety of
cellular processes that control cell proliferation, differentiation, motility, and survival
(Cargnello and Roux 2011). More than a dozen of these serine/threonine protein kinases
have been described in mammals and include extracellular signaling regulated kinases 1
and 2 (ERK1/2), p38 MAPK (p38) and c-Jun amino-terminal kinases 1,2 and 3 (JNKs);
ERK3/4, ERK5, ERK7/8 and Nemo-like kinase (NLK) (Cargnello and Roux 2011;
Pearson et al. 2001).
The MAPK family of pathways is composed of a set of three evolutionary
conserved protein kinases that are sequentially activated by phosphorylation. Once active,
the proteins interact with the proper substrate, each in turn, eliciting a response that
comprises a link in the chain of the entire cascade. Various stimuli can induce the
activation of different MAPK cascades. For instance, ERK1/2 and ERK5 are usually
activated by growth factors, while p38 and JNK respond to stress cues, such as osmotic
shock, cytokine stimulation or ionizing radiation. The specificity of the response will be
determined by the interaction with various scaffolding proteins, subcellular location and
substrate availability, which then direct the response in the appropriate direction (Roux
and Blenis 2004; Ohara and Nakahata 2009).
MAPK is involved in a wide variety of cellular processes. Depending on the
pathway, type of the stimuli and the duration of the stimulus itself, cells might be directed
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into activation of different cellular programs. Extracellular Signaling Regulated Kinase is
mostly involved in cell proliferation, cell cycle regulation and modulation of apoptotic
molecules. This array of functions correlates with the preferential activation of the
aforementioned pathway by growth factors (Chang et al. 2003). Activation of p38 occurs
as response to stress stimuli, which involves triggering mechanisms of cell cycle control,
DNA repair, chromatin remodeling, mRNA stability, protein degradation and apoptosis.
p38 can also be involved in endocytosis, cytoskeleton dynamics and cell migration
(Cuadrado and Nebreda 2010). In a similar manner, JNKs also respond to stress stimuli,
promoting regulation of altered gene expression, apoptosis, or cell survival (Manning and
Davis 2003).
Several members of the MAPK family play important roles in processes like
osteogenesis, neurogenesis, and adipogenesis (Change et al. 2003). The process of
adipogenesis is highly complex and requires multiple sequential steps and coordination
between the different players involved. MAPK is illustrative of this complexity, and
modulation of MAPK's activity can often produce opposite effects throughout the process
(Chang et al. 2003). Through a variety of approaches, the involvement of MAPK in the
adipogenic process has been thoroughly studied. These include the use of chemical
inhibitors, cell lines, over-expression of dominant negative proteins, cellular models and
MAPK knockouts.
1.5.3.2. The ERK Pathway
The story of ERK is that of needing different things at different times: at some
stages of adiopogenesis it is necessary to activate ERK and at others it is necessary to
inactivate it. The ERK pathway is one of the most extensively researched, as a result of
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its involvement in cell proliferation and activation by insulin, one of the major adipogenic
stimuli. In the early stages of ERK research, contradictory results were found regarding
ERK's role in pre-adipocyte differentiation. However, recent studies have shown
multiple functions for ERK in adipogenesis. The first potential link between ERK and
adipogenesis was a study showing the overexpression of Ras (a strong activator of ERK)
promoted adipocyte differentiation (Benito et al. 1991). Moreover, it was also shown that
ERK is required for adipogenesis, since its depletion inhibited the differentiation of
preadipocytes into mature adipocytes (Sale et al. 1995).
However, contradictory results were found when studies involving the
transcription factor Peroxisome Proliferator-Activated Receptor (PPARγ), indicated that
phosphorylation by ERK reduced the adipogenic capacity of cells, while
nonphosphorylatable mutations of PPARγ were more adipogenic (Camp and Tafuri 1997;
Adams et al. 1997). Several studies investigated these contradictory findings, and finally
established that ERK’s contribution to adipogenesis must be timely regulated (Liao et al.
2008; Wang et al. 2008). Compounds which inhibited and activated ERK were utilized to
elucidate the role of the ERK pathway in adipogenesis. Through the utilization of these
inhibitors, when ERK was inactivated during the early stages of differentiation,
adipogenesis was inhibited, while inactivation at the later stages exhibited no apparent
effect. Compounds that promote a sustained activation of ERK also have an inhibitory
effect on adipogenesis (Liao et al. 2008; Wang et al. 2008). Other experiments
demonstrated time periods where activation of ERK was required for adipogenesis. For
instance, during the early stages of adipogenesis there is a proliferative phase, also known
as mitotic clonal expansion (MCE), which is required for pre-adipocytes to reach full
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maturity. Activation of ERK is required during this step (see Figure 5 below). In
contrast, during the terminal differentiation phase at the later stages of adipogenesis,
inactivation of ERK is necessary to prevent PPARγ phosphorylation and therefore allow
the adipogenesis process to be complete (Rosen and Macdougald 2006; Qian et al. 2010;
Tang et al. 2003). Studies have also shown that certain adipokines, such as pigment
epithelium-derived factor (PEDF), exert an inhibitory effect on adipogenesis by
inactivating the ERK pathway and its effect on MCE (Tang et al. 2003). Lack of
activation of ERK prevents the phosphorylation of the CCAAT/enhancer-binding protein
C/EBPβ transcription factor, which is required primarily for MCE and later for activation
of C/EBPα and PPARγ (that are required to enter the final steps of differentiation) (Lee et
al. 2009; Wang et al. 2009; Tang et al. 2003; Tang et al. 2005).

Figure 5. MAPK pathways and adipocyte differentiation
Most studies involving ERK signaling were conducted with pre-adipocytes cell
lines to elucidate differentiation into adipocytes. ERK also plays a role in differentiation
of embryonic stem (ES) cells. A series of experiments have shown that activation of ERK
after treatment with retinoic acid (RA) is required for ES cells to commit to pre-adipocyte
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lineage. Additionally, inhibition of ERK during the ES cell differentiation results in a
strong inhibition of adipocyte formation, while having no effect on neurogenesis (Bost et
al. 2002; Binétruy et al. 2007). Extraceullar Signaling Regulated Kinase also plays a role
during development to maintain proliferating cells in an undifferentiated state. To
accomplish this, pre-adipocyte factor 1 (PREF-1) induces the phosphorylation of
ERK1/2, causing the activation of Sox9 which inhibits adipogenesis. Sox9, a highmobility-group-box DNA-binding transcription factor, binds to the promoter region of
C/EBPβ and C/EBPδ, and in doing so prevents the later activation of C/EBPα and
PPARγ. Therefore, in order for cells to undergo adipogenesis, Sox9 must be
downregulated (Wang et al. 2010).
1.5.3.3. The p38 pathway
Like ERK, research describing the role of p38 in adipogenesis has also shown
mixed results. The first studies that showed involvement of p38 in adipogenesis were
done using inhibitors of this kinase. They showed that activation of p38 was required for
adipocyte differentiation, suggesting C/EBPβ as a possible downstream target of the
kinase (Aouadi et al. 2007; Engelman et al. 1998). Another study showed that activation
of p38 by the constitutively active form of MKK6, an upstream activator of p38, induced
adipogenesis. However prolonged activation also induced cell death (Engelman et al.
1999). Later studies demonstrated that bone morphogenic protein-2, induces adipogenesis
by up-regulating PPARγ activity as a result of p38 activation. On the other hand,
treatment of pre-adipocytes with genistein, which reduced phosphorylation of p38, also
reduced differentiation into adipocytes (Zhang et al. 2009; Hata et al. 2003). Similarly,
treatment of pre-adipocytes with pseudoprotodiocsin reduces their adipogenic capacity.
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These cells also show diminished p38 phosphorylation, which might be alter the
expression pattern of the estrogen receptor alpha (ERα) isoform (Xiao et al. 2010). In
contrast with previous results, others have found that activation of p38 can inhibit
adipogenesis. Since active p38 phosphorylates the nuclear protein CHOP, it can then
interact with transcription factors from the C/EBP family, preventing them from
interacting with their classical binding sites and therefore inhibit differentiation
(Batchvarova et al. 1995; Wang and Ron 1996). In a similar way, p38 phosphorylates the
nuclear factor of activated T cells (NFAT), which is a protein involved in adipocyte
differentiation and dephosphorylation that allows nuclear translocation and
transcriptional activation to induce adipogenesis (Yang et al. 2002). Hence
phosphorylation of NFAT by p38 prevents it from reaching the nucleus and activating
PPARγ (Yang et al. 2002; Ho et al. 1998). Recent studies have shown that p38 plays a
role in differentiation through the epidermal growth factor receptor and the Erb2 receptor
(EGFR/EB2R) when cells are stimulated with low concentrations of EGF. Inhibition of
the receptors, or knockdown by siRNA, has shown a reduced activation of p38 and
expression of PPARγ (Harrington et al. 2007). Furthermore, p38 is a part of the
melanocortin system, where stimulation with adrenocorticotrophic hormone (ACTH)
significantly increases phosphorylation of p38, which mediates and in turn increases
uncoupling protein-1 (UCP)-1, which is a marker for brown adipose tissue (Iwen et al.
2008).
1.5.3.4. The JNK pathway
There is extensive evidence showing the involvement of JNK pathway in insulin
signaling and the development of obesity (Jaeschke et al. 2004), however little was

55

known about the possible role of this pathway in adipogenesis. One experiment showed
that activation of JNK and NF-KappaB by TNF-alpha inhibits adiopocyte differentiation
(Chae and Kwak 2003). Studies performed with human mesenchymal stem cells
demonstrated that repression of adipogenesis by JNK is in part due to inhibition of the
transactivating function of CRE-binding protein. Inhibition of JNK promoted
adipogenesis and increased adipogenic transcription factors like C/EBPβ and C/EBPδ as
well as PPARγ (Tominaga et al. 2005). c-Jun Amino-terminal Kinase signaling is
suppressed in adipogenesis under normal conditions where activation of the JNK
pathway by transforming growth factor 1 (TGF1) disrupts PPARγ dependent expression
of aP2, an adipocyte-specific gene (Hong et al. 2007). Moreover, activation of iNOS by
JNK also reduces expression of PPARγ affecting adipogenesis (Lee et al. 2010). Studies
performed in mesenchymal stem cells and fibrocytes indicate that JNK is involved in
determining the lineage commitment of these cells (Kilian et al. 2010). Activation of JNK
promotes commitment to osteoblast and myofibroblast, while inhibiting commitment to
and adipogenic lineage (see Figure 5 above) (Kilian et al. 2010).
1.6. Mitotic Clonal Expansion (MCE)
1.6.1. The Timing of Mitotic Clonal Expansion
After induction and growth arrest, preadipoyctes enter a proliferative phase called
mitotic clonal expansion (MCE) where cells restart the cell cycle to increase cell numbers
two to four fold (Tang et al. 2003). The first round of mitosis is completed 24 to 36 hours
after induction, and the second round is completed 48 to 60 hours after induction. After
60 hours, in experiments where only two rounds of mitosis have been observed, the cell
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number remained constant and by day 8, virtually every cell underwent adipogenesis (see
Figure 4 above) (Tang et al. 2003).
1.6.2. ERK and MCE
It has been reported that activation of ERK is required for MCE (Tang et al.
2003). Extracellular Signaling Regulated Kinase is necessary for the phosphorylation of
C/EBPβ, a critical step in facilitating MCE (see Figure 4 above). Tang et al. 2003
showed that the MEK-inhibitor U0126 at 40 μM, blocked ERK phosphorylation,
adipocyte differentiation (as indicated by failure to accumulate cytoplasmic
triacylglycerol), expression of cyclin A and cdk2 and completely blocked MCE (Tang et
al. 2003). It has also been reported that ERK activity is necessary for the expression of
the crucial adipogenic regulators C/EBPα, δ and PPARγ (Prusty et al. 2002). Inhibition of
adipocyte differentiation by chemical blockage of mitotic clonal expansion was
circumvented by the addition of a PPARγ agonist suggesting that the importance of
mitotic clonal expansion is linked to a concomitant production of PPARγ agonists
necessary for the initiation of adipocyte differentiation. Addition of U0126 after MCE
had been completed had no effect on the expression of adipocyte markers C/EBPα,
PPARγ, and 422/aP2 or the accumulation of cytoplasmic triacylglycerol (Tang et al.
2003). In sum, these results indicate that the adipogenic differentiation program depends
upon MCE.
As the cells cross the G1/S checkpoint, C/EBPβ acquires DNA-binding activity,
initiating a cascade of transcriptional activation (Tang and Lane 1996). Preadipocytes
traverse the G1/S checkpoint synchronously as evidenced by the expression/activation of
cdk2-cyclin-E/A, turnover of p27/kip1, hyperphosphorylation of Rb, translocation of
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cyclin D1 from nuclei to cytoplasm and GSK-3β from cytoplasm to nuclei, and
incorporation of [3H]thymidine into DNA (Patel and Lane 2000). The transcriptional
activation initiated by C/EBPβ culminates in the expression of the adipocyte phenotype
(see Figure 4 above) (Patel and Lane 2000).
It has been reported that C/EBPβ acts through induction of the expression of the
enzyme
xanthine oxidoreductase (XOR) (Hallenborg et al. 2014)It has been proposed that lipid
autooxidation by ROS generated by XOR then results in the production of substrates for
eLOX3 which then converts the peroxidized lipids into hepoxilin-like products that
function as endogenous PPARγ agonists (Hallenborg et al. 2014). An eLOX3 inhibitor,
baicalein, decreases PPARγ ligand generation (Madsen at al. 2003).
A number of compounds, some extracted from medicinal plants, inhibit mitotic
clonal expansion. For instance, dioscin, a steroidal saponin present in a number of
medicinal plants that has been shown to exert anticancer, antifungal and antiviral effects,
inhibits mitotic clonal expansion of cells by inducing G0/G1 phase arrest (Poudel et al.
2014). By applying these compounds at various time points in the adipogenic program,
and then assaying for molecular markers at these time points, mechanistic aspects of
adiopogenesis and mitotic clonal expansion can be elucidated. For instance, western blot
analysis revealed that dioscin inhibited the phosphorylation of the ERK and p38
pathways, but did not inhibit JNK. The inhibition of MCE by dioscin is accompanied by
an inhibition of the phosphorylation of the MAPKs, ERK1/2 and p38 (Poudel et al.
2014).
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Another compound, sulforaphane, similarly arrested the cell cycle at the
G0/G1 phase by decreasing expression of cyclin D1, CDK4, cyclin A, CDK2, and
phosphorylated Rb protein, but not cyclin E (Choi et al. 2012). Vitisin A, a resveratrol
tetramer, also inhibits adipogenesis through G1arrest by increased p21 expression, and
decreased cyclin A and B, CDK2 expression, but not cyclin E (Kim et al. 2008). The
expression of the CDK inhibitor p27, an upstream effector of cell cycle regulatory
proteins, was downregulated during adipogenesis, but sulforaphane restored the
expression suggesting that sulforaphane may induce cell cycle arrest at the G0/G1 phase
through the upregulation of the cell cycle inhibitor p27 in 3T3–L1 cells. Synthesis-phase
kinase-associated protein (Skp2) targets p27 for degradation by the 26S proteasome
during MCE. Sulforaphane decreased the phosphorylation of ERK1/2 and Akt (which are
stimulated by the adipogenic inducers in 3T3–L1 preadipocytes), Epigallocatechin gallate
and matrine also inhibit adipocyte differentiation by downregulating the ERK pathway
(Choi et al. 2012).
While invalidation of the ERK2 isoform is embroyonic lethal (Hatano et al.
2003), ERK1 deficient mice have defective thymocyte maturation, enhanced long-term
memory, and impaired adipogenesis (Mazzucchelli et al. 2002). The ERK1–/– mice
challenged with high fat diet are resistant to obesity and protected from insulin resistance
(perhaps as a result of serine phosphorylation of the insulin receptor substrate-1 protein, a
downstream effector of the insulin receptor) (Zick 2001). It has been hypothesized that
since ERK phosphorylation of C/EBPβ activates its transcriptional activity and knockout
of this gene leads to defective adipocyte differentiation, C/EBPβ represents a target that
could account for the ERK effect on both 3T3-L1 adipocyte differentiation and the
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phenotype of ERK1–/–mice (Hu et al. 2001; Tanaka et al. 1997). However, this hypothesis
is contradictory to recent results showing that C/EBPβ is a preferential target of ERK2
and not ERK1 (Hanlon et al. 2001). Further studies are necessary to resolve these
seemingly conflicting lines of evidence.
Pituitary adenylate cyclase activating peptide (PACAP) is a member of the
secretin/glucagon/vasoactive intestinal peptide (VIP) family which targets three different
receptor subtypes expressed in differentiating 3T3-L1 cells: PAC1, VPAC1 and VPAC2.
PACAP increased cAMP production within 15 minutes of stimulation and targeted the
expression and phosphorylation of MAPK (ERK1/2) (Arsenijevic et al. 2013).
Phosphorylation on Thr188 that occurs in G1 phase by MAPK primes C/EBPβ for
subsequent phosphorylation (Boucher et al. 2014). Cdk2/cyclinA maintains this
phosphorylated state throughout S phase and MCE, until the subsequent phosphorylation
by GSK3b induces DNA binding and transactivation activity of C/EBPβ. Since PACAP
is involved in direct activation of ERK1/2 early during MCE via induction of cAMP, it
has been hypothesized that PACAP may be necessary for MCE and adiopogenesis
(Arsenijevic et al. 2013).
1.6.3. Akt and MCE
Upon stimulation by the adipogenic inducer insulin, the insulin receptor in
preadipocytes is activated, insulin receptor substrates are phosphorylated, and the class I
phosphoinositide 3-kinase (PI3K) signaling pathway is activated (see Figure 5 above)
(Boucher et al. 2014). Activation of class I PI3K generates the polyphosphoinositide lipid
product phosphatidylinositol(3,4,5) triphosphate (PtdIns(3,4,5)P3), which is responsible
for the activation of protein kinase B (PKB)/Akt in 3T3-L1 cells (Gagnon et al. 1999).
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When Akt is activated by phosphorylation on Thr308 by 3-phosphoinositide-dependent
protein kinase-1 (PDK1) (Bunney and Katan 2010), it is followed by phosphorylation on
Ser473 by rapamycin (mTOR) complex 2 (Salamon and Backer 2013).
Activated Akt can then translocate to the nucleus and phosphorylate and
inactivate the transcription factor forkhead box O1 (FoxO1) by nuclear exclusion, thus
permitting adipogenic gene transcription (Tzivion et al. 2011). Inhibiting the PI3KPKB/Akt pathway inhibits adiopogenesis and MCE (see Figure 5 above) (Xia and
Serrero 1999).
The promotion of MCE is dependent on the ability of Akt to activate mTORC1
and its downstream effector eIF4E, which are required for Skp2 mRNA translation
during MCE. S-phase kinase associated protein 2 (Skp2) promotes MCE largely through
the degradation of p21 and p27 proteins. In the absence of Skp2, preadipocytes arrest in
the G2 phase of the cell cycle and fail to undergo MCE (Nogueira et al. 2012)
Both Akt1 and Akt2 are able to mediate insulin regulation of the transcription
factor forkhead box O1 (FoxO1) and the glucose transporter 4 (GLUT4). It is reported
that Akt1 plays the predominant role in MCE of preadipocytes (Kajno et al. 2015).
Protein kinase B (Akt2) mediates glucose transport into fat and muscle cells by inhibiting
the Rab GAP (GTP-hydrolysis activating protein) AS160, an Akt substrate, facilitates the
plasma membrane translocation of GLUT4 (glucose transporter 4) glucose transporters.
Additionally, Akt2 regulates glucose levels by decreasing hepatic gluconeogenesis
through inactivation of the transcription factor FoxO1. Deletion of both Akt1 and Akt2 is
required to completely block the formation of adipose tissue in mice (Kajno et al. 2015).
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It has been recently reported that caffeine treatment inhibits MCE by acting on
this pathway by increasing the expression of p21 and p27, the major regulators arresting
cell cycle progression at the G1/S checkpoint, and downregulating cdk2, an essential
factor for G1/S transition (Kim et al. 2016). Unlike most cell types that express cdk2
throughout the cell cycle including G1, 3T3-L1 preadipocytes do not express cdk2 in the
G1 phase of MCE (Montagnoli et al. 1999). Instead, expression of cdk2 occurs as the
preadipocytes synchronously enter S phase. Cdk2 reaches a maximum level of expression
concomitant with the incorporation of [3H]thymidine into DNA, the expression of cyclin
A, and the acquisition of DNA-binding activity by C/EBPβ (Kim et al. 2016).
Additionally, mouse embryo fibroblasts (MEFs) from C/EBPβ(−/−) mice neither undergo
MCE or differentiation into adipocytes but MCE and adipogenesis by C/EBPβ(−/−)
MEFs could be rescued by enforced expression of WT C/EBPβ (Tang et al. 2003). The
cyclin-dependent kinase inhibitor roscovitine also blocks MCE, the expression of cell
cycle and adipocyte markers, and adipogenesis and roscovitine-treated preadipocytes fail
to enter the S phase, as indicated by the complete inhibition of [3H]thymidine
incorporation into DNA and failure to proliferate (Hallenborg et al. 2014). These findings
support the notion that MCE is a prerequisite for adipogenesis.
1.6.4. p38 and MCE
Activation of p38 is also required to upregulate C/EBPβ phosphorylation during
MCE (see Figure 5 above). This is shown by both by the decrease of C/EBPβ
phosphorylation through the use of pyrindinyl imidazole inhibitors such as SB203580 to
inhibit P38 activation, and through the use of upstream activators of p38 (such as MKK6)
resulting in adipoycte differentiation (Takenouchi et al. 2004). Hata et al. 2003
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demonstrated that bone morphogenic protein-2 (BMP-2) oriented pluripotent
mesenchymal cell lines C3H10T1/2 into the adipocyte lineage through activation of p38.
Other studies suggest the opposite result, that p38 inhibits differentiation, and that CHOP
phosphorylation by p38 is required for its complete inhibitory effect (Wang and Ron
1996). Supporting an anti-adipogenic effect of p38, Yang et al. showed that once a
transcription factor, nuclear factor of activated T cells (NFATc4), is dephosphorylated, it
is translocated into the nucleus, increases PPARγ expression (not detected during MCE
but subsequently), and thus, adipogenesis (Yang et al. 2002). NFAT4c is phosphorylated
by p38 and this phosphorylation inhibits adipose cell formation in NIH3T3 (Yang et al.
2002). It is plausible that activation of p38 at different time points during the adipogenic
process has different effects which could resolve the apparent discrepancies in these lines
of evidence. Additionally, studying the effects of the different p38 isoforms could also
help elucidate this mechanism.
Carlson et al. 2003 showed that p38 activity participates in downregulation of
GLUT4 expression and is significantly higher in adipocytes isolated from type-2 diabetes
patients than in nondiabetics. Several studies show that inhibition of p38 improves
glucose transport in L6 and 3T3-L1 cell lines (Furtado et al. 2002, Furtado et al. 2003).
It is noteworthy that beyond the key role that p38 plays in C/EBPβ
phosphorylation during MCE, other co-factors are necessary for the process resulting in
MCE and in C/EBPβ then transcriptionally activating C/EBPα and PPARγ genes. Other
factors such as TC10-like/TC10βLong (TCL/TC10βL), regulators of G protein signaling
2 (RGS2), factor for adipocyte differentiation 104 (fad104), fad24, and paternally
expressed gene 10 (peg10), are also all required for MCE (Kawaji et al. 2010; Jomura et
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al. 2008; Hishida et al. 2007). Knockdown of their expression impairs MCE (Kawaji et
al. 2010; Jomura et al. 2008; Hishida et al. 2007). Additionally, it has been reported that
activating transcription factor 5 (ATF5) can bind to the promoter of C/EBPα via its direct
interaction with C/EBPβ (which is mediated via the p300-dependent acetylation of
ATF5), leading to enhanced C/EBPβ transactivation of C/EBPα (Zhao et al. 2014).
Additionally, p300 facilitates the interaction of ATF5 with C/EBPβ as well as for the
binding activity of this complex on the C/EBPα promoter (Zhao et al. 2014).
It has also been reported that Topo IIα (a DNA topoisomerase that is expressed in
dividing and pluripotent cells, resolve DNA topological features such as catenation and
supercoiling, arising during DNA replication, transcription and sister chromatid
entanglement during mitosis, and catalyzes double strand breaks) expression peaks
during MCE in adipocytes in a PI3K/mTOR-dependent manner and is essential for
adipogenesis (Jacobsen et al. 2016). Topoisomerase IIα expression is also involved in the
replication of the heterochromatin regions, and in chromatin remodeling (Jacobsen et al.
2016).
1.6.5. Fat Mass and Obesity Associated Gene (FTO), Factor for Adipocyte
Differentiation (FAD) Genes and MCE
Merkestein et al. 2016 recently reported that the fat mass and obesity-associated
(FTO) gene influences adipogenesis by regulating MCE. Single-nucleotide
polymorphisms in the first intron of the FTO gene were shown to increase susceptibility
to obesity in genome wide association studies first in Caucasians, and then in multiple
human populations and different ethnic groups (Yeo et al. 2014). Primary adipocytes and
mouse embryonic fibroblasts (MEFs) derived from FTO overexpression (FTO-4) mice
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exhibit increased potential for adipogenic differentiation, while MEFs derived from FTO
knockout (FTO-KO) mice show reduced adipogenesis (Yeo et al. 2014).
Fat Mass and Obesity-associted Gene is a nucleic acid demethylase that removes
methyl groups from both DNA and RNA. It demethylates N6methyladenosine (m6A)19,
which affects the processing, stability and alternative splicing of mRNAs. In 3T3-L1
cells, FTO controls mRNA splicing by regulating the ability of the splicing factor SRSF2
to bind mRNA in an m6A-dependent way. One of the targets of SRSF2 is Runt-related
transcription factor 1 (RUNX1T1), which exists in two splice variants, a long (L) and a
short (S) isoform. Overexpression of the S isoform of RUNX1T1 in 3T3-L1 cells
enhances adipogenesis, while overexpression of the L isoform of RUNX1T1 impairs
adipogenesis (Zhao et al. 2014). The L isoform of RUNXT1 is found at much higher
levels than the S isoform in 3T3-L1 cells. The effect of RUNX1T1 on adipocyte
differentiation and proliferation thus depends on the balance between the L and S
isoforms of RUNX1T1 (Yeo et al. 2014).
Fat Mass and Obesity-associted Gene acts during MCE to enhance adipocyte
number through expression of RUNX1T1, which enhanced adipocyte proliferation, and is
increased in FTO-wt MEFs and reduced in FTO-KO MEFs. Expression of RUNX1T1-S
was reduced in MEFs from FTO-KO mice and was increased in MEFs from mice
overexpressing FTO. Furthermore, knockdown of RUNX1T1 in WT MEFs reduced cell
proliferation and expression of cell cycle genes during MCE (Yeo et al. 2014).
Fat Mass and Obesity-associted Gene overexpression also leads to expression of
PPARγ and C/EBPα, as would be predicted from its inducement of MCE. In humans, a
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mutation in the catalytic domain of FTO (R316Q) results in a severe phenotype
accompanied by growth retardation (Boissel et al. 2009).
The mechanism by which the S isoform of RUNX1T1 stimulates the adipogenic
cascade has not been fully elucidated, but it has been hypothesized that it binds to, and
activates C/EBPβ (Merkestein et al. 2015). FTO has been shown to act as a
transcriptional coactivator of C/EBPβ (Wu et al. 2010).
Two other genes, factor for adipocyte differentiation (fad) gene-24 (fad24), and
factor for adipocyte differentiation (fad) gene-102 (fad102), were amongst 102 genes
found to be expressed at the beginning of the differentiation of 3T3-L1 cells (Imagawa et
al. 2016). Factor for adipocyte differentiation 23 and Fad102 are pro-adipogenic with
Fad23 knockdown inhibiting MCE. FAD24 regulates DNA replication by recruiting
histone acetyltransferase binding to ORC1 (HBO1) to DNA replication origins (Imagawa
et al. 2016).
1.6.6. Amino Acids, Polyamines, Reactive Oxygen Species, and MCE
Polyamine levels increase during adipogenesis, and their depletion inhibits
adipogenesis, MCE, and the activation of C/EBPβ and MCE (Brenner et al. 2015).
Catabolism of branched-chain amino acids contributes to both adipogenesis and
lipid accumulation. However, several proteolytic pathways are active during
adipogenesis, including autophagy, proteasomal degradation, and matrix
metalloproteinase-mediated proteolysis (Kirkwood et al. 2016). Amino acids increase at
both 24 and 48 hours post differentiation with the exception of proline and glutamate,
which were decreased at 24 and 48 hours compared to earlier time points(Kirkwood et al.
2016). Proline is a precursor to ornithine, the immediate precursor for the biosynthesis of
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polyamines. In addition, proline oxidation by the mitochondrial enzyme proline
dehydrogenase can produce reactive oxygen species (ROS) (Kirkwood et al. 2016).
Several studies report that ROS promote adipogenesis by accelerating MCE
(Vigilanza et al. 2011, Lee et al. 2009). It is hypothesized that diminished proline levels
during adipogenesis results from the need to supply it as a precursor to both polyamine
biosynthesis, and also to produce pro-adipogenic ROS, in addition to the ROS from
complex III and NADPH oxidase (Vigilanza et al. 2011, Lee et al. 2009).
Glutathione, a tripeptide antioxidant exists in oxidized (GSSG) and reduced
(GSH) forms and during adipogenesis, the ratio of GSSG to GSH increases. Antioxidants
that prevent the oxidative conversion of GSH into GSSG inhibit adipogenesis, and
inhibitors of GSH synthesis stimulate adipogenesis (Vigilanza et al. 2011, Lee et al.
2009).
1.6.7. Sirtuin 1 (SIRT1) and MCE
The NAD(+)-dependent protein deacetylase sirtuin 1 (SIRT1) is reported to have
an anti-adiopogenic effect. SIRT1-silenced mouse 3T3-L1 preadipocytes differentiate
into hyperplasic adipocytes and exhibit a phenotype associated with dysregulated
adipocyte metabolism and enhanced inflammation (Abdesselem et al. 2016).
Differentiating SIRT1-silenced preadipocytes exhibit enhanced mitotic clonal
expansion accompanied by reduced levels of p27 as well as elevated levels of C/EBPβ.
c-Myc levels are also elevated, c-Myc is hyperacetylated, levels of p27 are reduced, and
cyclin-dependent kinase 2 (CDK2) is activated upon SIRT1 reduction. c-Myc
hyperacetylation leads to higher preadipocyte proliferation potential and enhanced
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adipocyte MCE during differentiation, which ultimately results in dysfunctional
hyperplasic adipocytes (Abdesselem et al. 2016).
An important oncogene, c-Myc, is among the earliest expressed genes during
MCE of differentiating preadipocytes, and targets the key cell cycle regulator p27 and has
a repressive effect upon it. Additionally, C/EBPβ was up-regulated during MCE and late
differentiation in SIRT1-silenced adipocytes, suggesting a key role of these targets in the
regulation of MCE by SIRT1 (Abdesselem et al. 2016).
1.6.8. G9a and MCE
Peroxisome Proliferator Activated Receptor Gamma and C/EBPα are antimitotic
factors and thus their delayed expression ensures the successful progression of MCE
(Tang et al. 2012). During the time lag before expression of PPARγ and C/EBPα,
C/EBPβ is sequentially phosphorylated, first by MAPK/cyclin A/cdk2 on Thr188 and
subsequently by GSK3β on Ser184 or Thr179, which is critical for C/EBPβ to acquire its
ability to bind DNA and to prevent its calpain-dependent degradation (Li et al. 2007;
Zhang et al. 2012).
However, C/EBPβ phosphorylation cannot explain the time lag in the expression
of PPARγ and C/EBPα (increased expression at approximately 48 hours post induction),
since during MCE C/EBPβ already has DNA binding activity and transactivates several
other cell cycle genes (Guo et al. 2012). It has been hypothesized that epigenetic events
could account for this time lag (Li et al. 2013).
Euchromatic histone-lysine N-methyltransferase 2 (G9a) is one of the major
euchromatic methyltransferases involved in the methylation of histone H3 (K9 and K27)
and histone H1b (K26). Euchromatic histone-lysine N-methyltransferase 2 (G9a) plays
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roles in embryonic development, genomic imprinting, lymphocyte and neuronal function,
tumorigenesis, and metastasis (Li et al. 2007). Additionally, it has recently been reported
in 3T3-L1 cells that C/EBPβ transactivates G9a expression during MCE (Li et al.2007).
Additionally, G9a inhibits the expression of PPARγ and C/EBPα through H3K9
dimethylation of their promoters which may account for the observed time lag in their
expression (Li et al.2007).
It is noteworthy that PPARγ and C/EBPα expression increased 48 hours post
induction concomitant with G9a downregulation (Li et al.2007).
Abnormally early expression (that results from early downregulation of G9a) of
the two antimitotic factors PPARγ and C/EBPα interrupted MCE (Li et al. 2007).
Considerable evidence has suggested other epigenetic mechanisms, including
histone methylation, are critical for adipogenic differentiation. The histone H4 Lys-20
(H4K20) monomethyltransferase PR-Set7/Setd8 gene was upregulated by PPARγ during
adipogenesis (Wakabayashi et al. 2009). It has also been reported that SHARP1 inhibited
adipogenesis by targeting C/EBPβ activity, which is necessary to replace the corepressors
HDAC1 and G9a from the promoters of their transcriptional targets (C/EBPα and
PPARγ2) during differentiation (Wakabayashi et al. 2009).
1.6.9. miR-363 and MCE
Micro Ribonucleic Acid-363 was reported to be one of the most significantly
downregulated miRNAs during adipogenesis. Overexpression of miR-363 in adipocytes
inhibited MCE and terminal differentiation (Fajas et al. 2002). Ectopic introduction of
miR-363 into ADSCs significantly reduced the levels of E2F3, a key transcription factor
that regulates growth and proliferation during MCE (Fajas et al. 2002; Chen et al. 2014).
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Transcription factor E2F3 is the effector of the retinoblastoma protein pRB-E2F
pathway, which controls the G1/S transition during the cell cycle and regulates cell
proliferation and differentiation and is also a key transcription factor during MCE. E2F3
is a substrate of the cyclin-dependent kinases and directly effects cyclin E transcription,
which plays an important role in DNA synthesis and induces the G1/S transition (MCE)
(Chen et al.2014).
During the MCE, DNA replication and changes in the chromatin structure aid in
triggering the expression of C/EBPα, which transactivates genes resulting in terminal
differentiation. C/EBPα also blocks E2F3 expression by upregulating the CDK inhibitor
p21. Thus, cells exit MCE and enter a growth-arrested stage before terminally
differentiating (Chen et al.2014).
It has been reported that EGFP/RFP reporter assay, miR-363 can directly target
the 3'UTR of E2F3 (Fajas et al. 2002). During normal early stage of adipogenesis,
E2F3 is expressed and miR-363 is downregulated. Downregulation of miR-363 allows
this transitional switch from MCE to terminal differentiation to occur by reducing the
inhibition of E2F3. miR-143 expression was transiently decreased after adipogenic
induction while increased from day 3 and peaked on day 7 after induction (Fajas et al.
2002).
It has recently been reported that miR-143 directly represses MAP2K5, a key
member of the MAPKK family in the MAPK signaling pathway (Chen et al. 2014)
1.6.10. Proliferating Cell Nuclear Antigen (PCNA) and MCE
It has been reported that Proliferating Cell Nuclear Antigen (PCNA) is subject to
phosphorylation at the highly conserved tyrosine residue 114 (Y114). Mice challenged
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with a high fat diet who are genetically modified so as to replace the tyrosine residue 114
with phenylalanine (which is structurally similar to tyrosine but cannot be
phosphorylated) are resistant to obesity. Phosphorylation at Y114 is necessary for MCE
(Lo et al. 2013).
1.6.11. KCNK10 and MCE
Potassium channel, subfamily K, member 10 (KCNK10) expression is strongly
induced by 3-isobutyl-1- methylxanthine (IBMX), a potent inducer of adipocyte
differentiation. KCNK10, a member of tandem pore domain potassium channel family is
elevated during the early stage of adipogenesis of 3T3-L1 cells and that reduction of
KCNK10 expression inhibits adipocyte differentiation (Sato et al. 2010). It has recently
been reported that KCNK10 contributes to the regulation of MCE through the control of
C/EBPβ and C/EBPδ expression and insulin signaling (Nishizuka et al. 2014). The
reduction of KCNK10 expression suppressed the expression of C/EBPβ and C/EBPδ, the
phosphorylation level of Akt during the early phase of adipogenesis, and insulin-induced
Akt phosphorylation (Nishizuka et al. 2014).
In summary (see citations throughout above), the different MAPK pathways are
able to regulate several steps of adipogenesis (see Figure 5 above). Timely activation and
tight control of specific proteins is an essential step in the successful differentiation of
pre-adipocytes into mature adipocytes. Through the extensive study of the ERK signaling
pathway, it is now understood that activation of this pathway is required at the early
stages of adipogenesis, however, later inactivation is also necessary to achieve full
differentiation. In a similar way, the contribution of p38 to adipogenesis seems to
overlap with ERK’s contribution. p38 is also required at the beginning of adipogenesis,
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when cells are undergoing MCE, with later inactivation being required to guarantee fully
mature adipocytes. The JNK pathway is not yet fully understood, and there is little
information about the role it plays in adipogenesis, however it has been shown to
determine lineage commitment of mesenchymal stem cells, favoring the osteogenic
instead of the adipogenic lineage. Future research including experiments utilizing natural
products to inhibit adipogenesis may lead to therapeutic strategies in the treatment or
prevention of obesity and its associated disorders.The MAPK family plays an integral
role in the initiation of mitotic clonal expansion (MCE), a necessary step for
adipogenesis. For instance, it has been reported that MCE requires ERK and p38
activation to facilitate the phosphorylation of C/EBPβ, as well as a G9a mediated time lag
between this phosphorylation and expression of PPARγ and C/EBPα. In addition other
pathways and a chorus of other factors are also necessary for MCE to proceed, such as
the ability of Akt to activate mTORC1 and its downstream effector eIF4E, which are
required for Skp2 mRNA translation, which then degrades p21 and p27 proteins. The Fat
Mass and Obesity Associated Gene (FTO), Factor for Adipocyte Differentiation (FAD)
Gene expression are necessary for MCE, as are specific interplays between amino acids,
polyamines, reactive oxygen species, and MCE. Downregulation of miR-363 increases
the levels of E2F3, a key transcription factor that regulates growth and proliferation
during MCE. Differentiating SIRT1-silenced preadipocytes exhibit enhanced MCE
accompanied by reduced levels of p27 as well as elevated levels of C/EBPβ.
Phosphorylation of the Proliferating Cell Nuclear Antigen (PCNA) Y114 is necessary for
MCE. IBMX induced KCNK10 expression contributes to the regulation of MCE through
the control of C/EBPβ and C/EBPδ expression, the phosphorylation level of Akt during
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the early phase of adipogenesis, and insulin-induced Akt phosphorylation. The interplay
of these elements illustrates the complexity of molecular actors involved in the crucial
adipogenic step of MCE and the need for further studies to further delineate the
relationships between them.
1.7. Anti-adipogenic Compounds derived from Artemisia
1.7.1. History of Artemisia
Asteraceae is a family of flowering plants (Angiospermae), etymologically
derived from "aster", the Greek word for "star" (Barnhart 1995 et al.), presumably due to
the morphology of their emanating inflorescence resembling the projecting radiant light
from a star. Artemisia is a genus in the Asteraceae family, and numerous species within
this genus possess sesquiterpene lactones as active constituents (Giordano et al. 1990).
Long before these sesquiterpene lactones were extracted and isolated in the modern era,
traditional cultures recognized these species for their therapeutic and other properties
(Giordano et al. 1990).
One property of Artemisia that characterized conceptions of the plant by early
cultures is its bitterness due to its thujone content (DeBaggio and Tucker 2009). Thujones
are ketones and monoterpenes which naturally occur in two diasteromeric forms: (−)-αthujone and (+)-β-thujone (Oppolzer et al. 1997) and act upon GABA and 5-HT3
receptors in brain tissue (Deiml et al. 2007).
A common name for various species of Artemisia is wormwood (Chialva et al.
1983). Wormwood (as translated into English from the Hebrew word la'anah, which
means "curse" in both Hebrew and Arabic) is mentioned eight times in the Old Testament
of the Bible and possibly refers to either A. judaica L. or A. herba-alba (DeBaggio and
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Tucker 2009) since both these species are present in Middle Eastern regions where the
books of the Bible were written and compiled.
Artemisia judaica is a perennial fragment shrub that is abundant in North Africa
and Middle Eastern countries (Alzweiri et al. 2014) and has been used in traditional
Egyptian medicine for the treatment of gastrointestinal disorders (Liu et al. 2004).
Isolated compounds from A. judaica have exhibited antibacterial, antifungal, and
cytotoxic effects (Alzweiri et al. 2014; Abdelgaleil et al. 2008, Bos and Sharma 2011;
Hashem 2011). The composition of A. judaica includes artemisinic acid, methyl
wormwood, artemisinic alcohol, eucalyptol, Artemisia ketone, camphor, caryophyllene,
and piperitone (Charchari 2002; El-Sharabasy 2010). Gas Chromatography-Mass
Spectrometry and GC-FID results demonstrate that the isolated oil contains octenyl
acetate (2E) (26.6%), p-cymen-8-ol (26.6%), p-menth-3-en-8-ol (21.6%),
pentylcyclohexa-1,3-diene (6.6%), verbenyl acetate (4.4%), isophorone (3.5%), and
Artemisia ketone (3.5%) (Alzweiri et al. 2014). Some studies showed the presence of 1,8cineole, α-thujone, camphor, thymol, lavandulol, and santolina triene (Dob and
Chelghoum 2006), while others did not (Alzweiri et al. 2014). It has been proposed that
the oxygenated terpenes octenyl acetate and p-menth-3-en-8-ol are responsible for A.
judaica's carminative effect due to the hydrophilic oxygenated part and the hydrophobic
terpene part's optimal surface activity effect against interfacial tension (Alzweiri et al.
2014).
Artemisia herba-alba, the other candidate for the Biblical wormwood (DeBaggio
and Tucker 2009), is commonly found on the dry steppes of the Mediterranean regions in
northern Africa (Saharan Maghreb), western Asia (Arabian Peninsula), and southwestern
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Europe (Al-Waili 1986). In Iraqi folk medicine, A. herba-alba based teas were used for
the treatment of diabetes mellitus (Al-Waili 1986). The Bedouins in the Negev desert in
Israel utilize A. herba-alba as a traditional remedy for enteritis, and various
gastrointestinal disturbances (Friedman et al. 1986). In herbal medicine, A. herba-alba is
widely used for its antiseptic, vermifuge, and antispasmodic properties (Yashphe et al.
1987). Essential oils from A. herba-alba have been found to have cytotoxic effects on the
P815 mastocytoma and BSR kidney carcinoma cell lines, but not against peripheral blood
mononuclear cells PBMCs (Tilaoui et al. 2015). Gas Chromatrography and GC-MS
analysis demonstrated that the isolated oil from the leaves of A. herba-alba contained
oxygenated sesquiterpenes (39.9%), sesquiterpenes (29.0%), esters (24.0%).
monoterpenes with an α-thujone skeleton (1.24%), and monoterpenes with a pinane
skeleton (4.48%) (Tilaoui et al. 2015). Thujone was found to comprise 64% of the
essential oil of A. herba-alba collected from Tunisia, but was absent from samples
collected from Spain (Feuerstein et al. 1988; Salido et al. 2004). The proportion of
thujone varies by chemotype (34 to 94%), and seven chemotypes were identified from
samples collected from various Moroccan regions (Benjilali and Richard 1985; Benjilali
and Sarris 1982) Differential percentages of α- versus β- thujone is likely due to varying
geographical growth sites and climatic conditions (Ouyahya et al. 1990).
In the Old Testament of the Bible, wormwood (presumably A. judaica and/or A.
herba-alba) (DeBaggio and Tucker 2009) is used metaphorically to represent the
bitterness concomitant with troubled times. Wormwood, in accordance with its literal
Hebrew and Arabic meaning of "curse", is also utilized to represent sorrow, suffering,

75

and misfortune. This is perhaps due to assumptions made by traditional cultures
regarding the nexus between bitter taste and toxicity (Johnson 1891).
If the prevailing scholarly opinion that the books of the Old Testament were
written between the 8th and 5th centuries B.C. (Rahimi et al. 2010) is correct, and if the
Biblical wormwood does indeed refer to Artemisia, then it is plausible that traditional
cultures in Middle East regions where Artemisia was prevalent during this time period
recognized the plant for its bitterness and thought of this property as a defining
characteristic.
At some point in early Middle Eastern history, the potentialities of Artemisia
beyond its bitter taste were recognized. For instance, in traditional Iranian medicine, a
condition known as "zahir", which seems to parallel irritable bowel syndrome, has long
been treated by Artemisia and other local flora (Rahimi et al. 2010). These natural
products have also been utilized for their anti-inflammatory, anti-ulcer, wound healing,
and anti-diarrheal effects (Rahimi et al. 2010).
The origins of the word "artemisia" may derive from the Greek goddess Artemis
(the Roman Diana) (Rose 1959), the goddess of the hunt and the moon (DeBaggio and
Tucker 2009). It may also derive from historical individuals whose names were derived
from the goddess (DeBaggio and Tucker 2009). Two possible candidates are Artemisia I
and Artemisia II (DeBaggio and Tucker 2009). Artemisia I was the commander who
fought as an ally of Xerxes I and warned him before the Battle of Salamis in 480 B.C. not
to enter the narrow straits against the Greeks; an admonition that was ignored with dire
consequences for the Persians (Herodotus 450 B.C.). Artemisia II was a botanist who
died in 350 B.C. and her profession has been attributed to her association with Artemisia
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(DeBaggio and Tucker 2009). However, a bizarre part of her biography reveals that she
married her own brother and after his death drank his ashes (Boccaccio 1990). Since
Artemisia was associated in those times with bitterness (DeBaggio and Tucker 2009), it
may be that this ingestion of her brother-husband's ashes (often memorialized in
medieval art) was the precipitating etymological event behind the plant's namesake.
Beyond the Middle East, Artemisia has also been long known and utilized in
traditional cultures of the Far East. A. annua L. (quinghao, which translates to "green
herb) grows naturally as a part of steppe vegetation in northern parts of Chatar and
Suiyan province in China at 1,000–1,500 m above sea level and has been used in
traditional Chinese medicine since at least the second century B.C. A piece of silk
unearthed from the Mawangdui Han Dynasty tombs (168 BC) described A. annua as a
treatment for hemorrhoids. From as early as the medical writings of Ge Hong (283–343
A.D.) during the Jin Dynasty, A. annua was described as a remedy for fever. Rural areas
used the herb to treat malaria even before the initiation of a secret research project in
1963, called Project 523 (Cui and Su 2009).
Project 523 was initiated in a clandestine meeting held on May 23, 1967 (hence
the name Project 523, for 23rd of the fifth month) during the Vietnam War between Ho
Chi Minh and Mao Zedong. Ho Chi Minh was in desperate need of Mao Zedong's aid
since more North Vietnamese soldiers were dying from malaria than from armed
conflicts. The Chinese launched a program to find anti-malarial compounds both for the
North Vietnamese and for Chinese citizens (Graziose et al. 2010) and in 1972
artemisinin, a highly oxygenated sesquiterpene, containing a unique 1,2,4-trioxane ring
structure, was extracted and identified as an efficacious anti-malarial compound from A.

77

annua (Tu 1999). The effectiveness of artemisinin was initially underestimated in the
Western world (Attaran et al. 2004) but has demonstrated efficacy (along with its two
main derivatives artemether and artesunate) against both malaria and schistosomiasis
(Zhang et al. 2014).
After the initial isolation, extraction, and testing, several other A. annua antimalarial derivatives were subsequently produced including artemether and artesunate in
1987, and dihydroartemisinin (DHA) in 1992 (Cui and Su 2009; Liu et al. 2014).
Artemisinin derivatives have also proved efficacious against Schistosomiasis japonica in
China (Liu et al. 2014). As malaria still afflicts 5% of the world's population, artemisinin
combination therapy (ACT) to attempt to circumvent drug resistance is an essential antimalarial strategy (Bosman and Mendis 2007). Pyronaridine, lumefantrine (benflumetol),
and naphthoquine, which were synthesized in 1973, 1976, and 1986 respectively, are all
utilized in ACT (Cui and Su 2009). In the United States, A. annua was introduced in the
nineteenth century, nicknamed "Sweet Annie", and used as a preservative, for the
flavoring of vermouth, and as an addition to potpourri (Dhingra et al. 2000). Due to its
now known efficacy in treating chloroquine-resistant and cerebral malarias, A. annua is
currently cropped on a large scale in China, Vietnam, Turkey, Iran, Afghanistan, and
Australia. In India, it is cultivated on an experimental basis in the Himalayan regions, as
well as temperate and subtropical conditions (Bhakuni et al. 2001). Other traditional uses
of Artemisia in China include moxibustion, the burning of a roll of specially prepared
herbs containing A. vulgaris on acupuncture points (Hitosugi et al. 2001; Kobayashi
1988).
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Another traditional Chinese remedy is Yin Chen Hao Yin Chen, consisting of A.
scoparia Waldst. et Kit. and A. capillaris and used to treat liver and choleretic disorders.
This traditional remedy was found to exhibit a hepatoprotective effect by ameliorating
murine concanavalin A-induced hepatitis via suppression of interferon gamma (IFNγ)
and interleukin-12 (IL-12) production (Mase et al. 2010).
Other Asian countries, apart from China, also have a tradition of Artemisia use.
For instance, A. scoparia Waldst. et Kit. is native to Japan, Korea, and Mongolia. The
aerial part of this plant is used in traditional medicine as an antiphlogistic, diuretic, for
the treatment of hepatitis and urticaria, and as an antimold agent. Phytochemical
investigations of the aerial part of A. scoparia resulted in the isolation of flavonoids,
coumarins, and essential oils. Recently, A. scoparia has been shown to inhibit triglyceride
accumulation in 3T3-L1 preadipocytes (Yahagi et al. 2014).
In some cases, the history of extraction of a therapeutic compound from Artemisia
in a country consists of initial import followed by the establishment of domestic
industrial production. For instance, prior to 1919, Japan imported santonin, an
anthelmintic agent, entirely from Russia. In 1919 domestic production of santonin was
initiated by Nippon Shinyaku Co., Ltd. In 1927, A. maritima ssp. monogyna, which
contains santonin, was introduced from Europe and through cross breeding, additional
plant taxa were developed to produce santonin on Japanese soil (Yamaura 2011). In
Europe, Artemisia is also abundant in regions favorable to its growth. For instance, in
Spain, seven chemotypes of A. absinthium populate certain mountainous regions of the
Iberian Peninsula (Arinoa et al. 1999). Also, in the Americas, traditional cultures have
long utilized the therapeutic properties of Artemisia in native medical practices. For
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instance, various Native American tribes utilized Artemisia to treat gastrointestinal tract
conditions, gynecological disorders, malaria, as a vermifuge, and for a variety of other
conditions (DeBaggio and Tucker 2009). In various regions of South America, including
Southern Ecuador, Columbia and Peru, indigenous populations utilize the shrub Gynoxys
verrucosa in traditional medical practices. G. verrucosa is grown in the provinces of Loja
and Zamora-Chinchipe. The aerial parts of this plant are known as “guángalo” or
“congona” and the plant belongs to the Senecionea tribe of the Asteraceae family. It has
numerous therapeutic uses including direct application to the skin for the treatment of
skin infections and wound healing (Tene et al. 2007). One of the secondary metabolites
isolated from this species is the sesquiterpene lactone dehydroleucodine which possesses
numerous therapeutic properties (Tene et al. 2007).
In Argentina, dehydroleucodine has also long been used in traditional medicine as
an infusion of leaves of A. douglasiana, popularly known as ‘matico’. This traditional
preparation of boiled leaves was used to treat conditions such as gastric ulcers, external
treatment of skin injury, and dermal ulcers (Giordano et al. 1990). The first report of A.
douglasiana in Argentina was in 1967, in San Juan and Mendoza provinces (Snowden
2008), which led to the isolation and identification of dehydroleucodine, a sesquiterpene
lactone of the guaianolide type (Giordano et al. 1990). Dehydroleucodine was then
extensively studied by a number of Argentinean and other scientists for its therapeutic
action on a multitude of pathogenic conditions including peptic ulcer, gastric and
duodenal lesions concomitant with collitis, Allium cepa L. root growth, cancer, and
adipogenesis associated with obesity (Matsueda and Geissman 1967; Piezzi 1992;
Guardia et al. 1994; Sartor et al. 2001; Galvis et al. 2011; Costantino et al. 2013). Its
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absolute structure was elucidated by X-Ray analysis (Priestap et al. 2011), which was
consistent with previous NMR studies (Bohlmann and Zdero 1972).
1.7.2. Chemical Structure of Sesquiterpene Lactones
Sesquiterpene lactones are a large and structurally diverse group of plant
secondary metabolites (Heinrich et al. 1998). They are found in various plant families,
most ubiquitiously in Asteraceae (formerly Compositae) (Ivanescu et al. 2015).
Sesquiterpene lactones are sesquiterpenoids that contain a lactone ring (Chadwick et al.
2013). Lactones are cyclic esters of hydroxycarboxylic acids where an alkoxy group
replaces at least one hydroxyl group (Xavier et al. 2010).
Biosynthesis of sesquiterpene lactones occurs via farnesyl pyrophosphate (FPP),
in the endoplasmic reticulum of plants (Yu and Utsumi 2009). Three isoprene units are
condensed to synthesize a 15 carbon compound (Ren et al. 2016). Next, cyclization and
oxidative transformation occurs to create a fused lactone ring (Ramirez et al. 2016). The
lactonization process results from the oxidation of C12 to form the carbonyl function,
followed by hydroxylation at C6 or C8 (Chadwick et al. 2013).The resulting γ-lactone
ring is either cis or trans-fused (Ivanescu et al. 2015), and usually contains an αmethylene group, a group implicated mechanistically for various therapeutic effects of
sesquiterpene lactones (Arantes et al. 2011). This α-methylene-γ-lactone group acts as a
Michael acceptor and irreversibly alkylates nucleophiles (sulfhydryl or amino groups) in
enzymes, transcription factors, and other proteins (Schmidt 2006). The cytotoxic action
of sesquiterpene lactones likely derives from this irreversable alkylation, which results in
chemical and steric disruption of the moieties the α-methylene-γ-lactone group acts upon
(Kupchan et al. 1971). Sesquiterpene lactones with both α-methylene-γ-lactone groups
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and α,β-unsaturated ketones were found to be the most cytotoxic, but generally it is
believed that the α-methylene-γ-lactone group is the most responsible entity (Chadwick et
al. 2013). Sesquiterpene lactones with an OH or O-acyl group neighboring the αmethylene-γ-lactone are believed to have greater potency (Chadwick et al. 2013).
Other significant functional moieties in sesquiterpene lactones can include
hydroxyls, esterified hydroxyls, epoxide groups, halogen and sulfur atoms (Chaturvedi
2011).
While the alkylating effect of the α-methylene-γ-lactone group is implicated as the
primary mode of action of sesquiterpene lactones, other factors which confer biological
effects include the number of alkylating groups, lipophilicity, molecular geometry and
size, the target sulfhydryl, and functional groups in close proximity to the α-methylene-γlactone group (Chadwick et al. 2013; Chaturvedi 2011).
Since a single synthase may produce differential structures and post-sesquiterpene
synthesis modifications such as oxidation and glycosylation may take place (Lange et al.
1987; Little and Croteau 2002), sesquiterpene lactones possess significant structural
diversity with over 5000 reported chemical structures (Wedge et al. 2000). All structures
contain a fused 5-membered lactone group (γ lactone) with a carbonyl moiety at the alpha
position (Chadwick et al. 2013). However, numerous categories exist: germancranolides
(the most prevalent category and the precursor of the majority of sesquiterpene lactones)
possess a 10 membered ring; eudesmanolides have two fused 6 membered rings;
guaianolides have a 7 membered and a 5 membered ring, and a methyl group at C-4; and
pseudoguaianolides have a 7-membered and a 5-membered ring and a methyl group at C5. Oxidation of the 3C side chain of germacranolides is the genesis of the lactone ring in
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this category of sesquiterpene lactones, and guaianolides and eudesmanolides are further
derived from this precursor (Seaman 1982) (see Figure 6 below).

Figure 6. Sesquiterpene lactone structures (Chaturvedi 2011)
The chemical bonds of some sesquiterpene lactones are thought to possess the
source of their biological effects: for instance, in artemisinin, the cleavage of the peroxide
bond in vivo is thought to precipitate the release of reactive oxygen species which
neutralize the Plasmodium parasite which causes malaria (Ding et al. 2011) (see Figure 7
below). The chemical synthesis of artemisinin originated from a secret research project in
1963, called Project 523 (Cui and Su 2009) to find anti-malarial compounds both for the
North Vietnamese and for Chinese citizens (Graziose et al. 2010). In 1972, artemisinin, a
highly oxygenated sesquiterpene, containing a unique 1,2,4-trioxane ring structure, was
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extracted and identified as an efficacious anti-malarial compound from A. annua (Tu
1999). The effectiveness of artemisinin was initially underestimated in the Western world
(Attaran et al. 2004) but has demonstrated efficacy (along with its two main derivatives
artemether and artesunate) against both malaria and schistosomiasis (Zhang et al. 2014).

Figure 7. Artemisinin ((Ding et al. 2011)
Another chemical moiety in artemisinin, its endoperoxide bridge, is thought to
account for its anti-tumor effects. The iron in cancer cells cleaves the endoperoxide
bridge, and forms free radicals, which in turn, facilitate anti-cancer effects including
apoptosis, and inhibition of angiogenesis, invasion, and metastasis (Crespo-Ortiz et al.
2012).
Another sesquiterpene lactone, parthenolide, appears to work via a similar
mechanism as artemisinin on cancer cells: upon contact with Fe (II) in cancer cells,
parthenolide is cleaved to highly oxidizing cytotoxic metabolites (see Figure 8 below).

Figure 8. Parthenolide (Crespo-Ortiz et al. 2012)
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Additionally, parthenolide sensitizes cancer cells to other anti-cancer drugs such
as tamoxifen, by forming adducts with glutathione via cysteine bonding. Glutathione
functioning is subsequently impaired which leads to impaired intercellular redox balance
and a pro-apoptotic effect on the tumor cells (Guzman et al. 2005; Chadwick et al. 2013).
1.7.3. The Effect of Dehydroleucodine on the Proliferation and Migration of Tumor
Cells
Dehydroleucodine is a sesquiterpene lactone of the guaianolide group (Chaturvedi
2011), which also contains the α-methylene-γ-lactone ring (see Figure 9 below).
Dehydroleucodine was first isolated from Lidbeckia pectinata (Bohlman and Zdero
1972), but has also been reported from the aerial parts of A. douglasiana (Giordano et al.
1990).

Figure 9. Dehydroleucodine (Chaturvedi 2011)
Genotoxins that are used for cancer treatment usually affect cellular proliferation
by increasing replication stress (Jackson and Bartek 2009). Alterations in the coordinated
replication process typically result in the accumulation of stalled, asymmetric, or broken
replication forks (Gottifredi and Prives 2005). The defective activation of pathways that
repair DNA lesions generally trigger cell death programs (e.g., apoptosis), permanent cell
cycle withdrawal, or senescence (Bartek and Lukas 2007).
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Costantino et al. (Costantino et al. 2013) also showed the antiproliferative effect
of dehydroleucodine in human cancer cells. Analysis of the accumulation of DNA
damage markers revealed a striking correlation between the extent of DNA damage and
the activation of senescence and apoptosis programs, which were selectively stimulated
by lower and higher DhL concentrations, respectively. Clonogenic assays revealed the
very effective depletion of proliferating cells by dehydroleucodine-induced apoptotic and
senescence programs.
Further analysis of the novel role of dehydroleucodine in cellular senescence
showed that the antiproliferative process was associated with a delay in the progression
through the G2 phase that preceded an arrest in the following G1 phase. This phenomenon
was accompanied by reduced levels of cyclin B1 and higher p53 levels suggesting that
p53 has the ability to promote cell cycle withdrawal (Costantino et al. 2013). Transient
dehydroleucodine treatment (8 h) was equally as effective as continuous
dehydroleucodine treatment in terms of the numbers of cells that displayed premature
senescence. Our findings and others (Bailon-Moscoso et al. 2015) indicate that
dehydroleucodine activates different antiproliferative programs depending on the time
frame and on the concentration delivered to cells. Future studies on the effects of
dehydroleucodine in three-dimensional cultures and in solid tumors may lead to
improvements in the delivery efficiency of anticancer agents to regions of tumors that are
the most difficult to reach. Finally, it was demonstrated that the novel compound
dehydroparishin-B blocks cell proliferation (Priestap et al. 2012). Future work will be
required to address whether dehydroleucodine and dehydroparishin-B have additive
effects on cell cycle progression.
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It has been reported (Priestap et al. 2012) that dehydroparishin-B (DhP) inhibits
migration of B16 melanoma cells in a dose dependent manner (IC50 = 72.2 mM). In
addition, treatment of B16 melanoma cells with 5 mM (or higher) dehydroleucodine
significantly inhibits cell migration after 16 h exposure (IC50 = 5.4 μM). These
observations indicate an increased sensitivity of B16 melanoma cells to dehydroleucodine
as compared with dehydroparishin-B. The migratory inhibitory properties of
dehydroleucodine and dehydroparishin-B on this cell line are comparable with those of
staurosporine, a potent apoptotic agent (Wang et al. 2009). Consistent with these
observations, dehydroleucodine and dehydroparishin-B inhibit secretion of matrix
metalloprotease-2 (MMP-2), which is a known protease involved in migration and
invasion of B16 cells (Hofmann et al. 2000). In these assays, dehydroleucodine was 10
times more active than dehydroparishin-B, as well as 11,13-dihydro-dehydroleucodine.
Thus, it was hypothesized that the presence of the methylene γ-lactone moiety in the
molecule would be required for optimal activity.
1.7.4. The Effect of Dehydroleucodine on Bacterial Growth
The biomass of bacteria on Earth, comprising approximately 5×1030 cells, exceeds
that of all plants and animals (Whitman et al. 1998). Bacterial cells, which exceed human
cells in the human body by a ratio of ten to one (Sears et al. 2005), were here before us
and will most likely be here after us. With such a gargantuan presence in our bodies and
biosphere,the implications of bacteria on human health cannot be underestimated.
Parasitic bacteria are linked to approximately 20% of all human cancers (Zur Hausen et
al. 2009). Helicobacter pylori alone, which infects approximately half of all humans, is
linked to 5.5% of all cancers worldwide (Parkin 2006). Helicobacter pylori serotypes
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cause inflammation resulting in aberrant methylation in the CpG islands of multiple
promoters, including those of several tumor-suppressor genes, as well as general
hypomethylation, which is linked to the epigenetic loss of gene function, genomic
instability, and increased cancer risk (Niwa and Ushijima 2010).
Compounding the infectious disease problem is the emergence of a hyper
connected post-industrial world where abundant host-to-host interactions increase the
presence and proliferation of parasites (Okeke and Edelman 2001). This mass prokaryotic
exodus has resulted in the parasitic colonization of vulnerable hosts. Sepsis infection,
caused primarily by Gram-positive bacterial infection (Martin 2012), which can trigger
an inflammatory response leading to multiple organ failure, is characteristic of this trend.
While sepsis occurs in sterile and less crowded ICUs at a rate of 6%, it can occur at a rate
of up to 30% in more crowded ICUs (Vincent et al. 2006). Sepsis rates overall are
increasing and over 200,000 people die each year of sepsis in the United States alone; a
far greater number than mortality from HIV, breast cancer, or stroke (Martin 2012).
Increasing rates of antibiotic resistance are also alarming and add to the overall
magnitude of the infectious disease conundrum. It has been proposed that in Gramnegative bacteria the outer cell membrane (diderms) evolved as a protective mechanism
against antibiotic selection pressure (Gupta 2011). Due to this state of affairs, it is a
finding of significant importance that certain sesquiterpene lactones have been found to
exhibit significant antibacterial activity against both Gram-negative and Gram-positive
species (Vega et al. 2009).
Dehydroleucodine has been shown to be effective against several bacterial
species, including Bacillus cereus, Staphylococcus aureus, S. epidermis, Escherichia coli
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and Klebsiella pneumoniae (Vega et al. 2009). In addition, it has also been shown to be
active against H. pylori strains (Vega et al. 2009). Recent work has also shown
dehydroleucodine to be active against methicillin resistant S. aureus (MRSA) and S.
epidermis (MRSE), respectively (Ordonez et al. 2011). These observations show that
both the α-methylene-γ-lactone group and α-β-unsaturated moieties are structurally
necessary for the observed therapeutic effects although other structural moieties may also
be required. However, no mechanism of action has been proposed. More lately, we have
found that dehydroleucodine also inhibits growth as well as the secretion of several
toxins of Pseudomonas aeruginosa (i.e., ExoS and elastase A) (Mustafi et al. 2015).
Thus, sesquiterpene lactones have the potential to be utilized more specifically by
targeting a resistant mechanism, such as the inhibition of a multiple drug resistance efflux
pump and/or altering an unknown mechanism.
1.7.5. Additional Therapeutic Effects of Dehydroleucodine
Peptic ulcer disease is characterized by chronic inflammation of the stomach or
duodenum that affects as many as 10% of the population at some time in their lives
(Penissi et al. 2003). Traditional cultures in Argentina utilize A. douglasiana for
treatment of peptic ulcer, which led to cytoprotective studies of extracted
dehyrdroleucodine from A. douglasiana. These studies revealed that dehydroleucodine
pretreatment prevents gastrointestinal damage in response to necrosis-inducing agents
such as absolute ethanol in a dose-dependent manner (Giordano et al. 1990; Penissi et al.
2003).
Additionally, these studies revealed that the exocyclic methylene group
conjugated to a γ-lactone is required for dehyroleucodine's cytoprotective activity, but the
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presence of the β-substituted or α-β-unsubstituted cyclopentenone ring is not required,
although it is implicated in additional dehydroleucodine activity, including anti-tumor,
anti-microbial and anti-feedant properties (Giordano et al. 1990; (Penissi et al. 1998;
Penissi and Piezzi 1999), and in inhibiting pro-inflammatory mediator release from mast
cells (Penissi et al. 2003).
Given these structural and functional components of dehydroleucodine and its
cytoprotective effect, it is perhaps unsurprising that dehydroleucodine has also been
found to have antidiarrheal effects. In a study where it was suggested that the α2adrenergic receptors mediate the effect of dehydroleucodine on intestinal motility,
dehydroleucodine inhibited castor oil-induced diarrhea in mice and also reduced
intraluminal accumulation of fluid (Wendel et al. 2008).
Dehydroleucodine has various other therapeutic efficacies beyond its antiadipogenic, cytoprotective, and anti-diarrheal effects. For instance, it has been found to
have an anti-parasitic effect on Chagas disease, a tropical disease of the cardiac and
neurological system found primarily in endemic areas of 21 Latin American countries
through infection by the parasite Trypanosoma cruzi. Only two drugs, Benzindazol and
Nifurtimox, are accepted for treatment of Chagas disease, yet both cause severe side
effects and are of controversial efficacy. Dehydroleucodine was found to induce
apoptosis in the replicative epimastigote form, and the infective trypomastigote form,
whereas Benzindazol and Nifurtimox do not (Jimenez et al. 2014). Trypanocidal activity
of dehydroleucodine may be mainly dependent on the covalent bond formation between
the γ-lactone moieties and -SH group of trypanothione and trypanothione-dependent
enzymes affecting these parasite oxidative stress conditions (Krauth-Siegel et al. 2003).
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Thus, dehydroleucodine shows an adequate selectivity index comparable with
trypanocidal drugs.
Dehydroleucodine also inhibits the in vitro growth of Leishmania mexicana
(Barrera et al. 2008), an obligate intracellular protozoan parasite that causes the one form
of leishmaniasis which can present with ulcers of the skin, mouth, and nose (Barrett and
Croft 2012). This currently affects 12 million people worldwide, and causes between 20
to 50 thousand deaths each year (Lozano 2010). With two million new cases each year
(Lozano 2010), dehydroleucodine 's IC50 of 2–4 μM on Leishmania mexicana, which
constitutes a higher efficacy than ketoconazole, appears to be a much needed and
promising therapeutic modality.
Additional anti-microbial activity was found with in vitro treatment with
dehydroleucodine of Staphylococcus aureus and S. epidermidis (Ordonez et al. 2011).
The lactone ring of dehydroleucodine was found to be essential for this antimicrobial
activity (Ordonez et al. 2011). As S. aureus is the microbe implicated in methicillin
resistant S. aureus (MRSA), which has resulted in deaths that exceed the mortality rates
for HIV/AIDS in the United States, dehydroleucodine's effect on these microorganisms is
an important avenue for therapeutic investigation (Klevens et al. 2007). It is generally
accepted that the α-methylene-γ-lactone moiety is the most important part of these
compounds to confer biological activity. However, other sesquiterpene lactones
containing neither the α-methylene-γ-lactone moiety nor chlorine, bromine, and hydroyxl
groups (groups possessed by other sesquiterpene lactones which exhibit activity) in their
structure are active compounds (Ozcelik et al. 2009). Therefore, it is possible to
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hypothesize that these structural requirements are important, but not essential for a potent
antimicrobial activity.
1.8. Research Questions
The 3T3-L1 murine preadipocyte cell line is a common experimental model
system for adipogenesis research which allows for the observable accumulation of
triglycerides in this system upon differentiating in culture (Rosen and Spiegelman 2000).
Adipocyte differentiation is induced by the expression and/or phosphorylation of specific
genes such as AMPKα (Kemp et al. 2003), Akt1 (Rosen and Spiegelman 2000), Erk1/2
(Rosen and Spiegelman 2000), transcriptional factor peroxisome proliferator-activated
receptor γ (PPARγ) (Spiegelman et al. 1993) and factors from other transcription factor
families, including CCAAT/enhancer-binding proteins (C/EBPs) (Bost et al. 1990),
signal transducers and activators of transcription (STATs), and Kruppel-like factor (KLF)
proteins (Mori et al. 2005). Most of these regulators have been discovered in vitro,
utilizing the 3T3-L1 or 3T3-F442A murine preadipocyte cell lines (Rosen and
Spiegelman 2000).
After preadipoycte proliferation to confluence, an induction media (IM) cocktail
of insulin, dexamethasone, and 3-isobutyl-1-methylxanthine (IBMX) initiates the
differentiation program (Okamura et al. 2010). Growth arrest of confluent preadipoyctes
is followed by rapid expression of C/EBPβ but not its activation (Choi et al. 2013). Other
early adipogenic transcription factors include C/EBPδ , and Kruppel-like factors 4 and 5.
The process of mitotic clonal expansion (MCE), which coincides with the activation of
C/EBPβ, then follows, where growth arrested preadipocytes exit the cell cycle and
undergo two to four rounds of expansion (Tang et al. 2003). CCAAT/enhancer-binding
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proteins Beta is activated via sequentially phosphorylation, followed by dimerization of
the phosphorylated C/EBPβ, which enables it to bind its DNA binding element with the
help of reactive oxygen species (Tang et al. 2005; Tang et al. 1999; Kim et al. 2007; Lee
et al. 2009). The activation of ERK and p38 are necessary for this process and MCE is
required for the activation of the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)
pathway (Rosen and Macdougald 2006; Zhang et al. 2009).
Indicators of whether preadipocytes are undergoing MCE include assaying cyclin
and cyclin-dependent kinase (CDKs) cell cycle progression markers. The cell cycle
progression or its arrest is evidenced by either the initiation or downregulation of these
markers which correspond to different stages of the cell cycle. For instance, during G1
phase, D-type cyclins and cyclin E are activated. Next, activated cyclin D assembles with
CDK4 or CDK6 and cyclin E binds to CDK2 (Choi et al. 2012). Cyclins A and B are then
recruited to CDK2 and CDK1, respectively, and the resulting binding induces cell cycle
progression through S phase and mitosis. (Choi et al. 2012).
The aforementioned early adipogenic regulators such as C/EBPβ induce PPARα
and C/EBPγ expression approximately 36 to 48 hours after induction. Peroxisome
Proliferator Activated Receptor Alpha and C/EBPγ then stimulates the expression of
triglyceride synthesis genes, such as the genes for adipocyte fatty acid-binding protein 2
(aP2), fatty acid synthase (FAS), acetyl-coenzyme A carboxylase (ACC), which result in
the concentrated lipid droplets indicative of the mature adipoycte phenotype (Moseti et
al. 2016).
Using 3T3-L1 preadipocytes, an in vitro system for adipocyte differentiation, it
has been demonstrated that dehydroleucodine significantly inhibited the differentiation of
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murine preadipocytes and also resulted in a significant decrease in the accumulation of
lipid content by a dramatic downregulation of the expression of adipogenic-specific
transcription factors PPARγ and C/EBPα (Galvis et al. 2011).
Since the level of expression of PRARγ and C/EBPα is undetectable in
preadipocytes, but increases two days after induction of differentiation into mature
adipocytes, and are maximally expressed five days after the induction of differentiation
(Rosen et al. 2000), it would appear that the selective inhibition of PRARγ and C/EBPα
by DhL is responsible for its observable anti-adipogenic effects, which include the
inhibition of differentiation, and decreased triglyceride accumulation (Galvis et al. 2011).
However, numerous questions arise from these evidentiary foundations. To what
extent does DhL affect the process of preadipoycte proliferation which is a perquisite for
the subsequent process of mitotic clonal expansion? How early does DhL inhibit the
progression of the 3T3-L1 preadipocyte through the differentiation program? Does DhL
inhibit cell cycle regulators cyclin A, cyclin D, CDK2 and CDK6? If so, what is the
timing of this inhibition? By evaluating these queries and determining what genes may be
altered at what time points by DhL, a greater understanding of the precise role of the
mechanism through which DhL arrests adipogenesis will be achieved. Therefore, I
propose the following Specific Aims:
1.8.1. First Aim: Determine the role of dehydroleucodine during the early steps of in
vitro 3T3-L1 preadipocytes differentiation
I will examine the effect of dehydroleucodine on the expression of specific genes
involved in the two early and essential steps of adipogenesis: 3T3-L1 preadipocyte
proliferation and cloning expansion.
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1.8.2. Second Aim: Elucidate how 11,13-dihydro-dehydroleucodine derivatives affect
different steps of in vitro 3T3-L1 preadipocytes differentiation
Utilizing a variety of methods, I aim to study the anti-adipogenic effects of 11,13dihydro-dehydroleucodine derivatives on preadipoycte proliferation, and the molecular
timing of its mode of action in relation to PPARγ and mitotic clonal expansion, including
western blotting for signaling markers indicative of different temporal stages of these
processes, and ORO assaying of triglyceride accumulation after treatment subsequent to
the application of a PPARγ agonist.
1.8.3. Third Aim: Identify the additional compound(s) accountable for inhibition of
in vitro 3T3-L1 preadipocyte differentiation
As preliminary results showed that structures closely related to dehydroleucodine
may be responsible, compound(s) will be also tested for anti-adipogenic effects.
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II. DEHYDROLEUCODINE INHIBITS MITOTIC CLONAL EXPANSION DURING
ADIPOGENESIS THROUGH CELL CYCLE ARREST
2.1. Introduction
Dehydroleucodine (DhL), a sesquiterpene lactone of the guaianolide group, which
contains an α-methylene-γ-lactone ring, has been isolated from the aerial parts of
Artemisia douglasiana (Chaturvedi 2011; Giordano et al. 1990). Although DhL
significantly inhibited the differentiation of 3T3-L1 preadipocytes in a time and
concentration dependent manner by blocking the expression of PPARγ and C/EBPα
(Galvis et al. 2011), the exact cellular and molecular mechanism by which DhL affected
differentiation of 3T3-L1 preadipocytes is still not well understood. Interestingly, DhL
inhibited proliferation and altered the cell cycle of cancer cells (Costantino et al, 2013).
Therefore, the inquiry behind this line of experiments was founded on the hypothesis and
possibility that DhL affects the early stage of the differentiation of 3T3-L1 preadipocytes
(e.g., mitotic clonal expansion). The objective of this line of experiments was to explore
the effect of DhL on MCE during differentiation of 3T3-L1 preadipocytes, as well as
elucidate aspects of the mechanism by which these effects occur.
The effects of DhL were investigated on adiopgenic processes modeled in vitro by
utilizing a 3T3-L1 murine preadipoycte model system (Ruiz-Ojeda et al. 2016; Green and
Kehinde 1975), where cells are differentiated into mature adipocytes over the course of
approximately 9 days through stimulation with an induction media (IM) cocktail
consisting of growth media (GM) with dexamethasone, isobutylmethylxanthin (IBMX),
and insulin, in the first phase of differentiation, and GM with insulin alone in the second
phase of differentiation. The transition to a mature adipogenic phenotype is evidenced by
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the accumulation of triglycerides (Kassotis et al. 2017; Rosen and Spiegelman 2000), as
well as the expression and/or phosphorylation of numerous genes including Akt1, Erk1/2,
(Jeong et al. 2015), the transcriptional factor peroxisome proliferator-activated receptor γ
(PPARγ), and CCAAT/enhancer-binding proteins (C/EBPs) (Tao et al. 2016).
CCAAT/enhancer-binding Protein Beta is expressed within two to four hours of
treatment with IM, and crucially acquires DNA binding activity at 12 hours post
induction, which coincides with the essential process of mitotic clonal expansion (MCE).
Mitotic clonal expansion, where cells undergo growth arrest followed by two to four
rounds of mitosis, is a necessary phase for the progression and completion of the
adipocyte differentiation program (Tang et al. 2003). CCAAT/enhancer-binding Protein
Beta’s DNA binding functionality is aided by retinoblastoma protein (Rb) (Chen et al.
1996). In contrast to Rb’s role in negatively regulating transcription factor E2F-1 to
prevent quiescent cells from passing a restriction point in G1, Rb binds with and activates
C/EBPβ and does so specifically during the adipogenic differentiation process (Chen et
al. 1996). Mitotic clonal expansion also requires a synchronized activation of the ERK
and p38 signaling pathways (Aouadi et al. 2007; Tang et al. 2003; Yang et al. 2002).
Progression from G1 to S requires downregulation of p27 and activation of CDK2 by
cyclins E and A (Patel and Lane 2000; Sherr et al. 1999). Cyclin D1 and cyclin E are
activated during the G1 phase of the cell cycle (Choi et al. 2012). Once activated, cyclin
D1 assembles with CDK4 or CDK6, or both, and cyclin E binds to CDK2 (Choi et al.
2012). Cyclin A and B are then recruited to CDK2 and CDK1, respectively; associations
necessary for the inducement of cell cycle progression through S phase and mitosis (Choi
et al. 2012). Activated C/EBPβ, along with C/EBPδ, triggers the expression of C/EBPα,
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which leads to the expression of PPARγ (Farmer et al. 2006). Once C/EBPβ is activated
during MCE, it targets the promoter of the chromatin regulator gene Kdm4b, whereas
C/EBPβ as a co-factor targets the promoters of cell cycle genes, including Cdc45l (cell
division cycle 45 homolog), and demethylates H3K9me3 in their regulatory regions,
which in turn activates their transcription (Guo et al. 2012). Cyclin dependent kinase 451
is a component of the CMG complex, which is required for the initiation and elongation
steps of eukaryotic chromosomal DNA replication (Tercero et al. 2000). Histone
demethylase CDC25A is required for progression from G1 to the S phase of the cell
cycle, and acts by activating the pro-mitotic Cdc2 (CDK1) and also by activating G1/S
cyclin-dependent kinases CDK4 and CDK2 by removing inhibitory phosphate groups
from adjacent tyrosine and threonine residues (Goloudina et al. 2003). CCAAT/enhancerbinding Protein Beta also stimulates expression of histone H3K9 demethylase JMJD2B,
which removes H3K9me3 and H3K9me2 on the promoters of PPARγ and C/EBPα,
which stimulates their expression (Guo et al. 2012; Jang et al. 2017). Myeloid/lymphoid
or mixed-lineage leukemia protein 3 and MLL4, H3K4me1/2 methyltransferases that
become part of the activating signal cointegrator-2-containing complex (ASCOM), both
redundantly co-activate PPARγ and C/EBPα (Lee et al. 2008; Qi et al. 2003; Kuang et al.
2002; Hong et al. 2001). In opposition to these effects, histone methyltransferase G9a
represses PPARγ expression by adding H3K9me2 to the entire PPARγ gene locus and
promotes Wnt10a expression independent of its methyltransferase activity, therefore
repressing adipogenesis (Wang et al. 2013).
Therefore, to investigate the role of DhL during the early steps of in vitro 3T3-L1
preadipocytes differentiation, the aforementioned 3T3-L1 experimental system was

133

utilized and 3T3-L1 preadipocytes were incubated in IM with wells of 3T3-L1
preadipoyctes in growth media (without dexamethasone, IMBX, or insulin) as controls.
Artemesia douglasiana was obtained from Mendoza, Argentina, and DhL was extracted,
purified and identified. Treatments of varying concentrations of dehydroleucodine for
varying time points were then applied. To examine whether DhL causes stage-dependent
inhibition of adipocyte differentiation, 3T3-L1 cells were treated with 9 µM DhL at
several time points after induction with IM. The Oil Red O assay, in which lipid droplets
can be quantified (see Materials and Methods below) was utilized to determine whether
and when DhL inhibited differentiation.
Next, the effect of DhL on the expression of CBEPin 3T3-L1 cellsan early
marker of adipogenesis, was investigated via western blotting to gather additional
evidence regarding when in the molecular cascade DhL exerts its effects. Early stage
markers further down the cascade, PPARγ and C/EBPα, were also investigated in a
similar fashion utilizing western blot.
The effects of DhL on proliferation of 3T3-L1 preadipocytes after induction of
differentiation with IM were investigated via a cell proliferation assay. Additionally, the
effects of DhL on cell cycle progression were investigated via flow cytometry and via
western blotting of cyclin D1, cyclin A, and CDK2.
Since several histone methyltransferases and demethylases have been reported to
be involved in adipogenesis, the expression of JMJD2B and the cell cycle genes
CDC25A and CDC451 in DhL-treated 3T3-L1 cells during the MCE process to gain
further mechanistic clues, was investigated.
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Lastly, to examine whether whether DhL affects the expression of PPARγ as well
as methytransferases involved in its expression during adipogenesis, qPCR was utilized
to gage mRNA levels of PPARγ, MLL3, MLL4 and G9a in DhL–treated 3T3-L1 cells.
2.2. Materials and Methods
2.2.1. Reagents
3T3-L1 cells were purchased from the American Type Culture Collection
(Manassas, VA). The Dulbecco’s Modified Eagle’s Medium (DMEM), bovine calf
serum, and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA). All
reagents were obtained from Sigma-Aldrich unless otherwise stated. Antibodies against
C/EBPβ, PPARγ, FAS, phospho(p) AMPK, C/EBPα, cyclin A, cyclin D1, CDK2, CDK4,
p-Rb, p27, total(t)-Erk1/2, phospho(p)-Erk1/2, t-Akt, and p-Akt, were obtained from Cell
Signaling Technology (Beverly, MA). The dilution was 1 uL in 10 mL of tris-buffered
saline (TBS) and Polysorbate 20 (TBST) (1:10,000 dilution). All secondary antibodies
were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). All
chemicals were of analytical grade. A Triglyceride Quantification Kit was purchased
from BioVision Research Products (Mountain View, CA).
2.2.2. Cell Culture and Differentiation
Reagents used to culture these cells in growth media (GM) include DMEM, 1%
penicillin/streptomycin and 1% L-glutamine, all of which were purchased from
Mediatech, Inc. (Manassas, VA), and 10% fetal bovine serum purchased from Invitrogen
(Carlsbad, CA). Two different recipes for the induction media (IM) utilized to trigger
adipoycte differentiation were employed during different times in the process. For the IM
used during day 1 and day 3 of differentiation, GM was supplemented with 670 nM
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insulin (IS), 65 nM dexamethasone (DEX) and 0.5 mM 3-isobutyl-1-methylxanthine
(IBMX). Induction media applied to the 3T3-L1 cells during days 5, 7, and 9 of
differentiation consisted of GM supplemented with 670 nM of insulin. Cells of passage
three or below were grown to confluence in a humidified atmosphere of a 5% CO2
incubator at 37°C.
2.2.3. Treatments
Dehydroleucodine (DhL) and dehydroparishin-B (DhP) was isolated as previously
described (Giordano et al. 1990; Priestap et al. 1990) from Artemisia douglasiana
collected in Mendoza, Argentina, voucher #37546 (Figure 10). Dehydroleucodine was
gently reduced through the utilization of sodium borohydride to obtain the corresponding
11,13DH-[11R]-DhL epimer (DH-DhL), which was purified as previously described
(Galvis et al. 2011). 3T3-L1 cells were exposed to 11,13DH-[11R]-DhL throughout the
entire differentiation process, unless otherwise indicated.
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Figure 10. Artemisia douglasiana Voucher
2.2.4. Cell viability assay
The

MTT

(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl

tetrazolium

bromide)

(Thermo Fisher Scientific. Inc., Pittsburgh, PA) colorimetric assay was utilized to
quantify cellular viability. Cells (1 x 106 cells/mL) were incubated at 37°C and 5% CO2
in the absence or presence of different concentrations of 11,13DH[11R]-DhL for various
periods of time. After this initial incubation, cells were incubated with MTT reagent at a
final concentration of 10μl/ml, and further incubated at 37°C and 5% CO2. Next, the
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formazan crystals were dissolved in a detergent reagent of sodium dodecyl sulfate in
diluted hydrochloric acid, and each condition was then quantified via spectrophotometry
(Ultrospec 2100 Pro UV/Visible Spectrophotometer) at an optical density of 570 nm
(OD570). The trypan blue dye exclusion assay was also utilized for the DhP series of
experiments. Cells (1x105) were plated in 6-well plates in DMEM +10% FBS, serumstarved for 12 h, and then stimulated with 10% serum for 24 h in the absence or in the
presence of different concentration of dehydroparishin-B (1 to 9 μM). After incubation,
the cells were removed from the 6-well plate by treatment with trypsin. Cell suspensions
were aspirated, centrifuged at 600 rpm for 5 minutes and washed twice with sterile PBS
(pH 7.4). The cell suspension was then treated with trypan blue dye (0.4% solution) at a
ratio of cell suspension:dye 4:1 and placed in hemocytometer. Live (unstained) and dead
(blue stained) cells were counted using a 63x magnification in phase-contrast inverted
microscope. The untreated cells (control) were also processed simultaneously under the
identical conditions.
2.2.5. Oil Red O staining, microscopy, and spectrophotometry
On the tenth day of the differentiation program, the adipocytes were fixed with
10% formalin (Thermo Fisher Scientific. Inc., Pittsburgh, PA) solution in phosphate
buffer saline (PBS) for 1 hour at 4°C. After fixing, cells were washed with 60%
isopropanol, and then stained with 0.3% Oil Red O solution for 45 minutes at room
temperature. Cells were washed twice with double distilled water. The stained lipid
droplets were visualized by light microscopy and photographed with a digital Leica DC
500 camera at 100x magnification. Images from 250 3T3-L1-control cells and 250
11,13DH[11R]-DhL treated cells were examined. The size distribution of lipids droplets
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was analyzed by the NIH Image J software, which can be accessed at the web site
(http://rsb.info.nih.gov/nih-image/). For quantification of the lipid content, Oil Red O was
eluted from cells by adding 100% isopropanol for 20 minutes, and quantified by
spectrophotometry at OD540. Cells were treated for all days of the experiment with the
appropriate sesquiterpene lactone, unless otherwise indicated.
2.2.6. Triglyceride assay
The lipid droplets in the cellular suspension were analyzed for total concentration
of triglyceride in the following manner: cells were washed with PBS, scraped,
centrifuged, and lysed with 5% Triton X-100. Cell lysates were then centrifuged at
10,000 x g for 20 minutes at 4°C. Then, cell supernatants were used to measure the
conversion of triglycerides to fatty acids and glycerol. The supernatants were then
oxidized and quantified at OD540 based on a triglyceride standard curve (Cayman
Chemical, Arbor, MI).
2.2.7. Cell proliferation assay
The 3T3-L1 cells (5 x 104 cells/mL) were cultured in appropriate plates and then
incubated with GM. When 3T3-L1 cells reached confluence, cells were incubated in a
humidified atmosphere of a 5% CO2 incubator at 37°C with IM in the absence or in the
presence of various concentrations of 11,13 DH[11R]-DhL up to 48 hours. Cells were
then harvested and quantified using an automated cell counter machine from Bio-Rad
(Hercules, CA).
2.2.8. Western blot analysis
Cell lystate preparation was conducted via the washing of cell monolayers with a
mixture of ice-cold lysis buffer (20mM Tris-HCL pH7.5, 150mM NaCl, 1% NP40, 1mM
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Na2 EDTA, and 0.1% Na Deoxycholate), protease inhibitors, and phosphatase inhibitors.
After centrifugation, protein concentrations were quantified through the use of the BCA
protein assay. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose
membranes (Thermo Fisher Scientific. Inc., Pittsburgh, PA), blocked in 5% bovine serum
albumin overnight at 4°C, and probed with the appropriate primary antibodies.
Membranes were next incubated with horseradish peroxidase-conjugated secondary
antibodies overnight at 4°C. Bands were visualized with enhanced chemiluminescence
and the intensities of the bands were quantified in WCIF Image J for Windows
(University Health Network Research, Toronto, Canada) and relative levels of proteins
were determined by densitometric analysis.
2.2.9. Flow Cytometry Analysis
Cell cycle progression was measured by flow cytometric analysis after propidium
iodide staining. Post confluence 3T3-L1 preadipocytes were incubated with IM in the
absence or presence of 11,13DH[11R]-DhL for 24 hours. A suspension of cells were
fixed with 70% ethanol at 4°C and then incubated with propidium iodide staining buffer
for one hour. Cells were analyzed with an Acurri-C6 Flow Cytometer (BD Biosciences,
San Diego, CA) and cell cycle progression was measured with the Modfit LT program
(Verity Software House, Topsham, ME).
Caspase-3 was analyzed by flow cytometry using PE-conjugated monoclonal
active caspase-3 antibody apoptosis kit (BD Biosciences, USA). Cells (1x106 cells/0.5
mL) were collected, washed once with cold PBS and then washed twice with a washing
buffer, before PE-conjugated monoclonal anti-active caspase-3 antibodies (BD
Biosciences, 1:500) were added. After washing, cells were incubated for 30 minutes at
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room temperature. The marked samples were analyzed by flow cytometry as described
above.
2.2.10. High-performance liquid chromatography
The high-performance liquid chromatography (HPLC) equipment consisted of a
SpectraSystem SMC1000 solvent delivery system, vacuum membrane degasser, P4000
gradient pumps and AS3000 autosampler (Thermo Electro Corporation, San Jose, CA).
Column effluent was monitored at 254 nm with Spectra System UV6000LP variable
wavelength PDA detector and ChromQuest 4.1 software. DhL and DhP were separated
using a C18 YMC column (A-302, 150 Å~ 4.3 mm i.d., S-5 μ m, 12 nm; Waters) and the
following solvents: A. acetonitrile; B. 0.1 % TFA in water. System 1: linear gradient 10%
to 100% A in 120 min; flow rate 1 ml/min. Preparative HPLC was performed in the
above equipment with a XTerra Prep MS C18 OBD column, 15 μ m, 19 Å~ 50 mm
(Waters) and the solvent system 25% acetonitrile -75 % 0.1 % TFA in water (isocratic);
flow rate 2.5 ml/min.
2.2.11 Compound Extraction, Purification and Identification
The dried crushed plant material (100 g, dry weight) was exhaustedly extracted
with boiling methanol. The methanol extracts were extracted with hexane ethyl acetate,
acetone, and aqueous 5% acetic acid and 5% NaCO3H, respectively. The organic phases
were set-aside and evaporated. The aqueous NaCO3H phases containing dehydroparishinB were acidified with 0.1N HCl and extracted with ethyl acetate. The organic and water
phases were evaporated to dryness to give an oily residue (280 mg), which was subjected
to column chromatography on silica gel (60, H70-230, Merck 7734). The column was
eluted with hexane containing increasing proportions of ethyl acetate (0 to 40 %), and
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fractions were monitored by TLC. Fractions containing the Rf 0.29 compound were
joined and re-chromatographed in a similar way to give pure dehydroparishin-B (3.2 mg).
(7R)-2-Oxo-guaia-1(10),3(4),5(6),11(13)-tetraen-12-oic acid, dehydroparishin-B
(1): White needles (ethyl acetate); HPLC, Rt 14.92 min (system 1); UV/PDA, λmax 239,
256, 317 nm; GC/MS, Rt 18.74 min; MS (EI), m/z (rel. int.): 244 (100) [M]+, 198 (35.1)
[M-CO2-H2]+, 183 (63.3), 159 (46.6), 155 (46.9), 141 (34.1), 129 (50.6), 128 (48.5), 115
(64.0), 91 (48.1), 77 (38.2).1H NMR and 13C NMR, see Table 1. ESI-TOF-MS m/z
245.1162 [M + H]+ (calcd for C15H17O3, 245.1172), 267.0997 [M + Na]+ (C15H16O3Na,
267.0992), 289.0817 [M – H + 2Na]+ (C15H15O3Na2, 289.0811).
2.2.12. Real Time Quantitative PCR
After treatment of 3T3-L1 cells with DhL, RNA was extracted from 3T3-L1 cells
by using RNeasy Plus Mini Kit (QIAGEN, USA) and a cDNA library was synthesized by
using iScript cDNA synthesis kit (BIO-RAD, USA) according to manufacturer’s
suggestion. Reverse transcription was performed with 200 ng of total RNA-sample, 1X
iScript reaction mix and 1XiScript reverse transcriptase. Quantitative analysis of cDNA
was performed using CFX96 TouchTM real time PCR detection system (BIO-RAD, USA)
and SsoAdvancedTM 227 universal probes supermix (BIO-RAD, USA) according to
manufacturer’s instruction. Briefly, amplification of the target cDNA was carried out
with each 10 μL PCR mixtures containing 1 μL cDNA, 5 μL SSO probes, 0.5 μL primers
and 3.5 μL nuclease free water. Target cDNA was amplified by using verified
commercially available primer pairs (Target cDNA was amplified by using verified
commercially available primer pairs (Mm01205647_g1 for Beta actin, NM_007658.3 for
CDC25A, NM_003504 for CDC451, NM_172132.2d for JMJD2B, NM_001081383.1 for
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MLL3, NM_001290573.1 for MLL4, NM_001289413.1 for G9A, NM_002046.5 for
GAPDH, Mm00440940_m1 for PPARγ and Mm00514283_s1 for C/EBPα, Thermo
Fisher Scientific, USA). The conditions of the PCR reaction were set as follows: it was
begun by a denaturation cycle at 95°C for 30 min, followed by 95°C 10 min and 60°C for
25 min, respectively. The mRNA expression was normalized with beta-actin. Relative
gene expression was expressed as fold change in mRNA expression level compared with
the control.
2.2.13. Statistical analysis
All experiments were repeated at least three times. The standard error of the
mean (S.E.M.) of triplicates was utilized and significance was analyzed by one-way
ANOVA or Student’s Test. All statistical data reflect averages of the three independent
experiments. Results with *P<0.01 and **P<0.0001 were considered statistically
significant.
2.3. Results
2.3.1. Dehydroleucodine mostly inhibits early stages of adipocyte differentiation
through attenuation of mitotic clonal expansion
Previous studies have demonstrated that DhL and their epimers inhibited the
differentiation of 3T3–L1 preadipocytes into adipocytes (Galvis et. al., 2011). Structure
of DhL is depicted in Figure 11A. Adipocyte differentiation occurs through the
preadipocyte stages, which can be clearly divided into proliferation and mitotic cloning
expansion (early stage) and terminal differentiation (late stage) (Ali et al. 2013).
Accordingly, we examined whether DhL causes stage-dependent inhibition of adipocyte
differentiation. 3T3-L1 cells were treated with 9 M DhL at several time points after
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induction with IM as shown in Figure 11B. Treatment with DhL at early stages (days 0-2
and 2-4) significantly inhibited adipogenesis (Figure 11B). The treatment of DhL after
day 4 (days 4-6 and 6-8) showed moderate inhibition of adipogenesis for days 4-6 (16±2
% of inhibition), whereas the treatment for days 6-8 showed no inhibition at all. As
expected, the addition of DhL on day 0, strongly inhibited differentiation of 3T3–L1
preadipocytes (Figure 11B). Consistent with these observations, when cells were treated
with DhL during early stage (day 0-2) or during the whole process (day 0-8), the
intracellular triglyceride content significantly decreased in a concentration-dependent
manner (Figures 11C and E).
The model system that was utilized, 3T3-L1 preadipocytes, undergoes mitotic
clonal expansion through the upregulation of C/EBPβ and C/EBPδ during the early stage
of adipocyte differentiation (Wu et al. 1996). This process is followed by the activation
of the downstream signaling molecules PPARγ and C/EBPα, which are critical for
terminal adipocyte differentiation (Farmer 2005). Therefore, the effect of DhL on the
expression of CBEPwas examined during the first 48 hours after stimulation of 3T3-L1
preadipocytes with IM (Figure 11D). Expression of CBEP was significantly decreased
in a concentration-dependent manner when cells were treated with DhL (Figure 11D). In
addition, PPARγ and C/EBPα expression in adipocytes treated with DhL strongly
decreased compared with the control cells (Figure 11F).
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Figure 11. Inhibitory effect of dehydroleucodine on triglyceride content and
adipogenic transcription factors during mitotic clonal expansion. Preadipocytes were
cultured in differentiation medium containing 9 M dehydroleucodine for day 0-2, 2-4,
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4-6, 6-8 and 0-8, respectively. (A) Chemical structure of dehydroleucodine. (B)
Preadipocytes were treated as described above. Cells were stained with Oil Red O and
then visualized as described in Material and Methods. All values are presented as the
mean ± SEM of three independent experiments performed in triplicate. *P<0.01 vs. no
dehydroleucodine treatment. Cellular triglyceride content of preadipocytes treated with 0,
3, 6, and 12 M dehydroleucodine for day 0-2 (C) and 0-8 (E) was determined as
described in Material and Methods using a Triglyceride Kit. Results are shown as relative
percentage of control without dehydroleucodine. DMSO was used a vehicle control. All
values are presented as the mean ± SEM of three independent experiments performed in
triplicate. *P<0.01 versus no dehydroleucodine treatment. Cells were incubated with
dehydroleucodine, harvested and the lysates were subjected to western blot analysis for
PPAR, C/EBP(F) and C/EBPD). GAPDH was used as loading control. The
Western blots were performed three times, and a representative image of the three
independent experiments is shown (D, F).
2.3.2. Dehydroleucodine inhibits mitotic clonal expansion through down regulation of
cyclins A and D and cyclin-dependent kinases 2 and 4
CCAT/Enhancer Binding Protein Beta, a specific transcriptional factor expressed
in the early stage of adipogenesis, is also known to be required for MCE. Consequently,
we determined whether DhL affects proliferation of 3T3-L1 preadipocytes after induction
of differentiation with IM. As shown in Figure 12A, the treatment with DhL significantly
decreased the cell numbers of IM-induced 3T3-L1 preadipocytes during day 1 as well as
day 2 as compared to the cell numbers of control 3T3-L1 preadipocytes not treated with
DhL. Thus, the effects of DhL that cause inhibition of differentiation of 3T3-L1
preadipocytes appear to occur during the early stage of adipogenesis.
I then investigated whether DhL modulates cell cycle progression. When 3T3–L1
preadipocyte differentiation was induced, addition of DhL arrested the cell cycle at the
G0/G1 phase (Figure 12B). The percentage of preadipocytes in the G0/G1 phase was
about 71 ± 1.9 % in the absence of IM, while 41 ± 2.5 % in the presence of IM.
Interestingly, 72 ± 3.1 % of DhL-treated preadipocytes were in the G0/G1 phase. These
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observations indicated that DhL inhibited clonal expansion of the cell by inducing G0/G1
phase arrest. Cyclin D1, cyclin A and CDK2 are the cell cycle regulatory proteins at
G0/G1 phase. When the preadipocytes were treated with 9 µM DhL, the expression of
cyclin D1, cyclin A, and CDK2 was strongly inhibited (Figure 12C-E). These
observations suggest that DhL induces cell cycle arrest at the G0/G1 phase through the
upregulation of p27 expression, respectively.
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Figure 12. Dehydroleucodine inhibits proliferation of preadipocytes and cell cycle
progression during mitotic clonal expansion. Post-confluent preadipocytes (day 0)
were cultured in differentiation medium, and then treated once with different
concentration of dehydroleucodine as indicated (A). The number of cells treated with
dehydroleucodine for 24 and 48 h was determined using an automated cell counter
machine. DMSO was used a vehicle control and preadipocytes incubated in the absence
of differentiation medium was used a negative control. All values are presented as the
mean ± SEM of three independent experiments performed in triplicate. *P<0.01,
**P<0.001 vs. no dehydroleucodine treatment. Additionally, post-confluent
preadipocytes (day 0) were cultured in the absence or presence of differentiation medium
as indicated in the figure (B). After treatment of preadipocytes with 9 M
dehydroleucodine for 24 h, stained with a propidium iodine solution, and the cell
population was analyzed by flow cytometry as described in Material and Methods. The
percentage of cell population at each stage of the cell cycle was determined using Accuri
C6 software (B) After treatment of preadipocytes with 9 M dehydroleucodine for 24 h,
cells were harvested and the lysates were subjected to Western blot analysis for Cyclin A
(C), Cyclin D1 (D), CDK2 (E). Western blot analysis for GAPDH was used as loading
control. The Western blots were performed three times, and a representative image of the
three independent experiments was shown.
2.3.3. Dehydroleucodine blocks expression of C/EBP and histone demethylase
JMJD2B, CDC25A and CDC451 genes
Several histone methyltransferases and demethylases have been reported to be
involved in adipogenesis. These enzymes seem to regulate expression of C/EBPβ and
PPARγ (Guo et al. 2012; Lee et al. 2008). To further assess the regulators involved in the
DhL inhibition of MCE, I examined the expression of C/EBPβ in DhL-treated 3t3-L1
cells at the indicated time after IM induction as indicated in Figure 13A. Levels of
expression of C/EBPβ mRNA was increased in the presence of IM treatment during the
48 hours. However, the addition of DhL clearly diminished the C/EBPβ mRNA level
(Figure 13A), which expression has been correlated with the regulation of H3K9
demethylase JMJD2B and cell cycle genes (e.g., Cdc25c) genes. Thus, the expression of
JMJD2B and the cell cycle genes in DhL-treated 3T3-L1 cells during the MCE process
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was determined (Figure 13B-D). The JMJD2B mRNA level was also reduced by DhL
treatment (Figure 13D). Interestingly, I also observed a dramatic inhibition of the
expression of mRNA levels of cell cycle genes Cdc25A and Cdc451 during MCE
(Figure 13B-C).

Figure 13. Dehydroleucodine downregulates the expression of C/EBP histone
demethylase JMJD2B, CDC451 and CDC25A genes. Post-confluent preadipocytes
(day 0) were cultured in the presence of differentiation medium containing 9 M
dehydroleucodine for 24 h, then total RNA was extracted as indicated in Material and
Methods. mRNA levels of C/EBPβ, histone demethylase JMJD2B, CDC451 and

149

CDC25A were determined by qPCR (A-D). The qPCR data are represented as the mean
± SEM of there independent experiments. *P<0.01 vs. no dehydroleucodine treatment.
Next, the effect of DhL on the expression of PPARγ as well as methytransferases
involved in its expression during adipogenesis, were examined. To this end, the levels of
expression of MLL3, MLL4 and G9a in DhL–treated 3T3-L1 cells was determined at the
indicated time after IM induction (Figure 14A-D). As shown in Figure 14, DhL clearly
inhibited the expression of PPARγ and MLL4 (Figure 14A and C), without affecting the
expression of MLL3 and G9a, respectively (Figure 14B and D). These results suggest
that the DhL inhibition of MCE might be epigenetically regulated through
downregulation of C/EBPβ and PPARγ.
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Figure 14. Dehydroleucodine represses the expression of PPAR, MLL3, MLL4 and
G9A genes. Post-confluent preadipocytes (day 0) were cultured in the presence of
differentiation medium containing 9 M dehydroleucodine for 24 h, then total RNA was
extracted as indicated in Material and Methods. mRNA levels of PPARγ, MLL3, MLL4
and G9A were determined by qPCR (A-D). The qPCR data are represented as the mean ±
SEM of three independent experiments. *P<0.01 vs. no dehydroleucodine treatment, and
N.S.: not statistically significant as compared with no dehydroleucodine treatment.
2.4. Discussion
Approximately 50% of modern pharmaceuticals derive from traditional plant
compounds (Bilia et al. 2017). A deeper understanding of the anti-adipogenic mechanism
of action of the sesquiterpene lactone DhL, derived from Artemisia douglasiana, may
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thus have pharmacological import in the continuing search for therapeutic modalities to
ameliorate the effects of the global obesity epidemic. The aim of this line of experiments
was to further elucidate the potential mechanisms of action of DhL, that previous work
revealed acts upon middle stage, and possibly late stage, differentiation of 3T3-L1
preadipocytes (Galvis et al. 2011).
It is evident from the results that DhL has a multiplicity of effects on
adipogenesis, and therefore it is likely that DhL interacts with multiple molecular actors
and/or acts upstream of significant processes responsible for the progression of signaling
cascades necessary for MCE. I established that DhL has a marked effect on lipid
accumulation when applied to 3T3-L1 cells between 0 and 2 days post induction of
differentiation (Figure 11C). When applied from day 4 through day 8 post-induction, the
anti-adipogenic affect was drastically reduced (Figure 11B), indicating that one single
dose of DhL acts by inhibiting the early stage of adipogenesis, during which MCE
occurs. Results from a triglyceride assay confirmed these findings, demonstrating that
within this 0-2 day post-induction period, 12 µM of DhL worked most effectively in
decreasing triglyceride content, an observable marker of successful progression through
the adipogenic program (Figures 11C and E). Observable decreases in triglyceride
content were also found with as little as 3 µM of DhL.
CCAT/Enhancer Binding Protein Beta is expressed within 2 to 4 hours post
induction (Tang et al. 2003), and I observed that 3 µM of DhL led to a drastic
downregulation of protein levels of C/EBPβ (Figure 11D). As the acquisition of DNA
binding activity of C/EBPβ beginning at approximately 12 hours post induction is
essentially required for the progression of MCE (Tang et al. 2003), this represents strong
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evidence that DhL inhibits adipogenesis by obstructing the MCE process. As activated
C/EBPβ, along with C/EBPδ, triggers the expression of C/EBPα, which leads to the
expression of PPARγ (Farmer et al. 2006), the inhibitory effects of DhL on C/EBPβ
would be expected to result in a downregulation of protein levels of PPARγ and C/EBPα.
This is precisely what was observed when 9 µM of DhL was applied, which drastically
downregulated PPARγ and C/EBPα in an inversely correlated manner as concentration of
DhL was increased to 6 µM and beyond (Figure 11F).
Flow cytometry revealed that DhL arrested the cell cycle at the G0/G1 phase,
decreased cyclins A, D1 and CDK2 (Figure 12C-E). Consistent with this arresting of cell
cycle progression, DhL inhibited the proliferation of preadipoyctes during MCE in a
concentration dependent manner with the greatest effect observed at 12.5 µM of DhL.
Dehydroleucodine also repressed the expression of CDC25A, CDC451, and
JMJD2B (Figure 13B-D), which all act downstream of C/EBPβ to facilitate progression
through the cell cycle (Guo et al. 2012; Aressy and Ducommun 2008; Turowski et al.
2003; Goloudina et al. 2003). Messenger RNA levels of the H3K4me1/2
methyltransferase MLL4 was downregulated upon application of DhL (Figure 14C), and
PPARγ mRNA was also downregulated, as would be expected from the literature
reporting that MLL4 is part of the activating signal cointegrator-2 -containing complex
(ASCOM), which co-activates PPARγ (Lee et al. 2008; Qi et al. 2003; Kuang et al. 2002;
Hong et al. 2001). No significant effects were found on mRNA levels upon application of
DhL for the expression of MLL3 (Figure 14B), also a part of the ASCOM complex (Lee
et al. 2008), or the expression of G9A (Figure 14D), which represses PPARγ expression
(Wang et al. 2013).
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It is plausible that this multitude of effects which arrest the necessary step of
MCE, stem from the upstream inhibitory effect DhL has directly on C/EBPβ, or on
factors necessary to express C/EBPβ or activate C/EBPβ’s DNA binding activity. Such
targets could possibly include Rb, which DhL decreased phosphorylation of in this study,
and which binds to C/EBPβ and facilitates its activation (Chen et al. 1996). It is also
possible that DhL acts redundantly and directly on numerous processes downstream of
C/EBPβ activation, such as obstructing MLL4, which was downregulated in my
experiments and is a component of the ASCOM complex, which is responsible for the
activation of PPARγ and C/EBPα. In a similar fashion, DhL may act directly on the
epigenetic modifiers as shown in these experiments, which include CDC25A, CDC45l,
and JMJD2B (Figure 13B-D).
In summary, dehydroleucodine inhibits the accumulation of lipid droplets and
decreased the elevations of triglycerides, and inhibition of adipogenesis occurred during
the early stage of adipogenesis. Thus, not only did dehydroleucodine inhibit the
expression of C/EBPα and PPARγ, it also strongly blocked the expression of C/EBPβ, an
early stage biomarker of early adipogenesis, in a concentration-dependent manner. The
proliferation of preadipocytes was dramatically suppressed when dehydroleucodine was
added to the medium as early as 24 hours. These results indicate that dehydroleucodine
may specifically affect mitotic clonal expansion to inhibit preadipocytes
dedifferentiation. Dehydroleucodine arrested the cell cycle at the G0/G1 phase, increased
p27 and decreased both cyclins A and D and their partners (e.g., CDK2 and CDK4).
Furthermore, dehydroleucodine downregulated expression of histone demethylase JMJD2
as well as repressed the expression of histone methyltransferase MLL4, which in turn
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diminished the expression of C/EBPβ and PPARγ respectively. Collectively, the results
indicate that dehydroleucodine inhibits preadipocyte differentiation by blocking mitotic
clonal expansion via cell cycle arrest, which may be mediated by regulation selective
histone methylation/demethylation in transcription activation during the early stage of
adipogenesis.
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III. 11,13-DIHYDRO [11R]DEHYDROLEUCODINE BLOCKS MITOTIC CLONAL
EXPANSION DURING PREADIPOYCTE DIFFERENTIATION THROUGH CELL
CYCLE ARREST
3.1. Introduction
As discussed in the previous chapter, it was previously found that the
sesquiterpene lactone dehydroleucodine (DhL), extracted from the aerial parts of
Artemisia douglasiana, decreased phenotypic (lipid content) and molecular markers
(PPARγ and C/EBPα) of adipogenesis, indicating that this compound inhibited
differentiation of preadipocytes (Galvis et al. 2011). Enantiomers of 11,13-dihydrodehydroleucodine were found to inhibit 3T3-L1 preadipoycte differentiation (Galvis et al.
2011), but their effects on the various signaling molecules underlying the adipogenic
differentiation program were not fully investigated.
A selective reduction of dehydroleucodine generates its 11,13-dihydro derivative
of (11,13-dihydro-dehydroleucodine), which in turn shows very weak biological activity.
Thus, it is likely that the functional groups in dehydroleucodine are required for the
biological activities or that the cyclopentenone has more structural requirements for its
optimal pharmacological activity (Galvis et al. 2011).
Similarly, it was found that the addition of 11,13-dihydro-dehydroleucodine
during 3T3-L1 differentiation and HeLa cell proliferation, exhibited a weak effect
compared with the inhibitory effect observed for dehydroleucodine. More importantly,
one of the epimers of the reduced form of dehydroleucodine (i.e., 11R,13-dihydrodehydroleucodine) inhibited these processes, indicating that the α-methylene-γ-lactone
group was not required for such inhibition. However, the reduced form of
dehydroleucodine showed no toxicity in these biological assays (Galvis et al. 2011).
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In contrast, reduction of α,β-unsaturated carbonyl groups in other sesquiterpene
lactones (i.e., helenalin, hymentin, mexicanin, custonolide and parthonolide) showed a
differential biological effect: treatment with 11,13-dihydro-helenalin does not result in a
reduced biological activity, while 11,13-dihydro-hymentin had reduced biological
activity (Schmidt 1996).
Thus, by studying the effect of gene expression of 11,13-dihydrodehydroleucodine in 3T3-L1 differentiation, and comparing these results to the gene
expression of DhL, it is likely that the anti-adopogenic structural and conformational
requirements for anti-adipogenic therapeutics could be greater elucidated. This new
evidence could help aid researchers in synthesizing novel anti-adiopogenic compounds.
Additionally, on its own merits, such evidence will help evaluate the potential benefits
and deficits of 11,13-dihydro-dehydroleucodine as an adipogenic inhibitor, as well as
further clarify its mechanism of action.
In this series of experiments, I examined the effects of 11,13-dihydro-[11R]dehydroleucodine (11,13DH-[11R]-DhL), on the timing and expression of molecular
markers underlying the adipogenic program, including the process of MCE, in 3T3-L1
preadipocytes, in order to further elucidate the action, underlying mechanism, and
therapeutic import of dehydro derivatives of dehydroleucodine.
3.2. Materials and Methods
To examine whether DH-DhL modulates early steps of the differentiation of 3T3–
L1 preadipocytes into adipocytes, post-confluent preadipocytes were treated with
different concentrations of DH-DhL and the effect on lipid droplets were observed. Cells
were stained with Oil Red O and morphological changes of 3T3–L1 preadipocytes were
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monitored, and then photographed after 9 days from the onset of differentiation to
quantify lipid droplets, followed by spectrophotometry. Cell viability was determined by
the MTT assay.
Next, to further determine the effects on 3T3-L1 cells of DH-DhL, the effect of
DH-DhL on the PPARγ and C/EBPα expression was assayed via western blot.
Expression of additional adipogenic factors, FAS, and AMPK, were also assayed via
western blot.
To determine the stage of adipogenesis upon which DH-DhL exerts its effects on
3T3-L1 cells, DH-DhL was applied at various time points after induction with IM, and
the lipid content of the 3T3-L1 cells was then measured. Since, CBEP, a specific
transcriptional factor expressed in the early stage of adipogenesis, is also known to be
required for MCE, I examined the effect of DH-DhL on the expression of CBEPvia
western blotting, during the first 48 hour after stimulation of 3T3-L1 preadipocytes with
IM. To more fully characterize the effects of DH-DhL on 3T3-L1 preadipocytes, the
effect of DH-DhL on proliferation was also assayed.
To even further elucidate the effects of DH-DhL on 3T3-L1 preadipoyctes, I
investigated whether DH-DhL modulates cell cycle progression, via treatment with DHDhL followed by flow cytometry to determine cell cycle. As additional evidence of what
phase of cell cycle arrest resulted from DH-DhL treatment, western blot was utilized to
assay levels of cyclin D1, CDK4, cyclin A, and CDK2, cell cycle regulatory proteins at
the G0/G1 phase, Rb, and p27, an upstream effector of the cell cycle regulatory proteins.
As will be elaborated upon more fully in the Results and Discussion sections of
this chapter, as these experiments seemed to indicate that DH-DhL inhibited MCE, I then
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sought to determine the signaling pathway through which DH-DhL inhibited MCE by
investigating the expression as well as phosphorylation of Erk1/2 and Akt, proteins
involved in cell cycle progression, via western blotting.
The reagents, cell culture and differentiation, treatments, cell viability assay, Oil
Red O staining, microscopy, spectrophotometry, triglyceride assay, cell proliferation
assay, western blotting, flow cytometry, high-performance liquid chromatography,
compound extraction, purification, identification, and statistical analysis, were prepared
and performed as in Chapter 2, above.
Previous studies have demonstrated that DhL and their epimers inhibited the
differentiation of 3T3–L1 preadipocytes into adipocytes (Galvis et al. 2011). I further
examined whether the 11,13DH-[11R]DhL epimer (Figure 15A) modulates early steps of
the differentiation of 3T3–L1 preadipocytes into adipocytes.
3.3. Results
3.3.1. 11,13-dihydro-[11R]-dehydroleucodine inhibits 3T3–L1 adipocyte
differentiation
Post-confluent preadipocytes were treated with 0, 10, 20, 40, 80, 120 and 160 µM
11,13DH-[11R]-DhL every other day for 9 days. 11,13DH-[11R]-DhL decreased the
accumulation of lipid droplets in a concentration-dependent manner (Figure 15B). In
particular, 160 µM 11,13DH-[11R]-DhL completely inhibited the formation of lipid
droplets in the adipocytes with a half-maximal inhibitory concentration of 71.0 ± 4.1
µM. Interestingly, cell viability was not affected by 11,13DH-[11R]-DhL even at 200 µM
(Figure 15C).
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Figure 15. Inhibitory effect of 11,13-dihydro-[11R]-dehydroleucodine on adipocyte
differentiation. (A) Chemical structure of 11,13DH-[11R]DhL. (B) Preadipocytes were cultured
in induction medium containing different concentrations of 11,13DH-[11R]DhL as indicated in
the figure for 9 days. Cells were stained with Oil Red O and morphological changes of 3T3–L1
preadipocytes were monitored, and then photographed (x100) after 9 days from the onset of
differentiation. The percentages presented are relative to the 11,13DH-[11R]DhL-free control in
the presence of induction media (100%). (C) Preadipocytes were cultured in induction medium
containing different concentrations of 11,13DH-[11R]DhL for 3 days. Cell viability was
determined by the MTT assay. All values are presented as the mean ± SEM of three experiments
performed in triplicate. *P < 0.01 vs no 11,13DH-[11R]DhL treatment.

Quantification of intracytoplasmic triglyceride during preadipocyte differentiation
aids in evaluating the effect of 11,13DH-[11R]DhL. When the adipocytes were exposed
to 30, 60 and 120 µM 11,13DH-[11R]DhL for 9 days, cellular triglyceride content
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significantly decreased in a concentration-dependent manner (Figure 16A). The relative
triglyceride contents of the adipocytes treated with different concentration of 11,13DH[11R]-DhL were 31.1 ± 2.1%, 59 ± 2.8% and 85 ± 3.1%, respectively, with respect to the
control. The half-maximal inhibitory concentration of 11,13DH-[11R]-DhL for the effect
on triglyceride content was 69.3 ± 3.2 µM. Transcription factors such as PPARγ and
C/EBPα are critical for terminal adipocyte differentiation. PPARγ and C/EBPα
expression in adipocytes treated with 11,13DH-[11R]-DhL strongly decreased compared
with the control cells as well as other adipogenic factors (e.g., FAS, and AMPK).
Specifically, expression of FAS was decreased, while phosphorylation of AMPK was
increased (Figure 16B-E).
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Figure 16. Inhibitory effect of 11,13-dihydro-[11R]-dehydroleucodine on triglyceride
content and adipogenic markers. Preadipocytes were cultured in differentiation medium
containing 100 µM 11,13DH-[11R]DhL for 9 days. (A) Cellular triglyceride content was

166

determined and the percentages presented for the adipocytes treated with 100 µM 11,13DH[11R]DhL are relative to the control (100%). *P<0.01 vs no 11,13DH-[11R]DhL treatment. (BE) Preadipocytes treated with 100 µM 11,13DH-[11R]DhL for 9 days were harvested and the
lysates were subjected to western blot analysis for (B) C/EBP, (C) PPAR, (D) FAS and (E)
phospho(p) AMPK. The percentages presented are relative to the 11,13DH-[11R]DhL-free
control without inducers (100%). All values are presented as the mean ± SEM of three
experiments performed in triplicate. *P<0.01 vs no 11,13DH-[11R]DhL treatment. GAPDH was
used as loading control. The Western blots were performed three times, and a representative
image of the three independent experiments was shown.

In addition, 11,13DH-[11R]-DhL treatment significantly inhibited adipogenic
morphology (i.e., transition from a fibroblast-like shape to an increasingly rounded-up
appearance with an accumulation of lipid droplets (Figure 17 inset). Consistent with
these observations, it was found that 11,13DH-[11R]-DhL decreased the number as well
as the sizes of lipid droplets. The histogram was clearly asymmetric and showed a long
tail in the positive axis reflecting the presence of lipid droplets with sizes much higher
with respect to the mean of the population. Lipid droplets have a diameter in the range of
0.5 to 4.3 m. Analysis of the distribution of the numbers of lipid droplet sizes showed a
distinct shift of the lipid droplet size toward smaller lipid droplets following incubation
with 11,13DH-[11R]-DhL (Figure 17). These results suggest that 11,13DH-[11R]-DhL
may inhibit differentiation of 3T3-L1 preadipocytes by decreasing the expression of
several transcriptional factors (e.g., PPARγ and C/EBPα), consistent with the robust
effect of 11,13DH-[11R]-DhL on the number as well as the size of the lipid droplets.
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Figure 17. 11,13-dihydro-[11R]-dehydroleucodine decreased the number and the size of
lipid droplets during adipogenesis. Preadipocytes were cultured in induction medium
containing 100 µM of 11,13DH-[11R]DhL for 9 days. After differentiation, cells were stained
with Oil Red O, and then photographed. The total number of lipid droplets was quantified from,
at least, 100 cells. The perimeters of 1784 lipid droplets from 48 control cells and 1392 lipid
droplets from 52 11,13DH-[11R]DhL-treated cells were obtained by using NIH Image software.
The mean perimeter and the relative variance for the lipid droplets from control cells are 6.54
(2.08 diameter) and 0.51, while the corresponding values for lipids droplets the 11,13DH[11R]DhL-treated cells are 4.74 (1.51 diameter) and 0.45, respectively. *P<0.01 vs no 11,13 [R]dihydro-dehydroleucodine treatment.

3.3.2. 11,13-dihydro-[11R]-dehydroleucodine suppresses clonal expansion
during the early stage of adipogenesis
Adipocyte differentiation occurs through the preadipocyte stage and progresses
through several stages, which can be clearly divided between proliferation and mitotic
cloning expansion (early stage) and terminal differentiation (late stage). Thus, we
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examined whether 11,13DH-[11R]-DhL causes stage-dependent inhibition of adipocyte
differentiation. 3T3-L1 cells were treated with 120 M 11,13DH-[11R]-DhL at several
time points after induction with IM as shown in Figure 18.
Treatment with 11,13DH-[11R]-DhL at early stages (days 0-2 and 0-4) strongly
inhibited adipogenesis by 75 ± 2.1% and 82 ± 3.1 % respectively (Figure 18A). The
treatment of 11,13DH-[11R]-DhL after day 2 (days 2-8) showed moderate inhibition of
adipogenesis by 48 ± 2.5 %, whereas the treatment after day 4 (i.e., days 4-8 and 6-8)
showed only 20 ± 1.5 % inhibition or no statistically significant inhibition at all (Figure
18A). Consistent with these observations, when cells were treated with different
concentrations of 11,13DH-[11R]-DhL during early stage, the intracellular triglyceride
content significantly decreased in a concentration-dependent manner (Figure 18B). In the
early adipogenic stage, the number of preadipocytes greatly increases as a result of MCE.
CBEP, a specific transcriptional factor expressed in the early stage of adipogenesis, is
also known to be required for MCE. Therefore, we examine the effect of 11,13DH-[11R]DhL on the expression of CBEP, during the first 48 h after stimulation of 3T3-L1
preadipocytes with IM. Expression of CBEP was significantly decreased in a
concentration-dependent manner when cells were treated with 11,13DH-[11R]-DhL
(Figure 18C). In addition, I also determined whether 11,13DH-[11R]-DhL affects
proliferation of 3T3-L1 preadipocytes after induction of differentiation with IM. As
shown in Figure 18D, the treatment with 11,13DH-[11R]-DhL significantly decreased
the cell numbers of IM-induced 3T3-L1 preadipocytes during day 1 as well as day 2 as
compared to the cell numbers of control 3T3-L1 preadipocytes not treated with 11,13DH[11R]-DhL. Thus, the effects of 11,13DH-[11R]-DhL that cause inhibition of
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differentiation of 3T3-L1 preadipocytes appears to occur during the early stage of
adipogenesis.
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Figure 18. Inhibitory effect of 11,13-dihydro-[11R]-dehydroleucodine on mitotic clonal
expansion during the early stage of adipogenesis. (A) Preadipocytes were cultured in
differentiation medium containing 100 M 11,13DH-[11R]DhL for day 0-2, 0-4, 0-6, 0-8, 2-8, 48 and 6-8, respectively. Cells were stained with Oil Red O and then visualized as described in the
Material and Methods. All values are presented as the mean ± SEM of three independent. *P <
0.01 vs no 11,13DH-[11R]DhL treatment. N.S.: not statistically significant versus no 11,13DH[11R]DhL treatment. (B) Cellular triglyceride content of preadipocytes treated with 100 M
11,13DH-[11R]DhL for day 0-2 was determined as described in the Material and Methods using
a Triglyceride Kit. Results are shown as relative percentage of control without 11,13DH[11R]DhL. DMSO was used a vehicle control. All values are presented as the mean ± SEM of
three independent experiments performed in triplicate. *P<0.01 vs no 11,13DH-[11R]DhL
treatment. (C) Preadipocytes treated with 100 µM 11,13DH-[11R]DhL for day 0-2 were
harvested and the lysates were subjected to western blot analysis for C/EBP. The percentages
presented are relative to the 11,13DH-[11R]DhL -free control without inducers (100%). All
values are presented as the mean ± SEM of three experiments performed in triplicate. *P<0.01
versus no 11,13DH-[11R]DhL treatment. GAPDH was used as loading control. The western blots
were performed three times, and a representative image of the three independent experiments was
shown. (D) Post-confluent preadipocytes (day 0) were cultured in differentiation medium, and
then treated with 100 µM 11,13DH-[11R]DhL for 24 and 48 h. The number of cells treated with
11,13DH-[11R]DhL as well as control cells was determined using an automated cell counter
machine. DMSO was used a vehicle control and preadipocytes incubated in the absence of
differentiation medium was used a negative control. All values are presented as the mean ± SEM
of three independent experiments performed in triplicate. *P<0.01, **P<0.001 versus no
11,13DH-[11R]DhL treatment.

3.3.3 11,13-dihydro-[11R]-dehydroleucodine induces G0/G1 phase arrest
through p27 upregulation
I then investigated whether 11,13DH-[11R]DhL modulates cell cycle progression.
When 3T3–L1 preadipocyte differentiation was induced, addition of 11,13DH-[11R]DhL
arrested the cell cycle at the G0/G1 phase (Figure 19A). As expected, G0/G1 phase
decreased and both S and G2/M phases were statistically increased in the presence of IM.
The addition of 11,13DH-[11R]DhL reversed the effect of IM on the cell cycle.
Specifically, the percentage of preadipocytes in the G0/G1 phase was about 73 ± 1.5 %,
while 47 ± 2.1 % of the untreated adipocytes, and 78 ± 3.1 % of the 11,13DH-[11R]DhLtreated preadipocytes were in the G0/G1 phase. These observations indicated that
11,13DH-[11R]DhL inhibited clonal expansion of the cell by inducing G0/G1 phase
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arrest. Cyclin D1, CDK4, cyclin A, and CDK2 are the cell cycle regulatory proteins at the
G0/G1 phase. Additionally, phosphorylation of the Rb protein is upregulated during cell
cycle progression. When the preadipocytes were treated with 100 µM 11,13DH[11R]DhL, the expression of cyclin D1, CDK4, cyclin A, CDK2, and p-Rb was strongly
inhibited (Figure 19B-F). The expression of p27, an upstream effector of the cell cycle
regulatory proteins, also decreased during adipogenesis but 11,13DH-[11R]DhL restored
its expression (Figure 19G). These observations suggested that 11,13DH-[11R]DhL
induces cell cycle arrest at the G0/G1 phase through the downregulation of pRB and
upregulation of p27 expression, respectively.
To determine the signaling pathway through which 11,13DH-[11R]DhL inhibited
the clonal expansion during the early stage of adipogenesis, the expression as well as
phosphorylation of Erk1/2 and Akt, which are involved in cell cycle progression were
examined. Adipogenic inducers increased the phosphorylation of Akt and Erk1/2. When
the adipocytes were treated with 100 µM 11,13DH-[11R]DhL for 10 minutes or 3 hours,
both Akt and Erk1/2 phosphorylation was significantly decreased, but not to the level
demonstrated for cyclin protein abundance (Figure 19H-J).
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Figure 19. 11,13-dihydro-[11R]-dehydroleucodine regulates cell cycle progression. (A) 3T3–
L1 preadipocytes were cultured in induction medium containing 100 µM 11,13DH-[11R]DhL for
24 h, stained with a propidium iodide solution, and analyzed by flow cytometry. The percentage
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of cell population at each stage of the cell cycle was determined using the Modfit LT program.
All values are presented as the mean ± SEM of three experiments performed in triplicate. *P <
0.01 vs control in the absence of IM; #P < 0.01 vs control in presence of IM. (B-D) The cells were
harvested and the lysates were subjected to western blot analysis for (B) cyclin A, (C) cyclin D1,
(D) CDK2, (E) CDK4, (F) p-Rb, and (G) p27 by using specific antibodies as described in the
Material and Methods. (H) Adipocytes treated with 100 µM 11,13DH-[11R]DhL for 10 min or 2
h were harvested and the lysates were subjected to western blot analysis for total(t)-Erk1/2,
phospho(p)-Erk1/2, t-Akt, and p-Akt. The percentages presented are relative to the 11,13DH[11R]DhL-free control with induction media (100%). All values are presented as the mean ±
SEM of three experiments performed in triplicate. *P < 0.01 versus no 11,13DH-[11R]DhL
treatment.

3.4. Discussion
In this series of experiments, the effect of 11,13DH[11R]-DhL on adipocyte
differentiation in 3T3–L1 preadipocytes and the elucidation of the potential underlying
mechanism, was investigated. Preadipocytes can differentiate into adipocytes, which
possess a spherical shape and accumulate lipid droplets (Ruiz-Ojeda et al. 2016; Green
and Kehinde 1975; Raajendiran et al. 2016; Otto and Lane 2005; Ntambi and YoungCheul 2000; Tong and Hotamisligil 2001). 11,13DH[11R]-DhL inhibited lipid
accumulation during adipocyte differentiation with a half-maximal inhibitory
concentration value of 71 µM, as shown by the decreased numbers and sizes of lipid
droplets as well as reduced triglyceride content.
Adipocyte differentiation is regulated by a complex network of transcription
factors such as PPARγ and members of C/EBP family (C/EBPα, β, and δ) (Farmer 2006).
DhL, a sesquiterpene lactone compound abundant in the areal parts of Artemesia
douglasiana inhibits adipogenesis by downregulating PPARγ signaling in 3T3-L1 cells
(Galvis et al., 2011). 11,13DH[11R]-DhL strongly inhibited PPARγ expression,
suggesting that this compound may inhibit adipocyte differentiation by downregulating
the PPARγ pathway.
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Adipogenesis can be divided into early and late stages. 3T3-L1 preadipocytes
undergo mitotic clonal expansion through the upregulation of C/EBPβ and C/EBPδ
during the early stage of adipocyte differentiation. This is followed by the activation of
the downstream signaling molecules PPARγ and C/EBPα (Guo et al. 2015; Tang et al.
2003).
11,13DH[11R]-DhL inhibited the formation of lipid droplets and triglyceride
accumulation, and suppressed C/EBPβ expression during the early differentiation stage
(day 0–2). Clonal expansion occurs during the early stage of 3T3–L1 cell differentiation
at which time the cell population is increased by, at least, one fold (Tang et al. 2003). In
this study, 11,13DH[11R]-DhL inhibited adipocyte differentiation through the
suppression of cell proliferation. These results indicate that the primary target of
11,13DH[11R]-DhL action for preventing adipocyte differentiation in 3T3–L1 cells may
be clonal expansion during the early stage.
Cell proliferation during 3T3–L1 adipogenesis occurs through the G1/S
checkpoint as shown by the activation of CDK2-cyclin E/A and cyclin D1, turnover of
p27, and hyperphosphorylation of the Rb protein (Chen 1996; Patel and Lane 2000; Sherr
et al. 1999).
11,13DH[11R]-DhL arrested the cell cycle at the G0/G1 phase by decreased
expression of cyclin D1, CDK2, cyclin A, CDK4, and phosphorylated Rb protein.
11,13DH[11R]-DhL also inhibits the growth of human colon carcinoma HT-29 cells
through the upregulation of p21cip1, and the downregulation of cyclin D1, cyclin A,
followed by cell cycle arrest at the G1 phase. Similarly, helenalin, a sesquiterpene isolated
from Arnica montana, inhibits adipogenesis through G1 arrest by increased p21
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expression without change in mRNA transcripts, and increases its association with cdk2
in 3T3–L1 cells (Fernandes et al. 2008). The expression of the CDK inhibitor p27, an
upstream effector of cell cycle regulatory proteins, was downregulated during
adipogenesis, but sulforaphane restored the expression. These results suggest that
11,13DH[11R]-DhL may induce cell cycle arrest at the G0/G1 phase through the
upregulation of p27 in 3T3–L1 cells.
The MAPK pathway is involved in cell cycle progression and these MAPKs act
as a mitogenic signaling molecule in 3T3–L1 preadipocytes (Tang et al. 2003; Bouraoui
et al. 2010; Roberts et al. 2002). Adipogenic inducers stimulate the MAPK pathway,
followed by enhanced activity of C/EBPβ and induction of adipocyte differentiation
(Prusty et al. 2002; Guo et al. 2015; Tong and Hotamisligil 2001).
Epigallocatechin gallate and matrine inhibit adipocyte differentiation by
downregulating the ERK pathway (Xing et al. 2010; Hung et al. 2005).
The Akt pathway affects cell cycle progression, through regulation of cyclin D
and p27 expression (Ouyang et al. 2006; Collado et al. 2000). Activation of the Akt
pathway in 3T3–L1 preadipocytes can also induce adipocyte differentiation (Xu et al.
2004; Kohn et al. 1996; Cristancho et al. 2011).
In my experiments, 11,13DH[11R]-DhL decreased the phosphorylation of Erk1/2
and Akt, which were stimulated by adipogenic inducers in 3T3–L1 preadipocytes, but not
to the level demonstrated for cyclin protein abundance. 11,13DH[11R]-DhL inhibits
adipocyte differentiation by blocking clonal expansion via cell cycle arrest at the G 0/G1
phase, which may be mediated by upregulation of p27 expression.
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In conclusion, 11,13 dihydro-[11R]-dehydroleucodine blocked the accumulation
of lipid droplets stained with Oil Red O and inhibited the increase of triglycerides in the
adipocytes (IC50: 71.0 ± 4.1 M). Expression of PPARγ, C/EBPβ, and C/EBPα were
significantly inhibited by 11,13 dihydro-[11R]-dehydroleucodine. in a time and
concentration dependent manner. This is consistent with the inhibitory effect of 11,13
dihydro-[11R]-dehydroleucodine on the early stage of adipogenesis. The proliferation of
preadipocytes were also suppressed by addition of 11,13 dihydro-[11R]dehydroleucodine during the first 48 hours after induction. These results indicate that
11,13 dihydro-[11R]-dehydroleucodine may selectively affect mitotic clonal expansion to
block preadipocyte differentiation. 11,13 dihydro-[11R]-dehydroleucodine arrested the
cell cycle at the G0/G1 phase by diminishing the increase of phosphorylation of Rb,
Erk1/2 and Akt while increasing the expression of p27. Collectively, the results indicate
that the inhibition of early stage preadipocyte differentiation by 11,13 dihydro-[11R]dehydroleucodine may be associated with cell cycle arrest at the G0/G1 phase through
upregulation of p27 expression.
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IV. DEHYDROPARASHIN-B INHIBITS ADIPOYCTE DIFFERENTIATION
4.1. Introduction
Preliminary results from experiments on Artemisia douglasiana utilizing Nuclear
Magnetic Resonance (NMR) and Mass Spectrometry indicated that Fraction 5 inhibited
adipogenesis. This was evidenced by qualitative and quantitative analysis via ORO
staining of lipid droplets in 3T3-L1 cells, observation of their morphology, and
spectrophotometry.

Preliminary results identified this compound as a sesquiterpene

lactone acid. Despite the large number of sesquiterpenes documented for several families
of plants,
sesquiterpene acids are only occasionally reported (Fraga et al. 2010). The presence of
related unlactonized sesquiterpene acids in the genus Artemisia seems to be restricted to
parishin-B isolated from A. tridentata ssp. tridentata f. parishii Beetle (Fraga et al. 2010;
Kelsey and Shafizadeh 1979).
Based, on all this, the objective for this series of experiments was to identify the
additional compound(s) accountable for inhibition of in vitro 3T3-L1 preadipocyte
differentiation. As preliminary results showed that structures closely related to
dehydroleucodine may be responsible, compound(s) were also tested for anti-adipogenic
effects.
It has been reported (Priestap et al. 2012) that dehydroparishin-B (DhP), a
sesquiterpene lactone acid of the guaianolide group, inhibits migration of B16 melanoma
cells in a dose dependent manner (IC50 = 72.2 mM). In a similar fashion to experiments
(Preistrap et al. 2012) which compared the effects of various sesquiterpene lactones,
including DhL, DH-DhL, and DhP, on cancer cell migration, I tested the effects of DhP
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on adipogenesis in 3T3-L1 preadipoyctes to elucidate whether structural differences in
these sesquiterpene lactones could account for various differentials in their antiadipogenic effects.
4.2. Materials and Methods
3T3-L1 preadipoyctes were incubated in the presence of various concentrations of
DhP, and assayed lipid droplet concentration via an ORO assay. This experiment gaged
whether DhP inhibited adipogenesis in the first place and its effect on the number and
size of lipid droplets. The effect of DhP on the viability of 3T3-L1 preadipocytes by
incubating cells with IM in the presence of 9 μM DhP for 24 hrs (Day 1) or throughout
the entire 9 days of differentiation (Day 9) was then examined. Cell viability was then
measured using the incorporation of the trypan blue assay as described in the Material
and Methods below. Next, western blotting was utilized to investigate DhP’s effect on
key transcriptional factors including C-EBP, PPAR, FAS, and C-EBPα. These
experiments were thus designed to garner both molecular and morphological evidence as
to DhP’s effects and mode of action.The reagents, cell culture and differentiation,
treatments, cell viability assay, Oil Red O staining, microscopy, spectrophotometry,
triglyceride assay, western blotting, flow cytometry, high-performance liquid
chromatography, compound extraction, purification, identification, and statistical
analysis, were prepared and performed as in Chapter 2, above.
4.3. Results
4.3.1. DhP blocks differentiation of 3T3-L1 preadipocytes
A fraction of Artemesia douglasiana, containing DhP and lacking DhL exhibited
significant anti-adipogenic properties when applied to 3T3-L1 preadipocytes (see Figure
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20).

Figure 20. The Effect of Artemisia douglasiana methanol extract lacking DhL, and
containing DhP inhibits differentiation of 3T3-L1 preadipocytes. The effect of
Artemisia douglasiana extract lacking DhL and containing DhP on lipid content in 3T3L1 preadipoyctes (Figure 20A). Ethyl acetate and aqueous 5% NaCO3H which contains
DhP strongly inhibits differentiation of 3T3-L1 preadipocytes (Figure 20B and C).
To assess the possible role of DhP on the differentiation of 3T3-L1 preadipocytes,
cells were incubated in the presence of various concentration of DhP. Figure 21 (below),
shows that the presence of DhP inhibited the lipid content in a dose dependent manner
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with an IC50 of 2.506 μM, and more importantly, that the addition of 0.2% DMSO does
not affect 3T3-L1 preadipocytes differentiation.
The effect of DhP was then examined on the viability of 3T3-L1 preadipocytes.
Cells were incubated with induction media in the presence of 9 μM DhP for 24 hour (Day
1) or throughout the entire 9 days of differentiation (Day 9). Cell viability was measured
by utilizing the trypan blue assay as described in Material and Methods. DhP did not
significantly affect 3T3-L1 preadipocytes cell viability (compare 0.2 % DMSO controlcells 94.53.6 cell viability with 92.52.8 DhP-treated cells) These results suggest that,
up to a maximum concentration of 9 μM, DhP has a strong inhibitory activity of 3T3-L1
preadipocytes differentiation without significant effect on cell viability.
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Figure 21. DhP inhibits lipid content in a dose dependent manner
4.3.2. DhP diminishes the number as well as the size lipid droplets
Adipocyte differentiation can be also monitored by formation of intracellular lipid
droplets (Rosen and Spiegelman, 2000). As described above, 3T3-L1 preadipocytes were
differentiated into adipocytes with induction media in the absence or presence of 9 μM
DhP. At day 9, Oil Red O staining in untreated cells showed an abundant number of lipid
droplets suggesting a significant lipid accumulation in untreated differentiated cells.
However, lipid droplets were difficult to observe in untreated non-differentiated cells
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(Figure 21B above). These observations were further supported with the quantitative
measurement of lipid content by determining the absorbance at 540 nm (Figure 21A
above).
4.3.3. DhP inhibits accumulation of triglyceride.
Given that DhP inhibited differentiation to 3T3-L1 preadipocytes and also
affected the formation of lipid droplets, we next considered whether DhP would inhibit
triglyceride accumulation. Cells were treated as described in the Material and Methods in
the presence of several concentration of DhP. In Figure 22A, a statistically significant
decrease in the intracellular triglyceride treated with DhP as compared with control cells,
is displayed. As expected, DMSO-treated cells did not affect the formation of triglyceride
accumulation as compared with cells incubated with induction media alone (Figure
22A).
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Figure 22. DhP inhibits key adipogenic transcription factors
4.3.4. DhP inhibits key adipogenic transcriptional factors
Adipogenesis is a highly regulated process requiring coordinated expression and
activation of key transcriptional factors and signaling molecules (Rosen and Spiegelman,
2000). To investigate whether DhP affects the expression of C-EBP, PPARγ and CEBPα, 3T3-L1 preadipocytes were incubated with induction media in the absence or
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presence of 9 μM DhP as, and then harvested at day 9 for Western blot analysis using
specific antibodies. In Figure 22, it can be seen that the addition of DhP clearly
attenuated the expression of C-EBP, PPARγ, FAS, and C-EBPα. Taken together, this
data suggests that DhL selectively blocks expression of several transcriptional factors
during the differentiation of 3T3- L1 preadipocytes.
4.4. Discussion
The addition of DhP significantly decreased the accumulation of lipid content by
a dramatic inhibition of the differentiation 3T3-L1 preadipocytes in a concentration and
time dependent manner. The presence of DhP downregulates the expression of
adipogenic-specific transcriptional factors C/EBP PPARγ and C/EBPα as well as FAS.
Interestingly, I also found that the addition of DhP inhibited the number as well as
the size of the lipid droplets during the differentiation of 3T3-L1 preadipocytes. But at
what time point, and through which molecular targets is DhP exerting its anti-adipogenic
effects?
Since the acquisition of C/EBP DNA binding activity corresponds with the
initiation of the early adipogenic process of mitotic clonal expansion (MCE) (Tanaka et
al. 1997, Tang et al. 2012), and since the experiments revealed a downreulation of
C/EBP, it is likely that DhP inhibits adipogenesis at this early stage.
The downregulation of PPARγ and C/EBPα, pro-adipogenic markers in the early
stage of adipogenesis, comprises further evidence suggesting that the anti-adipogenic
effects of DhP observed in the experiments are temporally acting on early adipogenesis
and the process of MCE.
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Taken together, this data suggests that DhP has an important inhibitory effect on
cellular pathways regulating adipocyte differentiation at the early stage of adipogenesis
during MCE.
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V. CONCLUSIONS AND FUTURE DIRECTIONS
5.1. Conclusions and Future Directions for DhL, DH-DhL, and DhP
5.1.1. Hypothesized Model of Binding Action of DhL, DH-DhL, and DhP
As depicted in Figure 21 below, when comparing all three sesquiterpene lactones
investigated, DhL, DH-DhL, and DhP, all three displayed inhibitory effects on
adipogenesis. This was evidenced in multiple experiments including the Oil Red O assays
where both lipid droplet number and size were quantified after treatment with the
respective sesquiterpene lactone. However, although both number of lipid droplets and
size were reduced under all treatment conditions, DhP produced the most dramatic effect
(Figure 23 below).

Figure 23. Comparative effects of DhL, DH-DhL, and DhP on lipid droplet quantity
and size
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As it is evident that differential structural moieties determine binding differences
which then lead to functional demarcations, comparisons of points of structural
differences between all three sesquiterpene lactones may garner a hypothesized
explanatory model for these effects.
As depicted in Figure 9, DhL belongs to the guaianolide group of sesquiterpene
lactones (Chaturvedi 2011), and contains an α-methylene-γ-lactone ring. It has been
previously reported that the α, unsaturated carbonyl group of sesquiterpene lactones
like DhL can undergo a Michael-type addition of a suitable nucelophile, such as
nucleophilic attack of cysteine sulfhydryl groups (Heinrich et al. 1998). However, it has
also been reported that the exocyclic double bound of sesquiterpene lactones like DhL
can undergo nucleophilic attack by cysteine sulfhydryl groups (Blanco et al. 2001). Thus
the presence of the exocyclic double bond of DhL, and its corresponding absence in DHDhL and DhP, could be a key structural difference responsible for different binding
modes of action and functional effects.
DhL may affect a multitude of proteins in the adipogenic cascade through this
exocyclic double bond binding, to arrest adipogenesis. It is plausible that this multitude
of effects which arrest the necessary step of MCE, stem from the upstream inhibitory
effect DhL has directly on C/EBPβ, or on factors necessary to express C/EBPβ or activate
C/EBPβ’s DNA binding activity. Such targets could possibly include Rb, which DhL
decreased phosphorylation of in this study, and which binds to C/EBPβ and facilitates its
activation (Chen et al. 1996). It is also possible that DhL acts redundantly and directly on
numerous processes downstream of C/EBPβ activation, such as obstructing MLL3, which
was downregulated in this study and is a component of the ASCOM complex, which is
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responsible for the activation of PPARγ and C/EBPα. In a similar fashion, DhL may act
directly on the epigenetic modifiers as shown in this study, which include CDC25A,
CDC45l, and JMJD2B (Figure 5). Further studies can better clarify these mechanistic
issues.
It is also plausible that DhL induces different effects on 3T3-L1 cells in a
concentration dependent manner. In D384 astrocytoma cells, lower concentrations of
DhL induced a cytostatic effect, similar to that reported for other lactones such as
parthenolide, deoxyelephantopin, isodeoxyelephantopin and costunolide (BailonMoscoso et al. 2015). Higher concentrations of DhL induced an apoptotic effect on D384
cells (Bailon-Moscoso et al. 2015).
The plausibility of this biphasic effect is enhanced by DhL’s similar structure to
parthenolide, which has been hypothesized to result in similar functions for the two
sesquiterpene lactones (Ordonez et al. 2016). The functional moiety responsible for this
activity is likely the exocyclic methylene group (Ordonez et al. 2016). Both parthenolide
and DhL possess this moiety, which is lacking (and the only structural difference between
it and DhL) in leucodine. Parthenolide and DhL both exhibit cytotoxic activity against
acute myeloid leukemia (AML) cell lines by inducing apoptosis, whereas leucodine does
not (Ordonez et al. 2016). Both compounds downregulate the p65 transcription factor,
which is essential for NF-κB activation (Ordonez et al. 2016). Furthermore, surface
signature analysis of both molecules using their X-ray crystal structures reveals that the
areas of greatest functional similarity include the excoyclic methylene group, and consist
of the convex lipophilic parts of each molecule (Ordonez et al. 2016). This may indicate
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that the binding areas of DhL to molecular actors in the adipogenic program may consist
of lipophilic regions.
Additionally, previous studies revealed that DhL induced apoptosis in D384
astrocytoma cells by affecting specific agents in the apoptotic cascade. c-ABL
phosphorylates TAp73α on tyrosine Y99, which is required for the pro-apoptotic activity
of TP73 and its ability to transcriptionally activate BAX. Activated BAX then
translocates to the mitochondria to induce cytochrome c to release from the mitochondria,
a necessary step in the apoptotic program (Melino et al. 2004; Wang et al. 2000; Yuan et
al. 1999). DhL induced apoptosis in the astrocytoma D384 cell line, where increasing
expression of the transcription factor TP73, the apoptotic activator BAX and the cell
cycle inhibitor CDKN1A (p21), increasing phosphorylation of TP53 and TP73 at the S46
and Y99 amino acid residue, and phosphorylation of the DNA damage marker, γ-H2AX
(p-S139-H2AX) were observed (Bailon-Moscoso et al. 2015). Further research is needed
to elucidate whether the lipophilic moiety, which includes the exocyclic methylene group
of DhL, acts upon similar agents directly or indirectly in 3T3-L1 cells to induce
apoptosis.
In addition to oxidizing these possible protein targets in the adipogenic cascade,
DhL may also react in a similar covalent binding fashion with the cysteine sulfhydryl
groups of glutathione (GSH), thus rendering it inactive. By inhibiting GSH’s function in
preventing damage to cellular components involved in the adipogenic program by
reactive oxygen species such as free radicals, peroxides, lipid peroxides, and heavy
metals (Pompella et al. 2003), DhL could interfere with the normal progression of the
adipogenic process.
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In contrast to DhL, both DH-DhL and DhP lack DhL’s exocyclic methylene
moiety. In one study of a similar dihydro derivative of a sesquiterpene lactone to DHDhL, chemical reduction of the double bond did not affect the capacity of the compound
to inhibit aromatase activity (Blanco et al. 2001). Likewise, my results have shown that
the lack of DH-DhL’s and DhP’s exoyclic methlyene moiety does not negate their antiadipogenic effects. Unlike with DhL, it is likely that DH-DhL and DhP similarly bind
non-covalently to binding pockets with conformational and electrostatic structures that
favor such interactions.
Future elucidations of the potential binding sites and target molecules of these
sesquiterpene lactones in the adipogenic cascade would be a fertile area for future study.

DH-

5.1.2. Hypothesized Mechanisms of Inhibitory Action on Adipogenesis of DhL,
DhL, and DhP
This binding activity of DhL, DH-DhL and DhP to signaling molecules in the

adipogenic cascade, likely impairs factors responsible for facilitating the gene expression
that results in the formation and expansion of lipid droplets.
Lipid droplet size reflects a balance of lipogenesis (triglyceride synthesis) and
lipolysis (Miyoshi et al. 2008). Since my investigations revealed a decrease in lipid
droplet size for all three sesquiterpene lactones, the next step would be to investigate the
etiology of these transformations. At least four possibilities are evident: an arresting of
lipid droplet formation, an arresting of lipid droplet fusion, a facilitation of lipophagy, or
a facilitation of lipolysis (see Figure 24 below).
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Figure 24. Factors influencing lipid droplet genesis and morphological
transformation
Thus, mRNA and/or protein level investigations of gene expression underlying
these processes would be another fertile area of research that would further elucidate the
mechanistic picture painted by my investigations.
This line of research could include in vitro treatment of 3T3-L1 cells in the
manner described in this thesis, and then measurement of perilipin A levels, the most
abundant phosphoprotein on the surface of adipocyte lipid droplets which has a crucial
role in lipid storage and lipolysis (Miyoshi et al. 2008). Additionally, adipose triglyceride
lipase (ATGL) and hormone-sensitive lipase (HSL) the major rate-determining enzymes
for lipolysis in adipocytes (Miyoshi et al. 2008), could also be assayed, as could
perilipins which may protect lipid droplets from lipolysis by shielding the triglyceride
core of lipid droplets from lipases (Thiam et al. 2013). In addition, levels of enzymes
which mediate triglyceride synthesis at the surface of lipid droplets such as GPAT4,
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AGPAT3 and DGAT2 (Miyoshi 2008), could be assayed. Other proteins which affects
lypolysis include lipoprotein lipase (LPL), adipose triglyceride lipase (ATGL), and cell
death-inducing DFF45-like effector A (Cidea) (Manickam et al. 2010), which would all
be promising to measure. Phosphodiesterase-3B (PDE3B), GTP binding protein
(Giα1), hormone-sensitive lipase (HSL), and tumor necrosis factor α (TNF-α) also affect
lypolysis (Davis et al. 2012) and could be measured to gain insight into which process the
sesquiterpene lactones are inhibiting.
Additionally, measuring levels of proteins such as Fsp27 and EPA, which are
required to form unilocular lipid droplets from smaller lipid droplets during adipocyte
differentiation (Thiam et al. 2013), could be undertaken to investigate the possibility of
DhL, DH-DhL, and/or DhP interfering with the process of fusion. Lipid droplet protein
targeting signals such as amphipathic α helices (such as hepatisis virus core protein) and
hydrophobic hairpins (Thiam et al. 2013), could also be studied. Upregulation or
downregulation upon treatment of the sesquiterpene lactones of proteins that facilitate
formation of lipid droplets such as BSCL2/seipin and FIT proteins (Manickam et al.
2010), could also be assayed.
These and other experimental investigations can carry forward the inquiry I have
undertaken in this thesis, just as I have attempted to carry forward the foundational
inquiries that have preceded my work, and to which I owe a debt of appreciation.
5.2. References
Bailon-Moscoso N, González-Arévalo G, Velásquez-Rojas G (2015) Phytometabolite
Dehydroleucodine Induces Cell Cycle Arrest, Apoptosis, and DNA Damage in Human
Astrocytoma Cells through p73/p53 Regulation. PLoS ONE 10(8): e0136527

199

Blanco JG, Gil RR, Bocco JL, Meragelman TL, Genti-Raimondi S, Flury A (2001)
Aromatase inhibition by an 11,13-dihydroderivative of a sesquiterpene lactone. J
Pharmacol Exp Ther 297:1099-1105
Chaturvedi D (2011) Sesquiterpene lactones: structural diversity and their biological
Activities. In Opportunity, Challenges and Scope of Natural Products in Medicinal
Chemistry, Strack D (ed). Research Signpost: Assam; 313-334
Chen PL, Riley DJ, Chen Y, Lee WH (1996) Retinoblastoma protein positively regulates
terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 10:
2794-2804
Manickam E, Sinclair AJ, Cameron-Smith D (2010) Suppressive actions of
eicosapentaenoic acid on lipid droplet formation in 3T3-L1 adipocytes. Lipids in health
and disease 9:57
Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M (2004) p73 Induces
apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem
279: 8076–8083
Miyoshi H, Perfield JW, Obin MS, Greenberg AS (2008) Adipose triglyceride lipase
regulates basal lipolysis and lipid droplet size in adipocytes. J Cell Biochem 105:14301436
Ordóñez PE, Sharma K, Bystrom LM, Alas MA, Enriquez RG, Malagón O, Jones
DE, Guzman ML, Compadre CM (2016) Dehydroleucodine, a Sesquiterpene Lactone
from Gynoxys verrucosa, Demonstrates Cytotoxic Activity against Human Leukemia
Cells. J Nat Prod 79(4): 691–696
Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (2003) The changing faces
of glutathione, a cellular protagonist. Biochemical Pharmacology. 66 (8): 1499–503
Thiam AR, Farese Jr RV, Walther TC (2013) The biophysics and cell biology of lipid
droplets. Nature reviews Molecular cell biology 14:775-786
Wang JY (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene 19:
5643–5650.
Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY (1999) p73 is regulated by
tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399: 814–817

200

VITA
STEVEN ABOOD
Born, Cleveland, Ohio
1993-1997

B.A., Psychology, Political Science
Emory University

1999-2002

J.D., Emory University School of Law

2003-2009

Attorney, King and Spalding, Emory University

2014-2017

Doctoral Candidate
Florida International University
Teaching Assistant, General Biology, Cell Biology,
Human Biology

PUBLICATIONS AND PRESENTATIONS
American Society for Cell Biology Annual Conference 2015
Miami Biosymposium 2016
American Society for Cell Biology Annual Conference 2016
International Conference for Tropical Botany Presentation 2017
Florida International University Plant Symposium 2017
Florida International University History and Religious Studies Deparatment 2017
Biomedical Properties and Origins of Sesquiterpene Lactones, with a Focus on
Dehydroleucodine (Natural Product Communications, in press)
The Birth of the Adipocyte: Early Adipogenesis, the MAPK Pathway, and Mitotic
Clonal Expansion (Current Topics in Biochemical Research, in press)
Other potential original paper publications based on Chapter 2, 3, and 4 of this
are submitted for review

201

thesis

